Epitope engineering of cell surface receptors

By genetically engineering hematopoietic stem cells, introducing specific mutant genes, allowing them to bind to antibodies, thereby developing chimeric antigen receptor-T cells that can target specific cell surfaces, solving existing CAR-T cell therapies 对正常骨髓细胞靶向性不足的问题,提高了治疗恶性肿瘤的效能和安全性。

CN119095953APending Publication Date: 2024-12-06DANA FARBER CANCER INSTITUTE INC +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202380022625.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-11-17
Filing Date
2023-02-16
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing CAR-T cell therapy is immunosuppressive and severe hematopoietic toxicity in the treatment of malignant tumors such as B lymphoblastic leukemia, which limits its applicability before HSCT.

Method used

By genetically engineering hematopoietic stem cells, the introduction of specific mutations of FLT3, CD123 or KIT genes can reduce binding to the corresponding antibodies, thereby developing chimeric antigen receptor-T cells that can target specific cell surfaces. for the treatment of malignant tumors.

Benefits of technology

It improves the recognition and killing efficacy of CAR-T cells on target cells, reduces the toxicity to normal cells, expands the treatment window, and enhances the killing ability of malignant tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119095953A_ABST
    Figure CN119095953A_ABST
Patent Text Reader

Abstract

Genetically engineered hematopoietic cells, such as hematopoietic stem cells, having one or more genetically edited cell surface protein genes and therapeutic uses thereof, alone or in combination with immunotherapy targeting the cell surface proteins.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of priority to U.S. Provisional Application No. 63 / 311,707, filed on February 18, 2022, and U.S. Provisional Application No. 63 / 426,138, filed on November 17, 2022, the contents of which are incorporated herein by reference in their entirety. Technical Field

[0003] Provided herein are genetically engineered hematopoietic cells (such as hematopoietic stem cells) having one or more genetically edited cell surface protein genes, which can be used in combination with immunotherapy (i.e., cytotoxic agents such as chimeric antigen receptor T cells), and therapeutic uses thereof. Background Art

[0004] Innovations in gene transfer technologies have made it possible to reprogram immune cells to target molecules expressed on cancer cells. Extremely promising results led to FDA approval of the first adoptive cellular immunotherapy, called CD19 CAR-T cells, for the treatment of B lymphoblastic leukemia. Although these successes are expected to revolutionize the field of oncology, their application has been hampered by the fact that most suitable candidates typically share healthy bone marrow cells, resulting in immunosuppression and severe hematopoietic toxicity. Anti-myeloid / stem cell CAR-T-induced toxicities limit their applicability to salvage therapy within a limited time window prior to HSCT, which may not be sufficient to eradicate the disease. Therefore, effectively targeting cells of interest (e.g., cancer cells) without targeting or harming normal cell populations remains an unmet need. Summary of the invention

[0005] The present disclosure generally relates to genetically engineered hematopoietic cells, such as hematopoietic stem cells, having one or more genetically edited cell surface protein genes, and chimeric antigen receptors capable of targeting the same cell surface proteins.

[0006] In one embodiment, a genetically engineered hematopoietic stem cell (HSPC) is provided, which comprises a genetically engineered FLT3 gene, wherein the genetically engineered FLT3 gene is engineered so that the binding of its encoded protein to treatment anti-FLT3 antibodies is reduced. In one embodiment, the genetically engineered FLT3 gene comprises at least one mutation in exon 9 of the FLT3 gene. In one embodiment, at least one mutation in exon 9 of the genetically engineered FLT3 gene results in a polypeptide with a mutation at position N399. In one embodiment, the mutation at position N399 is N399D or N399G. In one embodiment, treatment anti-FLT3 antibodies are anti-FLT3 clone 4G8 antibodies. In one embodiment, treatment anti-FLT3 antibodies are antibodies having the same six CDRs as 4G8 antibodies or competing with 4G8 antibodies. In one embodiment, genetically engineered HSPCs are genetically engineered using a CRISPR system comprising a guide nucleic acid and a nuclease. In one embodiment, the nuclease is Streptococcus pyogenes Cas9 (SpCas9), Staphylococcus aureus (SaCas9), Lachnospiraceae bacterium Cas12a (LbCas12a), or Acidaminococcus sp. BV3L6 (AsCas12a). In one embodiment, the CRISPR system comprises SpCas9. In one embodiment, the guide nucleic acid is selected from the group consisting of SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, and SEQ ID NO: 16. In one embodiment, the CRISPR system further comprises a template DNA. In one embodiment, the template DNA is selected from the group consisting of SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, and SEQ ID NO: 43. In one embodiment, the nuclease is a catalytically impaired SpCas9 linked to a base editor enzyme. In one embodiment, the base editor enzyme is a nucleotide deaminase. In one embodiment, the nucleotide deaminase is a cytosine deaminase or an adenosine deaminase. In another embodiment, the catalytically impaired SpCas9 is a NG-SpCas9 or SpRY-SpCas9. In one embodiment, the catalytically impaired SpCas9 comprises a mutation at position D10A. In one embodiment, the catalytically impaired SpCas9 further comprises a mutation at position K918N.In one embodiment, the guide RNA is selected from the group consisting of SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20 and SEQ ID NO: 23. In one embodiment, the genetically engineered FLT3 gene encodes a polypeptide comprising the amino acid sequence SEQ ID NO: 51 or SEQ ID NO: 52. A genetically engineered hematopoietic stem cell (HSPC) population is also provided, comprising the genetically engineered HSPC as described above. In some embodiments, a method for treating a hematopoietic malignancy is provided, the method comprising administering to a human subject: (a) a genetically engineered hematopoietic stem cell population as described above, and (b) a therapeutically effective amount of at least one agent comprising an anti-FLT3 antibody binding domain or an antibody or antibody fragment comprising an anti-FLT3 binding domain. In one embodiment, at least one agent comprises a chimeric antigen receptor-T (CAR-T) cell comprising an anti-FLT3 antibody binding domain. In one embodiment, the hematopoietic malignancy is B lymphoblastic leukemia (BLL), acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia (T-ALL). In one embodiment, the method further comprises obtaining HSPCs from a biological sample from a human subject and genetically engineering the HSPCs in the biological sample from the human subject to form a genetically engineered HSPC population. In one embodiment, the biological sample is bone marrow cells, blood, umbilical cord blood cells, or mobilized peripheral blood derived CD34+ hematopoietic stem and progenitor cells.

[0007] In one embodiment, a genetically engineered hematopoietic stem cell (HSPC) is also provided, which includes a genetically engineered CD123 gene, wherein the genetically engineered CD123 gene is engineered so that its encoded protein is reduced in combination with treatment anti-CD123 antibodies. In one embodiment, treatment anti-CD123 antibodies are cloned 7G3 antibodies or their humanized counterparts CSL362. In one embodiment, the genetically engineered CD123 gene includes at least one mutation in exon 2 of the CD123 gene. In one embodiment, at least one mutation in exon 2 of the genetically engineered CD123 gene results in a polypeptide with a mutation at position S59. In one embodiment, the mutation at S59 is S59P or S59F. In one embodiment, treatment anti-CD123 antibodies are anti-CD123 clone 6H6 antibodies or anti-CD123 clone S18016F antibodies. In one embodiment, the genetically engineered CD123 gene includes at least one mutation in exon 3 of the CD123 gene. In one embodiment, at least one mutation in exon 3 of the genetically engineered CD123 gene results in a polypeptide with a mutation at position P88. In one embodiment, the mutation at P88 is P88L or P88S. In one embodiment, the genetically engineered HSPC is genetically engineered using a CRISPR system comprising a guide nucleic acid and a nuclease. In one embodiment, the guide nucleic acid is selected from the group consisting of SEQ ID NO: 24, SEQ ID NO: 27, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 33 and SEQ ID NO: 34. In one embodiment, the nuclease is a catalytically impaired SpCas9 connected to a base editor enzyme. In one embodiment, the base editor enzyme is a nucleotide deaminase. In one embodiment, the base editor enzyme is a cytosine deaminase or an adenosine deaminase. In one embodiment, the catalytically impaired SpCas9 is NG-SpCas9 or SpRY-SpCas9. In one embodiment, the catalytically impaired SpCas9 includes a mutation at position D10A. In one embodiment, the catalytically impaired SpCas9 also includes a mutation at position K918N. In one embodiment, the genetically engineered CD123 gene encodes a polypeptide comprising the amino acid sequence SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57 or SEQ ID NO: 58. Also provided herein is a genetically engineered hematopoietic stem cell (HSPC) population comprising a genetically engineered HSPC as described above.A method for treating hematopoietic malignancies is also provided, the method comprising administering to a human subject: (a) a genetically engineered hematopoietic stem cell group as described above, and (b) a therapeutically effective amount of an antibody or antibody fragment comprising an anti-CD123 antibody binding domain or comprising an anti-CD123 binding domain. In one embodiment, at least one agent comprises a chimeric antigen receptor-T (CAR-T) cell comprising an anti-CD123 antibody binding domain. In one embodiment, hematopoietic malignancies are B lymphoblastic leukemia (BLL), acute myeloid leukemia (AML), T cell acute lymphoblastic leukemia (T-ALL) or mother cell plasmacytoid dendritic cell leukemia (BPCDN). In one embodiment, the method further comprises obtaining HSPC from a biological sample from a human subject and genetically engineering the HSPC in the biological sample from the human subject, thereby forming a genetically engineered HSPC group. In one embodiment, the biological sample is bone marrow cells, blood, cord blood cells, or mobilized peripheral blood derived CD34+ hematopoietic stem cells and progenitor cells.

[0008] In some embodiments, a genetically engineered hematopoietic stem cell (HSPC) group is provided, comprising: (i) a genetically engineered FLT3 gene, wherein the genetically engineered FLT3 gene encodes a protein that is reduced in combination with treatment anti-FLT3 antibodies, and (ii) a genetically engineered CD123 gene, wherein the genetically engineered CD123 gene encodes a protein that is reduced in combination with treatment anti-CD123 antibodies. In one embodiment, the genetically engineered FLT3 gene comprises at least one mutation in exon 9 of the FLT3 gene. In one embodiment, at least one mutation in exon 9 of the genetically engineered FLT3 gene results in a polypeptide with a mutation at position N399. In one embodiment, the genetically engineered CD123 gene comprises at least one mutation in exon 2 of the CD123 gene. In one embodiment, at least one mutation in exon 2 of the genetically engineered CD123 gene results in a polypeptide with a mutation at position S59. In one embodiment, treatment anti-FLT3 antibodies are anti-FLT3 clone 4G8 antibodies. In one embodiment, the therapeutic anti-CD123 antibody is an anti-CD123 clone 7G3 antibody or a CSL362 antibody. In one embodiment, a CRISPR system comprising at least two guide nucleic acids and a nuclease is used to genetically engineer the HSPC population. In one embodiment, at least two guide nucleic acids are 1) SEQ ID NO: 18 or SEQ ID NO: 20 and 2) SEQ ID NO: SEQ ID NO: 24 or SEQ ID NO: 27. In one embodiment, at least two guide nucleic acids are SEQ ID NO: 20 and SEQ ID NO: 27. In one embodiment, the nuclease is a catalytically impaired SpCas9 connected to a base editor enzyme. In one embodiment, the base editor enzyme is a nucleotide deaminase. In one embodiment, the base editor enzyme is a cytosine deaminase or an adenosine deaminase. In one embodiment, the catalytically impaired SpCas9 is NG-SpCas9 or SpRY-SpCas9. In one embodiment, the catalytically impaired SpCas9 comprises a mutation at position D10A. In one embodiment, SpCas9 also comprises a mutation at position K918N. Also provided is a method for treating a hematopoietic malignancy, the method comprising administering to a human subject: (a) a population of HSPCs as described above, and (b) a therapeutically effective amount of at least one agent comprising one or both of the following: (1) an anti-FLT3 antibody binding domain or an antibody or antibody fragment comprising an anti-FLT3 binding domain, and / or (2) an anti-CD123 antibody binding domain or an antibody or antibody fragment comprising an anti-CD123 binding domain.In one embodiment, at least one agent comprises a chimeric antigen receptor-T (CAR-T) cell comprising an anti-FLT3 antibody binding domain and / or an anti-CD123 antibody binding domain. In one embodiment, hematopoietic malignancies are B lymphoblastic leukemia (BLL), acute myeloid leukemia (AML), T-cell acute lymphoblastic leukemia (T-ALL) or mother cell plasmacytoid dendritic cell leukemia (BPCDN). In one embodiment, the method also includes obtaining HSPC from a biological sample from a human subject and genetically engineering the HSPC in the biological sample from the human subject, so as to form a genetically engineered HSPC group. In one embodiment, the biological sample is bone marrow cells, blood, umbilical cord blood cells or mobilized peripheral blood derived CD34+ hematopoietic stem cells and progenitor cells.

[0009] In one embodiment, a genetically engineered hematopoietic stem cell (HSPC) is also provided, comprising a genetically engineered KIT gene, wherein the genetically engineered KIT gene is engineered so that the binding of its encoded protein to a therapeutic anti-KIT antibody is reduced. In one embodiment, the genetically engineered KIT gene comprises at least one mutation in exon 7 of the KIT gene. In one embodiment, at least one mutation in exon 7 of the genetically engineered KIT gene results in a polypeptide with a mutation at position H378. In one embodiment, the mutation at position H378 is H378R. In one embodiment, the therapeutic anti-KIT antibody is an anti-KIT clone Fab79D antibody. In one embodiment, the genetically engineered HSPC is genetically engineered using a CRISPR system comprising a guide nucleic acid and a nuclease. In one embodiment, the guide nucleic acid is selected from the group consisting of SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, and SEQ ID NO: 39. In one embodiment, the nuclease is a catalytically impaired SpCas9 linked to a base editor enzyme. In one embodiment, wherein the base editor enzyme is a nucleotide deaminase. In one embodiment, the base editor enzyme is a cytosine deaminase or an adenosine deaminase. In one embodiment, the catalytically impaired SpCas9 is NG-SpCas9 or SpRY-SpCas9. In one embodiment, the catalytically impaired SpCas9 comprises a mutation at position D10A. In one embodiment, SpCas9 also comprises a mutation at position K918N. A genetically engineered hematopoietic stem cell (HSPC) population is also provided, comprising a genetically engineered HSPC as described above. A method for treating a hematopoietic malignancy is also provided, the method comprising administering to a human subject: (a) a genetically engineered hematopoietic stem cell population as described above, and (b) a therapeutically effective amount of at least one agent comprising an anti-KIT antibody binding domain or an antibody or antibody fragment comprising an anti-KIT binding domain. In one embodiment, at least one agent comprises a chimeric antigen receptor-T (CAR-T) cell comprising an anti-KIT antibody binding domain. In one embodiment, the hematopoietic malignancy is B lymphoblastic leukemia (BLL), acute myeloid leukemia (AML) or T acute lymphoblastic leukemia (T-ALL). In one embodiment, the method further comprises obtaining HSPCs from a biological sample from a human subject and genetically engineering the HSPCs in the biological sample from the human subject to form a genetically engineered HSPC population. In one embodiment, the biological sample is bone marrow cells, blood, umbilical cord blood cells, or mobilized peripheral blood derived CD34+ hematopoietic stem and progenitor cells.

[0010] In some embodiments, a genetically engineered hematopoietic stem cell (HSPC) group is also provided, comprising: (i) a genetically engineered KIT gene, wherein the genetically engineered KIT gene encodes a protein with reduced binding to treatment anti-KIT antibodies, and (ii) a genetically engineered CD123 gene, wherein the genetically engineered CD123 gene encodes a protein with reduced binding to treatment anti-CD123 antibodies. In one embodiment, the genetically engineered KIT gene comprises at least one mutation in exon 7 of the KIT gene. In one embodiment, at least one mutation in exon 7 of the genetically engineered KIT gene results in a polypeptide with a mutation at position H378. In one embodiment, the genetically engineered CD123 gene comprises at least one mutation in exon 2 of the CD123 gene. In one embodiment, at least one mutation in exon 2 of the genetically engineered CD123 gene results in a polypeptide with a mutation at position S59. In one embodiment, treatment anti-KIT antibodies are anti-KIT clone Fab79D antibodies. In one embodiment, treatment anti-CD123 antibodies are anti-CD123 clone 7G3 antibodies or CSL362 antibodies. In one embodiment, a HSPC population is genetically engineered using a CRISPR system comprising at least two guide nucleic acids and a nuclease. In one embodiment, at least two guide nucleic acids are 1) SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38 or SEQ ID NO: 39 and 2) SEQ ID NO: 24 or SEQ ID NO: 27. In one embodiment, at least two guide nucleic acids are SEQ ID NO: 37 and SEQ ID NO: 27. In one embodiment, the nuclease is a catalytically impaired SpCas9 connected to a base editor enzyme. In one embodiment, the base editor enzyme is a nucleotide deaminase. In one embodiment, the base editor enzyme is a cytosine deaminase or an adenosine deaminase. In one embodiment, the catalytically impaired SpCas9 is NG-SpCas9 or SpRY-SpCas9. In one embodiment, the catalytically impaired SpCas9 comprises a mutation at position D10A. In one embodiment, SpCas9 also comprises a mutation at position K918N. Also provided is a method of treating a hematopoietic malignancy, the method comprising administering to a human subject: (a) a population of HSPCs as described above, and (b) a therapeutically effective amount of at least one agent comprising one or both of the following: (1) an anti-KIT antibody binding domain or an antibody or antibody fragment comprising an anti-KIT binding domain, and / or (2) an anti-CD123 antibody binding domain or an antibody or antibody fragment comprising an anti-CD123 binding domain.In one embodiment, at least one agent comprises a chimeric antigen receptor-T (CAR-T) cell comprising an anti-KIT antibody binding domain and / or an anti-CD123 antibody binding domain. In one embodiment, hematopoietic malignancies are B lymphoblastic leukemia (BLL), acute myeloid leukemia (AML), T-cell acute lymphoblastic leukemia (T-ALL) or mother cell plasmacytoid dendritic cell leukemia (BPCDN). In one embodiment, the method further comprises obtaining HSPC from a biological sample from a human subject and genetically engineering the HSPC in the biological sample from the human subject, thereby forming a genetically engineered HSPC group. In one embodiment, the biological sample is bone marrow cells, blood, umbilical cord blood cells or mobilized peripheral blood derived CD34+ hematopoietic stem cells and progenitor cells.

[0011] Also provided herein is a genetically engineered hematopoietic stem cell (HSPC) population comprising: (i) a genetically engineered FLT3 gene, wherein the genetically engineered FLT3 gene encodes a protein that has reduced binding to a therapeutic anti-FLT3 antibody, and (ii) a genetically engineered KIT gene, wherein the genetically engineered KIT gene encodes a protein that has reduced binding to a therapeutic anti-KIT antibody. In one embodiment, the genetically engineered FLT3 gene comprises at least one mutation in exon 9 of the FLT3 gene. In one embodiment, at least one mutation in exon 9 of the genetically engineered FLT3 gene results in a polypeptide with a mutation at position N399. In one embodiment, the genetically engineered KIT gene comprises at least one mutation in exon 7 of the KIT gene. In one embodiment, at least one mutation in exon 7 of the genetically engineered KIT gene results in a polypeptide with a mutation at position H378. In one embodiment, the therapeutic anti-FLT3 antibody is an anti-FLT3 clone 4G8 antibody. In one embodiment, the therapeutic anti-KIT antibody is an anti-KIT clone Fab79D antibody. In one embodiment, a HSPC population is genetically engineered using a CRISPR system comprising at least two guide nucleic acids and a nuclease. In one embodiment, at least two guide nucleic acids are 1) SEQ ID NO: 18 or SEQ ID NO: 20 and 2) SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38 or SEQ ID NO: 39. In one embodiment, at least two guide nucleic acids are SEQ ID NO: 20 and SEQ ID NO: 37. In one embodiment, the nuclease is a catalytically impaired SpCas9 connected to a base editor enzyme. In one embodiment, the base editor enzyme is a nucleotide deaminase. In one embodiment, the base editor enzyme is a cytosine deaminase or an adenosine deaminase. In one embodiment, the catalytically impaired SpCas9 is NG-SpCas9 or SpRY-SpCas9. In one embodiment, the catalytically impaired SpCas9 comprises a mutation at position D10A. In one embodiment, SpCas9 also comprises a mutation at position K918N. Also provided is a method for treating a hematopoietic malignancy, the method comprising administering to a human subject: (a) a population of HSPCs as described above, and (b) a therapeutically effective amount of at least one agent comprising one or both of the following: (1) an anti-FLT3 antibody binding domain or an antibody or antibody fragment comprising an anti-FLT3 binding domain, and / or (2) an anti-KIT antibody binding domain or an antibody or antibody fragment comprising an anti-KIT binding domain. In one embodiment, at least one agent comprises a chimeric antigen receptor-T (CAR-T) cell comprising an anti-FLT3 antibody binding domain and / or an anti-KIT antibody binding domain.In one embodiment, the hematopoietic malignancy is B lymphoblastic leukemia (BLL), acute myeloid leukemia (AML), T-cell acute lymphoblastic leukemia (T-ALL) or blastic plasmacytoid dendritic cell leukemia (BPCDN). In one embodiment, the method further comprises obtaining HSPC from a biological sample from a human subject and genetically engineering the HSPC in the biological sample from the human subject to form a genetically engineered HSPC population. In one embodiment, the biological sample is bone marrow cells, blood, umbilical cord blood cells, or mobilized peripheral blood derived CD34+ hematopoietic stem cells and progenitor cells.

[0012] In some embodiments, a chimeric antigen receptor (CAR) comprising a polypeptide is also provided, wherein the polypeptide comprises: (a) one or more epitope binding fragments that bind to an epitope of one or more cell surface lineage-specific proteins, (b) a hinge domain, (c) a transmembrane domain, (d) a co-stimulatory domain, and (e) a cytoplasmic signaling domain, wherein the one or more cell surface lineage-specific proteins are selected from FLT3, CD123 and / or KIT.

[0013] In some embodiments, the cell surface lineage-specific protein is FLT3, and the CAR comprises the amino acid sequence SEQ ID NO: 73. In some embodiments, the cell surface lineage-specific protein is FLT3, and one or more epitope-binding fragments include one or more epitope-binding fragments from SEQ ID NO: 73. In some embodiments, the cell surface lineage-specific protein is FLT3, and one or more epitope-binding fragments include the following CDR sequences: GYTFTSYWMH (SEQ ID NO: 96), EIDPSDSYKDYNQKFK (SEQ ID NO: 97), RAITTTPFDF (SEQ ID NO: 98), RASQSISNNLH (SEQ ID NO: 99), YASQSIS (SEQ ID NO: 100) and QQSNTWPYT (SEQ ID NO: 101). In some embodiments, the cell surface lineage-specific protein is CD123, and the CAR comprises the amino acid sequence SEQ ID NO: 75, SEQ ID NO: 86 or SEQ ID NO: 87. In some embodiments, the cell surface lineage-specific protein is CD123, and the one or more epitope-binding fragments include one or more epitope-binding fragments from SEQ ID NO: 75, SEQ ID NO: 86, or SEQ ID NO: 87. In some embodiments, the cell surface lineage-specific protein is CD123, and the one or more epitope-binding fragments comprise the following CDR sequences: GYSFTDYYMK (SEQ ID NO: 104), DIIPSNGATFYNQKFKG (SEQ ID NO: 105), ARSHLLRASWFAY (SEQ ID NO: 106), SQSLLNSGNQKNYLT (SEQ ID NO: 107), WASTRES (SEQ ID NO: 108), and QNDYSYPYT (SEQ ID NO: 109). In some embodiments, the cell surface lineage-specific protein is CD123, and one or more epitope binding fragments include the following CDR sequences: DIIPSNGATFYNQKFKG (SEQ ID NO: 105), SQSLLNSGNQKNYLT (SEQ ID NO: 107), WASTRES (SEQID NO: 108) and QNDYSYPYT (SEQ ID NO: 109). In some embodiments, the cell surface lineage-specific protein is KIT, and CAR includes the amino acid sequence SEQ ID NO: 69 or SEQ ID NO: 71.In some embodiments, the cell surface lineage-specific protein is KIT, and the one or more epitope-binding fragments include one or more epitope-binding fragments from SEQ ID NO: 69 or SEQ ID NO: 71. In some embodiments, the cell surface lineage-specific protein is KIT, and the one or more epitope-binding fragments include the following CDR sequences: GFNISVYMMH (SEQ ID NO: 88), SIYPYSGYTYYADSVKG (SEQ ID NO: 89), ARYVYHALDY (SEQ ID NO: 90), RASQRGLRNVAVA (SEQ ID NO: 91), SASSLYS (SEQ ID NO: 92) and QQWAVHSLIT (SEQ ID NO: 93). In some embodiments, one or more cell surface lineage-specific proteins are FLT3 and CD123, and the CAR comprises the amino acid sequence SEQ ID NO: 77 or SEQ ID NO: 79. In some embodiments, the one or more cell surface lineage-specific proteins are FLT3 and CD123, and the one or more epitope-binding fragments include one or more epitope-binding fragments from SEQ ID NO:77 or SEQ ID NO:79. In some embodiments, the one or more cell surface lineage-specific proteins are FLT3 and CD123, and the one or more epitope-binding fragments comprise the following CDR sequences: GYTFTSYWMH (SEQ ID NO: 96), EIDPSDSYKDYNQKFK (SEQ ID NO: 97), RAITTTPFDF (SEQ ID NO: 98), RASQSISNNLH (SEQ ID NO: 99), YASQSIS (SEQ ID NO: 100), QQSNTWPYT (SEQ ID NO: 101), GYSFTDYYMK (SEQ ID NO: 104), DIIPSNGATFYNQKFKG (SEQ ID NO: 105), ARSHLLRASWFAY (SEQ ID NO: 106), SQSLLNSGNQKNYLT (SEQ ID NO: 107), WASTRES (SEQ ID NO: 108), and QNDYSYPYT (SEQ ID NO: 109). In some embodiments of any of the above-mentioned CARs, the hinge domain is a CD28 hinge, an IgG4 hinge, or a CD8α hinge. In some embodiments of any of the above-mentioned CARs, the transmembrane domain is a CD28 TM, a CD8α TM, or a 4-1BB TM. In some embodiments of any of the above-mentioned CARs, the costimulatory domain is CD28z, 4-1BB, ICOS, or OX40.In some embodiments of any of the above CARs, wherein the cytoplasmic signaling domain is CD3z.

[0014] Also provided herein are cells expressing any of the above CARs. In some embodiments, the cells are immune cells. In some embodiments, the immune cells are T cells.

[0015] Also provided herein is a method of treating a hematopoietic malignancy, the method comprising administering to a human subject: (a) a genetically engineered hematopoietic stem cell population (such as any of those described above), and (b) cells (such as immune cells) expressing any of the above-described CARs.

[0016] Also provided herein is a polypeptide sequence comprising a polypeptide sequence that is at least 80% identical to the sequence shown in SEQ ID NO: 51, wherein the polypeptide sequence comprises a mutation at N399D, and wherein the polypeptide sequence has reduced binding to a therapeutic anti-FLT3 antibody.

[0017] Also provided herein is a polypeptide sequence comprising a polypeptide sequence that is at least 80% identical to the sequence shown in SEQ ID NO: 52, wherein the polypeptide sequence comprises a mutation at N399G, and wherein the polypeptide sequence has reduced binding to a therapeutic anti-FLT3 antibody.

[0018] Also provided herein is a polypeptide sequence comprising a polypeptide sequence that is at least 80% identical to the sequence shown in SEQ ID NO: 54, wherein the polypeptide sequence comprises a mutation at S59P, and wherein the binding of the polypeptide sequence to a therapeutic anti-CD123 antibody is reduced.

[0019] Also provided herein is a polypeptide sequence comprising a polypeptide sequence that is at least 80% identical to the sequence shown in SEQ ID NO: 55, wherein the polypeptide sequence comprises mutations at Y58H and S59P, and wherein the binding of the polypeptide sequence to a therapeutic anti-CD123 antibody is reduced.

[0020] Also provided herein is a polypeptide sequence comprising a polypeptide sequence that is at least 80% identical to the sequence shown in SEQ ID NO: 56, wherein the polypeptide sequence comprises a mutation at S59F, and wherein the binding of the polypeptide sequence to a therapeutic anti-CD123 antibody is reduced.

[0021] Also provided herein is a polypeptide sequence comprising a polypeptide sequence that is at least 80% identical to the sequence shown in SEQ ID NO: 57, wherein the polypeptide sequence comprises a mutation at P88S, and wherein the binding of the polypeptide sequence to a therapeutic anti-CD123 antibody is reduced.

[0022] Also provided herein is a polypeptide sequence comprising a polypeptide sequence that is at least 80% identical to the sequence shown in SEQ ID NO: 58, wherein the polypeptide sequence comprises a mutation at P88L, and wherein the binding of the polypeptide sequence to a therapeutic anti-CD123 antibody is reduced.

[0023] Also provided herein is a polypeptide sequence comprising a polypeptide sequence that is at least 80% identical to the sequence shown in SEQ ID NO:67, wherein the polypeptide sequence comprises mutations at F316S, M318V, I319K, V323I, I334V, E360K, P363V, E366D, E376Q, and H378R, and wherein binding of the polypeptide sequence to a therapeutic anti-KIT antibody is reduced.

[0024] Also provided herein is a polypeptide sequence comprising a polypeptide sequence that is at least 80% identical to the sequence shown in SEQ ID NO: 68, wherein the polypeptide sequence comprises a mutation at H378R, and wherein binding of the polypeptide sequence to a therapeutic anti-KIT antibody is reduced.

[0025] Also provided herein are nucleic acids encoding any of the above polypeptides.

[0026] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Methods and materials for use in the present invention are described herein; other suitable methods and materials known in the art may also be used. The materials, methods, and examples are illustrative only and are not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In the event of a conflict, the present specification (including definitions) shall prevail.

[0027] Other features and advantages of the invention will be apparent from the following detailed description and drawings, and from the claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 The structures of cytokine receptors encoded by genes such as FLT3 or KIT are described. Figure 1 (Left) Illustration of an epitope engineering approach to eliminate therapeutic antibody binding by introducing mutations in the extracellular domain. Figure 1 (Right) Shown are the key features of epitope-engineered surface proteins: loss of antibody recognition, but retention of ligand affinity, protein function, and intracellular signaling.

[0029] Figure 2On the left is a schematic diagram of the Sleeping Beauty transposase experiment, which includes the design of transfer vectors to introduce cDNA sequences of desired receptor variants into human or murine cell lines to assess recognition of such variants by different antibody clones or to measure ligand affinity by flow cytometry. K562 cells were electroporated with 100 ng of transfer plasmid and 500 ng of pSB100x transposase using a Lonza 4D-Nucleofector. Figure 2 Flow cytometry plots of K562 cells transduced with human wild-type FLT3 (hFLT3), murine FLT3 (mFLT3), and epitope-modified variant eFLT3-01 by Sleeping Beauty transposase are shown on the right, and the eFLT3-01 has amino acid substitutions within the extracellular domain 4. Transduced cells were identified by mCherry fluorescence (y-axis). Cells were stained with FLT3BV10A4 clone (control antibody, binding to ECD2), FLT34G8 therapeutic clone (binding to ECD4), anti-murine FLT3 antibody, and AF488 conjugate human FLT3L to assess binding affinity.

[0030] Figure 3 At the top is a sequence alignment of human FLT3 extracellular domain 4 with orthologous genes from several animal species. The black rectangle highlights the mutated region in eFLT3-01 and is contained in Figure 5 The less conserved residues in the combinatorial libraries are shown. Figure 3 Bottom is a sequence alignment of human KIT extracellular domain 4 with orthologous genes from several animal species. Black rectangles highlight less conserved residues that have been mutated in eKIT-01 and are predicted to contribute to the epitope bound by clone Fab79D.

[0031] Figure 4A is a flow cytometry graph showing co-staining of Sleeping Beauty transduced K562 cells with a control antibody (clone BV10A4) and a therapeutic antibody (clone 4G8). Overexpression of the eFLT3-01 variant shows a lack of recognition by the 4G8 clone, while wild-type FLT3 is bound by both the therapeutic and control Abs.

[0032] Figure 4B Figure 2 is a flow cytometry graph showing fluorescent FLT3-ligand binding of K562 cells transduced with Sleeping Beauty. Cells were incubated with AF488-conjugated human FLT3L and control antibody BV10A4 that recognizes ECD2. The MFI ratio between the control antibody and AF488-conjugated human FLT3L is reported in the figure. The eFLT3-01 variant exhibits ligand binding affinity comparable to wild-type FLT3.

[0033] Figure 4CIt is a western blot of protein extracts of K562 cells transduced by Sleeping Beauty. Cells were placed in a serum starvation state for 16h, then stimulated with FLT3L 100ng / mL or not stimulated and lysed to obtain protein extracts. K562 (untransduced), K562 overexpressing wild-type FLT3, and K562 overexpressing eFLT3-01 were probed with antibodies recognizing the extracellular domain of FLT3, phosphorylated FLT3 Y589-591, or actin (control). The eFLT3-01 variant shows kinase domain phosphorylation similar to wild-type FLT3 when responding to FLT3L stimulation.

[0034] Figure 5 (Top left) Shown is the design of the FLT3 combinatorial library cloned in the Sleeping Beauty plasmid. Figure 5 (Bottom left) Flow cytometry images of K562 cells transduced with wild-type FLT3 or a FLT3 combinatorial library and stained with a control antibody (clone BV10A4) and a therapeutic antibody (clone 4G8) are shown. NGS sequencing of sorted single-positive and double-positive cells highlighted the presence of the N399D mutation only in the sorted single-positive samples. Figure 5 (Right) Validation of the FLT3 N399D mutation overexpressed in K562 cells by Sleeping Beauty transduction. Co-staining with BV10A4 and 4G8 clones showed lack of binding by the latter, whereas ligand affinity was retained as assessed with AF488-conjugated FLT3L.

[0035] Fig. 6A is a flow cytometry graph showing co-staining of Sleeping Beauty transduced NIH3T3 cells with a control antibody (clone 104D2) and a therapeutic antibody (clone Fab79D). Overexpression of the eKIT-01 variant shows a lack of recognition by the Fab79D cloned Ab, while wild-type KIT is bound by both the therapeutic and control Abs.

[0036] Figure 6B Figure 2 is a flow cytometry graph showing fluorescent SCF binding of NIH3T3 cells transduced with Sleeping Beauty. Cells were incubated with AF488-conjugated human SCF and control antibody 104D2. The MFI ratio between the control antibody and AF488-conjugated human SCF is reported in the figure. The eKIT-01 variant exhibits ligand binding affinity comparable to wild-type KIT.

[0037] Figure 6CWestern blot of protein extracts of NIH3T3 cells transduced with Sleeping Beauty. Cells were serum starved for 16 h and then stimulated or not stimulated with SCF 100 ng / mL and lysed to obtain protein extracts. NIH3T3 (untransduced), NIH3T3 overexpressing wild-type KIT, and NIH3T3 overexpressing eKIT-01 were probed with antibodies recognizing the extracellular domain of KIT, phosphorylated KIT Y719, or actin (control). The eKIT-01 variant showed kinase domain phosphorylation similar to wild-type KIT in response to SCF stimulation.

[0038] Fig.6D Flow cytometry plots of HEK-293T cells transduced with the Sleeping Beauty system with several mutated KIT variants in addition to wild-type KIT are reported. Cells were stained with a control antibody (clone 104D2) and a therapeutic antibody (Fab79D) to identify the best candidate mutations to abrogate Fab79D binding while retaining surface expression.

[0039] Figure 7 The upper left is the experimental design of the KIT extracellular domain 4 degenerate library screening, which is used to locate the epitope of cloned Fab79D. Each amino acid residue within ECD 4 is replaced by a completely degenerate codon (NNN) to allow any amino acid substitution, and the amino acid residues are cloned into the Sleeping Beauty plasmid with mTagBFP2 as a co-expression tag for transduced cells. The library is electroporated into HEK-293T cells. Figure 7 Bottom left is the gating strategy for FACS sorting of the KIT ectodomain 4 degenerate library to isolate single positive cells for NGS sequencing (for KIT control antibody clone 104D2). Figure 7 On the right is a heat map matrix with each amino acid position within the library region of the extracellular domain 4 as a column and the amino acid substitutions enriched in single-positive and double-positive FACS sorted and sequenced cells. The most frequently mutated amino acid positions represent residues involved in Fab79D epitope recognition (reported at the top of the figure).

[0040] Figure 8It is an experimental layout for inserting upstream of the targeted EF1-α promoter of the FLT3 and IL3RA (CD123) reading frames mediated by CRISPR-Cas9 or Cas12a homology-directed repair. The purpose of this experiment is to generate a reporter cell line to allow enhanced and faster evaluation of editing results by flow cytometry, because unmodified K562 cells do not express either gene. The same strategy has been applied to the KIT gene to overexpress it from its endogenous locus. K562 is electroporated with an RNP complex together with a dsDNA donor template with homology arms of the FLT3 or IL3RA promoter region. Cells expressing the desired gene are then FACS sorted, single-cell cloned, and screened to identify clones with the highest expression.

[0041] Fig. 9 is a map of the anti-CD123 clone 7G3 epitope on the CD123 N-terminal domain. Each amino acid position has been substituted with alanine or an evolutionarily conserved amino acid and screened for 7G3 binding. White squares identify residues that have no effect on 7G3 binding, while progressively darker grey squares correlate with 25-50-75% loss of clone 7G3 binding. Similarly, Fig. 9 The bottom portion shows the IL3 binding site on CD123.

[0042] Fig. 10A The locations of several sgRNAs associated with IL3RA exons 2 and 3 used in base editing screening experiments to identify gRNAs and mutations that can eliminate clone 7G3 binding while retaining CD123 surface expression are shown. The legend reports the type of Cas protein associated with each sgRNA.

[0043] Fig. 10B Representative flow cytometry plots of K562 reporter cells expressing CD123 from endogenous loci edited with different sgRNAs and base editors are shown (indicated above and to the left of each figure). Cells were stained with control antibodies, CD123 clone 9F5, and 3 different therapeutic antibodies (CD123 clones 7G3, 6H6, and S18016F). The sgRNA and plasmid doses electroporated into cells are reported in the accompanying drawings.

[0044] Fig.11 Base editing screening experiments on CD123 reporter cells edited with several sgRNA-base editor pairs (reported on the left or top of the figure, respectively). Cells were electroporated with 360 pmol sgRNA and 500 ng base editor plasmid using Lonza 4D-Nucleofector and evaluated by flow cytometry after 72 h. Cells were stained with control antibodies, CD123 clone 9F5, and 3 different therapeutic antibodies (CD123 clone 7G3).

[0045] Fig. 12A The design of lentiviral vectors encoding the FLT3 4G8 CAR and a truncated EGFR transduction (LV) marker / safety switch is reported. Generation 3 LV vectors were generated and fresh PBMC-derived T cells were transduced on days 2-3 of stimulation with CD3-CD28 Dynabeads and cultured for 14 days in medium containing IL7 and IL15. For co-culture killing experiments, K562 cells expressing no FLT3, wild-type FLT3, or epitope-engineered variants of FLT3 were plated in 96-well plates with 4G8-CAR T cells or untransduced (UT) T cells at different effector:target ratios (ET).

[0046] Fig. 12B (Top row) Flow cytometry images of plated K562 cells showing expression of FLT3 by co-staining with control antibody (clone BV10A4) and therapeutic antibody (clone 4G8). Fig. 12B (Middle and bottom rows) are flow cytometry images of live cells (LiveDead yellow-AnnexinV-) in co-culture killing assays 4 and 48 hours after plating. Effector cells were identified by CellTrace fluorescence or CD4 / CD8 expression, while target cells were CellTrace and CD4 / CD8 negative and FSC-A high.

[0047] Fig. 12C is a graph showing the percentage of live target cells (LiveDead-AnnexinV-) at 4 h under all conditions tested.

[0048] Fig.12D is a graph showing CD107a surface staining on T lymphocytes at 4 hours as a marker of degranulation during co-culture with target cells.

[0049] Fig.12E is a graph reporting the CellTrace Yellow MFI 48h after co-culture with target cells to assess T cell proliferation by dye dilution.

[0050] Fig.13ASchematic diagram showing the position of 3 gRNAs relative to FLT3 exon 9 for the CRISPR-Cas homology-directed repair (HDR) editing strategy. 2 gRNAs were designed for use in combination with AsCas12a and the other for use in combination with SpCas9 nuclease. Single-stranded oligodeoxynucleotides (ssODNs) were used as template donors, and the designs of 4 different variants were reported. Black squares within the ssODN sequence identify mutated codons that differ from the wild-type sequence (including additional mutations to reduce the rate of re-cutting by Cas nucleases after HDR-mediated repair). The reverse complement of each ssODN was also tested.

[0051] Fig. 13B It was reported Fig.13A Flow cytometry plots of the results of CRISPR-Cas HDR editing experiments performed on reporter K562 cells expressing FLT3 using the gRNAs and ssODNs reported in. Cells were co-stained with a control antibody (clone BV10A4) and a therapeutic antibody (clone 4G8). Black squares highlight edited cells.

[0052] Fig.14A Schematic diagram showing the positions of two sgRNAs used in combination with an adenine base editor (ABE) relative to FLT3 exon 9 and N399 codons.

[0053] Fig. 14B The sequence of each gRNA relative to the N399 codon and PAM sequence is reported.

[0054] Fig. 14C Schematic representation of three adenine base editor variants with mutated Cas9 to allow use with alternative PAM sequences.

[0055] Fig.14D It is used to show Fig.14A and Fig. 14B The sgRNAs and Fig. 14C Flow cytometry plots of the results of base editing experiments with ABE reported in K562 reporter cells expressing FLT3. Cells were co-stained with a control antibody (clone BV10A4) and a therapeutic antibody (clone 4G8). Each plot reports the gating of edited cells and the percentage of edited cells.

[0056] Fig.15A Schematic diagram showing the positions of five sgRNAs used in combination with an adenine base editor (ABE) to introduce the N399D mutation relative to FLT3 exon 9 and the N399 codon. The legend shows the different PAM and SpCas9 requirements for each sgRNA.

[0057] Fig. 15BThe sequence of each gRNA relative to the N399 codon and PAM sequence is reported.

[0058] Fig. 15C It is used to show Fig.15A and Fig. 15B Flow cytometry plots of the results of base editing experiments performed on K562 reporter cells expressing FLT3 using the depicted sgRNA and two adenine base editors (NG-ABE8e and SPRY-ABE8e-V106W 3xNLS). Cells were co-stained with a control antibody (clone BV10A4) and a therapeutic antibody (clone 4G8). Each plot reports the gating of edited cells and the percentage of edited cells.

[0059] Fig.16A Flow cytometry plots of FLT3 reporter K562 cells overexpressing different FLT3 variants by Sleeping Beauty transduction and co-stained with anti-FLT3 control antibody (clone BV10A4) and AF488-conjugated human FLT3L. The slope of the double-positive population is proportional to the FLT3L affinity (each graph reports the MFI ratio between FLT3 control antibody and FLT3L staining).

[0060] Fig. 16B is a histogram showing the distribution of MFI ratios between FLT3 control antibody and AF488-conjugated FLT3L staining compared to wild-type FLT3 (grey overlay).

[0061] Fig.17A Shown is the design of a pmRNA plasmid to generate a custom clone of base editor mRNA for editing human CD34+ cells.

[0062] Fig. 17B The workflow of the in vitro transcription protocol for generating BE mRNA is described.

[0063] Fig. 17C Agilent fragment analyzer profile of in vitro transcribed SpRY-ABE8e-V106W mRNA. The x-axis is nucleotide size and the y-axis is relative fluorescence unit (RFU) signal.

[0064] Fig.18, Panel A is a flow cytometry graph showing the results of base editing experiments performed on K562 reporter cells expressing FLT3 using the FLT3-18-NRNsgRNA and IVT adenine base editor mRNA (SpRY-ABE8e-V106W3xNLS) depicted in Figure 15 (Panel B). Cells were co-stained with a control antibody (clone BV10A4) and a therapeutic antibody (clone 4G8). Each graph reports the gating of edited cells and the percentage of edited cells. Experiments were performed with different mRNA and sgRNA doses (reported at the top and left of the figure, respectively). Fig.18 B is a dot plot illustrating the dose-effect correlation between mRNA, gRNA and editing efficiency by flow cytometry. Fig.18 (Panel C) is a dot plot illustrating the dose-effect correlation between edited mRNA, gRNA and cell viability.

[0065] Fig.19A The report was performed on FLT3 reporter K562 cells (with Fig.18 Figure 2. Heatmap of editing efficiency at each adenine base position of the FLT3-18-NRN sgRNA using different mRNA and sgRNA doses (reported on the left). The gRNA sequence and expected editing window are reported on the top of the heatmap.

[0066] Fig.19B It is a dot plot illustrating the dosage effect correlation between mRNA, gRNA and editing efficiency by gDNA sequencing (only editing at base positions A6 and A7 is reported).

[0067] Fig. 20A Figure 1 shows the experimental design of a FLT3 base editing experiment performed on human mobilized peripheral blood-derived CD34+ HSPCs using IVT mRNA and FLT3-18-NRN sgRNA. The composition of the culture medium is reported on the right, while the timeline reports the time points for flow cytometry and gDNA collection.

[0068] Fig. 20B A gating strategy for flow cytometric assessment of the stem cell phenotype of cultured CD34+ HSPCs is reported.

[0069] Fig. 20C is a bar graph reporting the fold expansion of CD34+ HSPCs cultured on days 0, 3, and 6 after editing.

[0070] Fig.20D is a bar graph showing the composition of CD34+ HSPCs cultured on days 3 and 6 after editing by flow cytometry ( Fig. 20B Gating is reported in ).

[0071] Fig.21Ais a heat map reporting the editing efficiency at each adenine base position of the FLT3-18-NRN sgRNA using different mRNA and sgRNA doses (reported on the left) performed on mobilized peripheral blood-derived CD34+ HSPCs (same as Figure 20).

[0072] Fig. 21B It is a dot plot illustrating the dose-effect correlation between mRNA, gRNA and editing efficiency by gDNA sequencing of CD34+HSPC.

[0073] Fig.22A Is a flow cytometry diagram showing a CAR-T co-culture killing assay, where the target cells are unmodified or base-edited FLT3-expressing K562 cells. The target cells were seeded with 4G8-CAR T cells or untransduced T cells at different effector: target ratios (reported at the top) and evaluated by flow cytometry at 6h. Live cells (AnnexinV-LiveDead yellow-) were plotted and relative percentages were reported.

[0074] Fig. 22B The target cell viability at each E:T ratio 6 h after co-culture is reported (AnnexinV-LiveDeadyellow-).

[0075] Fig. 22C T cell degranulation by CD107a surface staining at each E:T ratio at 6 h after co-culture is reported.

[0076] Fig.23A Figure 1 is a flow cytometry graph showing a CAR-T co-culture killing assay, where the target cells were unmodified or base-edited human CD34+ HSPCs (editing efficiency 46%). Target cells were plated with 4G8-CAR T cells or untransduced T cells at different effector: target ratios (reported at the top) and evaluated by flow cytometry at 48 h.

[0077] Fig. 23B The specific killing of CD34+ cells by 4G8CAR-T cells at 48h was reported.

[0078] Fig.23C reported specific killing of CD34+CD90+ stem cell-enriched subsets by 4G8CAR-T cells at 48 h.

[0079] Fig.24A The experimental design of an in vivo experiment evaluating the resistance of FLT3 epitope engineered CD34+ HSPCs to 4G8 CAR-T cells is reported. The experimental timeline and procedures, as well as the number of treatment groups, are reported.

[0080] Fig. 24B is a bar graph reporting the relative abundance and absolute counts of human CD45+ engraftment in the bone marrow (BM) at sacrifice for each treatment group.

[0081] Fig.24C is a bar graph depicting the lineage composition of human engraftments derived from xenografted CD34+ HSPCs that were either unmodified or base edited in the FLT3 gene.

[0082] Fig.25A Figure 24 is a bar graph reporting the relative abundance and absolute counts of human CD45+ engrafted human CD34+CD38- progenitor cells in the bone marrow at sacrifice (same experiment as Figure 24). Mice xenografted with unmodified CD34+ HSPCs showed a significant decrease in CD34+CD38- progenitor cells after 4G8CAR-T administration.

[0083] Fig.25B is a bar graph reporting the percentage of CAR-T cells to CD69+ cells (T cell activation marker) in the spleens of treated mice (same experiment as Figure 24).

[0084] Fig.25C is a bar graph reporting T cell phenotype (assessed by surface expression of CD62L and CD45RA) classified as central memory (CD45RA-CD62L+, CM), effector memory (CD45RA-CD62L-, EM), naive (CD45RA+CD62L+), or effector memory cells re-expressing CD45RA (CD45RA+CD62L-, TEMRA).

[0085] Fig.25D Depicted is the flow cytometry gating strategy of bone marrow samples from an in vivo xenograft experiment (same as FIG. 24 ) to identify lineage-negative human progenitor cells (live / hCD45+ / CD3- / CD19- / CD33- / CD34+ / CD38-).

[0086] Fig.25E Cumulative flow cytometry plots obtained from pooled events of mice under the same conditions (same experiment as Figure 24) showing the percentage of human CD34+CD38- progenitor cells in the bone marrow at the time of sacrifice are reported.

[0087] Fig.26A The experimental design for a dual base editing experiment of FLT3 and CD123 using IVT mRNA and FLT3-18-NRN and CD123-N sgRNAs in human mobilized peripheral blood-derived CD34+ HSPCs. The composition of the culture medium is reported on the right, while the timeline reports the time points for flow cytometry and gDNA collection.

[0088] Fig.26Bis a bar graph reporting the fold expansion of CD34+ HSPCs cultured on days 0, 3, and 7 after editing.

[0089] Fig.26C Flow cytometry plots of edited CD34+ HSPCs highlighting the loss of CD123 clone 7G3 recognition under CD123 base editing conditions. Cells were co-stained with a control CD123 antibody (clone 9F5) and a therapeutic antibody (7G3). Cells were pre-gated with CD34+CD90+CD45RA-.

[0090] Fig. 27 is a heat map reporting the editing efficiency at each adenine base position of FLT3-18-NRN and CD123-N sgRNAs using different mRNA and sgRNA doses (reported on the left) performed on mobilized peripheral blood-derived CD34+ HSPCs (same as Figure 26).

[0091] Fig.28A Flow cytometry plots of K562 cells base-edited with FLT3-18-NRN sgRNA or CD123-N sgRNA in combination with SpRY-ABE8e-V106W or SpRY-K918-ABE8e-V106W to show the improvement in CD123 base editing efficiency.

[0092] Fig.28B The sequences of 3 different gRNAs used to target the CD123 S59 residue are reported.

[0093] Fig.28C Several different adenine base editor designs with modified SpCas9 are depicted, including higher-fidelity variants (HF1, Sniper), K918N variants, BlackJack variants (more tolerant to longer gRNAs), and combinations of these mutations.

[0094] Fig.28D Is the report used Fig.28B The 3 gRNAs in (plus FLT3-18-NRN as a control) and Fig.28C Heat map of editing efficiencies of base editor variants in .

[0095] Fig.29A The experimental design for a dual base editing experiment of FLT3 and CD123 using IVT mRNA and FLT3-18-NRN and CD123-R sgRNAs in human mobilized peripheral blood-derived CD34+ HSPCs. The composition of the culture medium is reported on the right, while the timeline reports the time points for flow cytometry and gDNA collection.

[0096] Fig.29BFlow cytometry plots demonstrating the gating strategy for obtaining CD123 base editing efficiency in cultured CD34+ HSPCs.

[0097] Fig.29C is a bar graph reporting the fold expansion of CD34+ HSPCs cultured on days 0, 3, and 6 after editing.

[0098] Fig.30 Figure 29 is a heat map reporting the base editing efficiency of FLT3-18-NRN and CD123-R sgRNAs at each adenine position (same experiment as Figure 29). The target base is reported at the bottom of the heat map. The heat map on the right reports the percentage of CD123 bases edited by flow cytometry.

[0099] Fig.31 is a heat map reporting the base editing efficiency of KIT-gRNA-Y targeting residue H378 on CD34+ HSPCs at each adenine position from the same experiment as Figure 29.

[0100] Fig.32A Report the experimental design of an in vivo xenograft experiment to confirm the resistance of FLT3 epitope engineered human CD34+ HSPCs to 4G8CAR-T cells. Report the experimental timeline and treatment groups and numbers.

[0101] Fig.32B FLT3 base editing efficiencies were reported for peripheral blood samples taken 8 weeks after transplantation for all mice.

[0102] Fig.33A The percentages of human CD45+ engrafted polymorphonuclear granulocytes (CD3-CD19-CD33+SSChi, PMN) and granulocytic monocytic progenitors (lineage-CD34+CD38+CD45RA+FLT3+, GMP) in the bone marrow at sacrifice are reported (same experiment as Figure 32).

[0103] Fig.33B The FLT3 editing efficiency on genomic DNA of 4G8CAR-T cell treated and untreated mice at several time points is shown. LC, liquid culture (pre-transplantation sample); W8, W12, bleeding at week 8 and week 12; BM, bone marrow; CFU, colony-forming unit-derived cells (plated from bone marrow samples at sacrifice).

[0104] Fig.34Representative flow cytometry graphs showing the relative abundance of polymorphonuclear granulocytes (CD3-CD19-CD33+SSChi, PMN), granulocytic monocytic progenitors (lineage-CD34+CD38+CD45RA+FLT3+, GMP) and hematopoietic stem cells (lineage-CD34+CD38-CD90+CD45RA-, HSC) in the bone marrow of mice xenografted with FLT3 or AAVS1-edited CD34+HSPCs.

[0105] Fig.35 Several alternative designs of mono- or bispecific chimeric antigen receptors (CARs) expressed as two separate constructs or as tandem CARs (two scFvs on the same molecule, separated by a linker) are depicted.

[0106] Fig.36 A is a schematic diagram of a type III receptor tyrosine kinase (FLT3, KIT) with an extracellular domain (ECD) recognized by control or therapeutic (magenta) monoclonal antibodies. AF488-conjugated FLT3L or SCF ligands were used to assess binding affinity of mutant receptors.

[0107] Fig.36 B is a flow cytometry graph showing loss of therapeutic mAbs (4G8 and Fab79D for FLT3 and KIT, respectively) to chimeric receptors with 16 or 10 amino acid substitutions, respectively (top); and fluorescent ligand binding assays for wild-type (WT) and mutant receptor variants (bottom).

[0108] Fig.36 C is a Western blot of pFLT3 Y589-591 and pKIT Y719 of cell lines expressing FLT3 and KIT variants that were unstimulated or incubated with 100 ng / mL FLT3L or SCF.

[0109] Fig.36 D is a Sleeping Beauty plasmid containing FLT3 cDNA with human or mouse codons at 16 amino acid positions of ECD4 (top left); K562 cells transduced with the FLT3 library and FACS-sorted (4G8- and 4G8+) for NGS sequencing of the library region (top right); and a schematic diagram showing the sequence logo of the relative amino acid frequency at positions 384-413 (bottom).

[0110] Fig.36 E is a Sleeping Beauty plasmid containing a degenerate codon (NNN) at each position of ECD4 (upper left); K562 cells transduced with a KIT library and sorted by FACS (Fab79D- and Fab79D+) for NGS sequencing of the library region (upper right); and lowSchematic representation of sequence logos with log fold changes of amino acid substitutions enriched in double positive cells (aa.314 to 381) (bottom; positions with multiple enriched amino acid substitutions are consistent with previously predicted contact points).

[0111] Fig.36 F is a schematic diagram of the tested gRNAs targeting FLT3 codon N399 (left); and representative images of K562 FLT3 reporter cells electroporated with base editor expression plasmids (NG-ABE8e or SpRY-ABE8e) and sgRNAs, assessed by flow cytometry 72 hours after editing (right; the percentage of cells positive for control mAb BV10A4 and negative for clone 4G8 is reported in each graph; gating strategy is shown for unedited conditions).

[0112] Fig.36 G shows CD123 epitope screening by base editing. Top: sgRNAs targeting base editing of 7G3 contact residues for screening. Dark blue, NGG PAM; gray, NGN PAM; light blue, NRN PAM. PAM positions are indicated by arrows. Bottom: FACS plots of CD123 reporter K562 cells treated with SpRY-cytidine (top row) or adenine (bottom row) base editors. The percentage of cells that are positive for the control mAb 9F5 and negative for the therapeutic clone 7G3 is reported in the lower right corner of each figure.

[0113] Fig.36 H shows the affinity of therapeutic antibodies to stealth receptor variants measured on K562 (for FLT3 and CD123) or NIH-3T3 (for KIT) cells expressing receptor variants. Mean ± SD (N = 3) of the MFI of the therapeutic mAbs normalized to the control mAb after background subtraction. Comparisons were made by two-way ANOVA.

[0114] Fig.36 I is FLT3, SCF and IL3 affinity assay. Cell lines expressing receptor variants via Sleeping Beauty transposase were incubated with fluorescent ligands and assessed by flow cytometry. Mean ± SD of MFI of ligands (N = 3 FLT3 / CD123; N = 4 KIT). Comparisons were made by two-way ANOVA.

[0115] FIG. 37A is a full-length sequence logo of the FLT3 EC4 combinatorial library showing the frequency of amino acids at each position (357 to 421) of ECD4 in FACS sorted 4G8- and 4G8+ cells.

[0116] Figure 37B shows the design of the Sleeping Beauty transposon encoding FLT3 variants with mCherry and a puromycin N-acetyltransferase (PAC) reporter gene / resistance cassette (top), and flow cytometry graphs showing loss of 4G8 recognition of the N399D and N399G variants expressed in K562 cells (bottom).

[0117] Figure 37C shows that FLT3, KIT and CD123 reporter K562 cells are generated by targeted homology-directed repair integration of the EF1α promoter upstream of the gene transcription start site (TSS). dsDNA donors with 50bp long homology arms are generated by PCR of the plasmid template encoding the complete EF1α promoter. K562 cells are electroporated with SpCas9 (FLT3, KIT) or AsCas12a nuclease (CD123) and gRNA identifying the upstream region of each gene coding sequence. 0.5 to 10ug dsDNA donor templates are co-electroporated with CasRNP in 20 μL electroporation volume. Representative flow cytometry diagrams show cell populations that are positive for overexpressed genes, sorted and amplified by FACS. For FLT3 and CD123, single cell cloning is performed to the sorted cells to separate clones with the highest surface expression. Unless otherwise stated, all epitope editing tests and optimizations are performed on K562 reporter cells. The dual FLT3 / CD123 reporter gene was obtained by performing a second round of CD123-targeted RNP+donor electroporation on FLT3-expressing K562 cells (data as Fig.49 B).

[0118] Figure 37D shows the introduction of FLT3N399D mutation by homology-directed repair mediated by CRISPR-Cas. K562 reporter cells were electroporated with SpCas9 or AsCas12a nuclease, gRNA and 200-bp ssODN template donors encoding N399D mutation (or their reverse complements, rev.comp.). Additional silent mutations were included to reduce the risk of nuclease re-cutting after HDR repair. Cells were evaluated by flow cytometry 72 hours after editing. In addition to 4G8-, the percentage of FLT3+ cells (by control mAb BV10A4) is reported in the lower right corner.

[0119] Figure 37E shows the characterization of KIT mutations derived from the epitope map. For amino acid positions derived from the KIT epitope map, substitutions obtained with adenine BE (ABE, red) or cytidine BE (CBE, blue) were cloned individually into the Sleeping Beauty transposon and electroporated into HEK-293T cells. After puromycin selection, cells were stained with Fab-79D and control Ab104D2. The ratio between the Fab-79D MFI and 104D2 MFI for each mutation is reported. In order to exclude variants that affect the binding of SCF to KIT, the same variants were incubated with SCF conjugated to AF488 and control mAb 104D2 (which does not impair SCF binding). The ratio of SCF to 104D2 median fluorescence is reported in the bar graph. The horizontal line shows the reference mutation H378R.

[0120] Figure 37F shows KIT H378R adenine base editing optimization. SpRY-ABE8e was co-electroporated into K562 cells with an sgRNA targeting codon H378 within exon 7. The editing efficiency of each adenine within the protospacer on the gDNA is reported (position number relative to the KIT-Y sgRNA).

[0121] Figure 37G top shows the design of the Sleeping Beauty transposon encoding a KIT variant with mTagBFP2 and a puromycin N-acetyltransferase (PAC) reporter gene / resistance cassette; and bottom shows a flow cytometry graph showing loss of Fab79D recognition of KITH378R expressed in HEK-293T cells.

[0122] Figure 37H shows CD123 epitope screening by base editing. Figure 1 sgRNAs for targeted base editing of 7G3 contact residues reported in G were co-electroporated into CD123 reporter K562 cells along with adenine (ABE) or cytidine base editor (CBE) expression plasmids. Each graph reports the percentage of cells that were positive for control mAb 9F5 and negative for therapeutic clone 7G3. Gating strategy is shown for unedited conditions. BE4, evoApobec-1 BE4max.

[0123] Figure 37I shows that CD123 CBE with sgRNA-F resulted in loss of binding for clones 6H6 and S18016F. The same conditions from the BE screen reported in Figure 37H were stained with CD123 targeting clones 6H6 and S18016F with different epitopes than clone 7G3.

[0124] FIG. 37J shows the design of the Sleeping Beauty transposon encoding a CD123 variant that co-expresses the common β chain CSFR2B to allow intracellular signaling.

[0125] Fig.38 A shows that the variants of FLT3 epitope engineering retain kinase activation. Western blot of protein extracts from K562 cells expressing FLT3 variants by Sleeping Beauty transposase. The cells were placed in a serum starved state overnight and stimulated with different concentrations of human FLT3L for 10 minutes at 37°C. pFLT3 Y589-591, total FLT3 and actin were detected on the same lysate. Total FLT3 was detected after stripping the pFLT3 membrane. The normalized pFLT3 signal intensity (on actin) is reported on the right. Comparison was made by two-way analysis of variance.

[0126] Fig.38 B shows that KIT epitope engineered variants retain kinase activation. Western blot of protein extracts from NIH-3T3 cells expressing KIT variants through Sleeping Beauty transposase. Cells were serum starved overnight and stimulated with different concentrations of human SCF at 37°C for 10 minutes. pFLT3 Y719, total KIT, and actin were probed on the same lysate. The right figure reports the normalized pKIT signal intensity (on total KIT). Comparison was made by two-way ANOVA.

[0127] Fig.38 C shows that the CD123 epitope engineered variants retain STAT5 activation. BaF3 cells expressing CD123 variants by Sleeping Beauty transposase were placed in a state lacking murine IL-3 and stimulated with different concentrations of human IL-3. After 48 h, STAT5 phosphorylation of cells was assessed by intracellular flow cytometry (left, representative FACS diagrams showing CD123 S59P status at different hIL-3 doses; right, pSTAT5 PE MFI).

[0128] Fig.38 D shows that the variants of FLT3, KIT, and CD123 epitope engineering induce a proliferation response similar to that of the WT receptor. BaF3 cells expressing FLT3, KIT, and CD123 variants by Sleeping Beauty transposase were left in a state of lacking murine IL-3 overnight, and stimulated with different concentrations of human FLT3, SCF, and IL-3, respectively. Cells were cultured for 5 days and analyzed by flow cytometry to obtain absolute counts (CountBead). The figure reports the absolute counts normalized by unstimulated conditions.

[0129] Fig.39 A top shows a schematic diagram of a bidirectional lentiviral vector (LV) co-expressing a second-generation CAR and a truncated human epidermal growth factor receptor (EGFRt); and the bottom shows a schematic diagram of T cell culture, transduction, and analysis for generating CAR-T cells.

[0130] Fig.39 B shows the percentage (left) and fold expansion (right) of EGFRt surface expression on T cells at the indicated days (D) after transduction with LV 4G8-CAR at different multiplicities of infection (MOI).

[0131] Fig.39 C shows that FLT3 N399D or N399G avoids 4G8 CAR killing. K562 cells expressing FLT3 variants through Sleeping Beauty transposase were cultured with 4G8 CAR-T cells at different effector: target ratios (E: T). Left: Representative flow cytometry images of K562 cells expressing FLT3 WT or N399D after 48h of co-culture with 4G8CAR. T cells and target cells were identified by CD3 and FLT3 staining, respectively. From left to right, i) a graph reporting the fraction of sustained live target cells relative to E: T = 0 (absolute counts of AnnexinV-7AAD- cells); ii) T cell activation (%) stained by CD69 and iii) FLT3 surface expression on residual live target cells by BV10A4 staining, normalized to E: T = 0. Mean ± SD (N = 4). Comparison was made by two-way ANOVA.

[0132] Fig.39 D shows that KIT H378R avoids 79D CAR killing. Left: Representative flow cytometry images of K562 cells expressing KIT WT or H378R by Sleeping Beauty transposase after 48 h of co-culture with 79D CAR. T cells and target cells were identified by CD3 and KIT staining, respectively. From left to right, the figure reports i) the fraction of persistent live target cells relative to E: T = 0 (absolute counts of AnnexinV-7AAD- cells); ii) T cell activation (%) by CD69 staining and iii) KIT surface expression on residual live target cells by 104D2 staining, normalized to E: T = 0. K562: Not transduced. Mean ± SD (N = 4). Comparison was performed by two-way ANOVA.

[0133] Fig.39 E shows CD123 S59BE cells are resistant to CSL362 CAR. Left: Representative flow cytometry graphs of CD123 base-edited or unmodified CD123 reporter K562 after 48h co-culture with CSL362 CAR. T cells are identified by CD3 / 4 / 8 staining. From left to right-the figure reports i) the fraction of sustained live target cells relative to E:T=0 (absolute counts of AnnexinV-7AAD- cells); ii) T cell activation (%) stained by CD69 and iii) CD123 surface expression on residual live target cells by 9F5 staining. Mean ± SD (N = 4). Comparison was performed by two-way ANOVA.

[0134] Fig.40 A shows the CD4 / CD8 composition of CAR-T cells during in vitro culture. Fresh healthy donor-derived PBMCs were cultured with CD3 / CD28 Dynabeads (bead: cell ratio = 3: 1), IL-7 5ng / mL, and IL-15 5ng / mL, and transduced with a lentiviral vector (LV) encoding 4G8CAR on day 2 (D). The culture composition was assessed by flow cytometry on days 2, 4, 6, and 12. The figure reports N=5 conditions for LV transduction with different multiplicity of infection (MOI). Mean ± SD.

[0135] Fig.40 B shows the phenotype of CAR-T cells by flow cytometry. T cell subsets (CD45RA+62L+, initial / T stem memory cells; CD45RA-62L+, central memory, CM; CD45RA-62L-, effector memory, EM; CD45RA+62L-, terminally differentiated EM cells re-expressing CD45RA, EMRA) are assessed by CD62L and CD45RA staining. Representative FACS graphs (left) and culture compositions (right) by CD4+ and CD8+ subpopulations are reported. D0 refers to uncultured peripheral blood T cells after Ficoll separation. Mean ± SD (N = 5).

[0136] Fig.40 C shows FLT3 WT Cells were eliminated by 4G8CAR-T cells, while FLT3 N399 BE cells were protected. N399Base-edited FLT3 reporter K562 cells were subjected to 4G8 CAR-T cell co-culture assay. (Left) Representative flow cytometry plots of early time points (6h) gated on live cells (AnnexinV-7AAD-). T cells were identified by CellTrace markers, while the K562 target was FLT3+. (From left to right) Target cell viability at 6h (%), T cell degranulation by CD107a surface staining at 6h (%), and FLT3 expression on viable target cells at 48h (MFI, normalized to E:T=0). N=2. Comparisons were performed by two-way ANOVA.

[0137] Fig.40 D shows that the epitope engineered receptor provides protection from CAR-T cells. Each row reports additional graphs (with Fig.39 C, 39D, 39E reported the same experiment). Columns from left to right are: CellTrace MFI of CAR-T cells at 48h of co-culture, target cell viability (%) after 48h of co-culture with CAR-T cells, target cell viability (%) after 48h of co-culture with untransduced T cells, absolute count of live cells after 48h of co-culture with untransduced T cells (AnnexinV-7AAD-, normalized to E:T=0), CD69+ untransduced T cells after 48h of co-culture (%), FLT3, CD123 and KIT MFI on target cells after 48h of co-culture with untransduced T cells (unnormalized). Mean ± SD, N = 4.

[0138] Fig.40 E shows the experimental layout of co-culture assay with two target cell populations, one expressing FLT3 and the other expressing CD123. Unmodified or epitope-edited FLT3 and CD123 K562 reporter cells were mixed at a ratio of about 1: 1 and co-cultured with T cells expressing 4G8 CAR, CSL362 CAR or untransduced. The percentage of FLT3+ / CD123+ composition of live target cells (pre-gated for FLT3+ or CD123+) is reported in the form of a bar graph of each composition of different effectors: target (E: T) ratios. Mean ± SD, N = 4.

[0139] Fig.41 A is a schematic diagram of CD34+ HSPC culture, base editing and analysis. mPB, mobilized peripheral blood; HSPC, hematopoietic stem and progenitor cells; FLT3L, FLT3 ligand; SCF, stem cell factor; TPO, thrombopoietin; SR-1, StemRegenin.

[0140] Fig.41B is a representative graph reporting the editing window and editing efficiency of CD34+ HSPCs for each adenine within the gRNA sequence for FLT3, KIT, and CD123 measured after electroporation with different doses of adenine BE mRNA. Mean ± SD.

[0141] Fig.41 C shows editing efficiency in bulk CD34+ cells or FACS sorted stem cell-enriched CD90+ or ​​stem cell-depleted CD90- subsets. Mean ± SD (N = 2 donors).

[0142] Fig.41 D shows the immunophenotype of epitope-edited CD34+ HSPCs. Left: Representative flow cytometry images showing the CD90 / CD45RA subset within CD34+133+ HSPCs during in vitro culture on day 5 after base editing. Right: Representative flow cytometry images showing FLT3 N399 、KIT H378R 、CD123 S59 Bar graph of CD90 / CD45RA subset composition of epitope-edited CD34+ cells. Mean ± SD. Sample sizes are reported in the bar graphs.

[0143] Fig.41 E is in FLT3 N399 In vitro 4G8 CAR killing assay performed on epitope-edited HSPCs. 48h after co-culture with 4G8 CAR or non-transduced T cells, the fraction of persistent live cells (left) and the viability of CD34+45RA+ cells (FLT3 base-edited or AAVS1 base-edited) stained by AnnexinV-7AAD (right). Mean ± SD (N = 4). Comparison by two-way ANOVA.

[0144] Fig.41 F is in CD123 S59 In vitro CSL362 CAR killing assay performed on epitope-edited HSPCs. After 48 h of co-culture with CSL362CAR or untransduced T cells, CD123 S59 The fraction of persistently viable CD90+ cells in AAVS1-BE or AAVS1-BE HSPCs (left) and CD34+ cell viability by Annexin V-7AAD staining (right). N=8, 2 different HSPC donors. Comparisons were performed by two-way ANOVA

[0145] Fig.41 G shows KIT relative to a no mAb control plated with increasing concentrations of Fab-79D mAb and cultured for 48 h. H378Absolute fraction of live CD34+ cells of BE or AAVS1 BE HSPCs. Mean ± SD. N = 6, 2 different HSPC donors. Comparisons were performed by two-way ANOVA.

[0146] Fig.41 H shows absolute counts of total CD34+ and CD90+45RA- cells (upper left) and myeloid and erythroid colonies (N=2, lower left) of base-edited HSPCs. Right: Representative images of CFU plates (one of two replicates) 14 days after plating.

[0147] Fig.41 I is FLT3 N399 Schematic representation of primary and secondary xenotransplantation and analysis of AAVS1 or AAVS1 BE HSPCs.

[0148] Fig.41 J Left shows human engraftment (hCD45+ cells) in primary recipients at different time points by flow cytometry; and right shows BM lineage composition as a percentage of total human (hCD45+) cells by flow cytometry. PMN, polymorphonuclear granulocyte; mono, monocyte; lin-, lineage negative. Mean ± SD. FLT3 N399 N = 7, AAVS1 BE N = 4. Comparisons were made by two-way ANOVA.

[0149] Fig.41 K shows the level of FLT3 editing in total circulating cells, hematopoietic organs or CFU measured at different time points for primary and secondary transplanted mice. Mean ± SD. LC, liquid culture; W8, week 8; W12, week 12; SP, spleen; BM, bone marrow; CFU, colony forming unit.

[0150] Fig.42 A is a schematic representation of a plasmid template for in vitro transcription (IVT) of base editor mRNA. The template was linearized using the type IIS restriction enzyme BbsI. T7, T7 RNA polymerase promoter; UTR, untranslated region; HBB, hemoglobin beta gene; polyA, polyadenine sequence (about 110-120 nt).

[0151] Fig.42 B is a representative image of purified IVT SpRY-ABE8 emRNA analyzed for quality control using the Agilent Fragment Analyzer RNA. >90% of the IVT mRNA corresponds to the predicted size.

[0152] Fig.42 C is a comparison of sgRNA-18 targeting FLT3 N399Dose-finding testing of SpRY-ABE8e V106W mRNA in base-edited FLT3 reporter K562 cells. On the right is the correlation of FLT3 editing efficiency by flow cytometry with mRNA x sgRNA dose and by flow cytometry with gDNA analysis. Spearman r is reported. 2 and p-value.

[0153] Fig.42 D shows CD34+ HSPC base editing mRNA optimization. Several SpRY-ABE8e mRNA variants were tested in dual FLT3 / CD123 editing experiments. Variables tested included: mRNA purification method (beads, sparQ PureMag magnetic beads; columns, NEB Monarch RNA columns), dephosphorylation, replacement of UTP with N1-methylpseudouridine (N1m-U) or 5-methoxyuridine (5me-U), capping technology (CleanCap, Trilink CleanCap AG; ARCA, NEB 3′-O-Me-m7G(5′)ppp(5′)G RNA cap structure analog), and addition of the K918N SpCas9 mutation (reported to improve nuclease efficiency) 64 The bar graphs show the FLT3 and CD123 editing efficiency (%) by genomic DNA (gDNA) analysis and the absolute counts of bulk (CD34+) and stem cell-enriched (CD90+45RA-) cells at the end of in vitro culture.

[0154] Fig.42 E shows the optimization of culture conditions for base editing. CD34+ HSPCs were cultured with SpRY-ABE8e mRNA and FLT3 N399sgRNA was base edited and supplements were added during electroporation (RNAsin, Promega RNAsin RNAse inhibitor; glycerol) or under different culture conditions, including adjustment of cytokine concentrations (standard: 100 ng / mL FLT3L, SCF and 50 ng / mL TPO; 1.5x: 150 ng / mL FLT3L, SCF and 75 ng / mL TPO; 3x: 300 ng / mL FLT3L, SCF and 150 ng / mL TPO; +IL-3: standard, with hIL-3 20 ng / mL added), different stem cell retention compounds (standard: SR-1 0.75 μM, UM171 35 nM; SR-1 only 0.75 μM; UM171 only 35 nM; no SR-1 / UM171), and addition of anti-inflammatory compounds (PGE2, prostaglandin-E2 10 μM; DEX, dexamethasone 1 μM). Bar graphs show FLT3 editing efficiency (%) by gDNA analysis and absolute counts of bulk (CD34+) and stem cell-enriched (CD90+45RA-) cells at the end of in vitro culture.

[0155] Fig.42 F is a bar graph. CD34+HSPCs were electroporated at different time points (24h, 48h, 72h) after thawing. Each condition was edited for all combinations of two of our selected targets (FLT3, CD123, KIT). The bar graph shows the editing efficiency (%) analyzed by gDNA and the absolute counts of bulk (CD34+) and stem cell-enriched (CD90+45RA-) cells at the end of in vitro culture.

[0156] Fig.42 G is a representative flow cytometry graph showing the gating strategy for analyzing edited CD34+ HSPCs. From left to right, cells are gated for single state (FSC-H / FSC-A graph), live (PI / FSC-A graph; PI, propidium iodide), physical parameters (SSC-A / FSC-A graph), CD34+ (CD34 / CD90 graph), CD133+ (CD34 / CD133 graph), and CD45RA-90+, CD45RA-90-, CD45RA+90- (CD45RA / 90 graph). After pre-gating for single state (S), bead (B) gating can identify CountBead (FSC-A low PI high ), which were further gated according to two additional fluorescence parameters to exclude debris (not shown).

[0157] Fig.42H shows that epitope-edited HSPCs retain a proliferative response to cytokine stimulation. FLT3, KIT and CD123 base-edited CD34+ HSPCs were seeded with different concentrations of the corresponding ligands and cultured for 4 days. Absolute counts were obtained by flow cytometry using CountBead.

[0158] Fig.42 I shows the editing efficiency at the experimental endpoint (technical replicates were pooled together for gDNA analysis) (see Fig.42 H). Mean ± SD. N = 4, 2 healthy donors. Two-way ANOVA multiple comparisons.

[0159] Fig.43 A shows the expression of hCD45+ in 4% of the samples from Figure 3 Human engraftment in peripheral blood at week 12 (W12) and in bone marrow (BM) at endpoint in secondary recipient NBSGW mice of BM cell xenografts from the experiment depicted in I (each naive mouse was engrafted into one secondary recipient mouse). Mean ± SD. Comparisons were made by two-way ANOVA.

[0160] Fig.43 B shows the absolute counts of myeloid (left) and lymphoid (right) lineages in the BM of secondary xenografted mice. BE N=4, FLT3 N399 N = 7. Mean ± SD. Comparisons were performed by two-way ANOVA. HSC, hematopoietic stem cell; MPP, multipotent progenitor cell; LMPP, lymphoid preconditioned multipotent progenitor cell; CMP, common myeloid progenitor cell; GMP, granulocytic monocytic progenitor cell; myeloid blasts, defined as CD33 / 66b+19-14-11c-34-SSC low ; mono, monocyte; iPMN, immature polymorphonuclear granulocyte; mature PMN, mature granulocyte.

[0161] Fig.43 C shows the expression of 1MCD34+HSPC (AAVS1 or KIT) in peripheral blood and xenotransplanted at week 9 and 11 (W9 and W11) by flow cytometry. H378 Human engraftment (% hCD45+) in the BM of NBSGW (edited). Mean ± SD. Comparisons were made by two-way ANOVA.

[0162] Fig.43 D shows the absolute counts of myeloid (left) and lymphoid (right) lineages in the BM of mice from C. Comparisons were made by two-way ANOVA. AAVS1 N=5, KIT H378 N=4.

[0163] Fig.43E shows KIT editing efficiency measured on liquid culture (LC), total blood cells at week 9 (W9) post-transplantation, and on FACS-sorted B (CD19) and myeloid (CD33) BM cells at the end of the experiment. Mean ± SD.

[0164] Fig.43 F is a schematic representation of a lentiviral vector encoding mNeonGreen fluorescent protein under the hPGK promoter used to transduce human PDX (left); and is a representative flow cytometry graph showing the transduction efficiency of patient-derived AML xenografts on bone marrow (PDX-1) or spleen (PDX-2) samples (right). PDX cells were transduced overnight ex vivo, transplanted into NBSGW mice for expansion, and mNeonGreen+ cells were FACS sorted and injected into secondary recipients.

[0165] Fig.43 G shows the genetic characteristics (left) and surface immunophenotype (right) of AML PDX at thaw for in vivo experiments. The heat map reports the genetic mutations and the percentage of positive cells for each marker. ITD, internal tandem duplication; TKD, tyrosine kinase domain mutation.

[0166] Fig.44 A: FLT3 co-transplanted with AMLPDX-1 and treated with 4G8CAR-T cells N399 Schematic representative diagram of xenotransplantation and analysis of AAVS1 or AAVS1 BE HSPCs.

[0167] Fig.44 B shows FLT3 base editing measured in liquid culture (LC), total blood cells (weeks 8, 9), and sorted CD33+ and CD19+ bone marrow (BM) cells at the end point of mice treated or untreated with 4G8CAR-T cells. Multiple unpaired t-test. Mean ± SD.

[0168] Fig.44 C is a representative flow cytometry image of BM samples from mice transplanted with CD34+HSPC, CD34+HSPC+AML PDX-1 or CD34+HSPC+AML PDX-1 and treated with 4G8 CAR--T. The figure is pre-gated for human CD45+; CART cells are identified by CD3 staining, and AML PDX cells are mNeonGreen+. Mean ± SD. Comparison was performed by one-way analysis of variance.

[0169] Fig.44 D is a bar graph showing the percentage of CD3+ cells within hCD45+mNeonGreen-BM cells. Mean ± SD. Comparisons were made by one-way ANOVA.

[0170] Fig.44 E is a bar graph showing the percentage of AML cells within hCD45+CD3- BM cells. Mean ± SD.

[0171] Fig.44 F is a bar graph showing the percentage of AML (mNeonGreen+) cells in total BM-derived CFU measured by flow cytometry. Mean ± SD. FLT3 was analyzed by one-way ANOVA. N399 Statistical comparisons were made with the AAVS1 BE condition.

[0172] Fig.44 G is shown with FLT3 N399 Representative FACS plots of BM B cell (CD19+) depletion by 4G8 CAR-T in mice transplanted with AAVS1 BE HSPCs or AAVS1 BE HSPCs. The plots are pre-gated for hCD45+CD3-mNeonGreen-.

[0173] Fig.44 H, 44I and 44J are diagrams showing pre-B (CD19+10+34-) within hCD45+CD3-mNeonGreen- Fig.44 H), pro-B (CD19+10+34+) ( Fig.44 I) and immature granulocytes (CD33 / 66b+14-10-11c-SSC) in myeloid cells (CD33 / 66b+ high )( Fig.44 I) Bar graph of percentages. Mean ± SD. One-way ANOVA was performed to analyze the FLT3 N399 Statistical comparisons were made with the AAVS1 BE condition.

[0174] Fig.44 K is a representative FACS plot showing the composition of lineage-CD34+38+10- progenitor cells. Granulomonocytic progenitors (GMMPs) are defined as CD45RA+FLT3+, common myeloid progenitors (CMPs) are defined as CD45RA-FLT3+, and megaloerythroid progenitors (MEPs) are defined as CD45RA-FLT3-.

[0175] Fig.44 L is a bar blot showing the % GMP within lin-CD34+38+. Mean ± SD.

[0176] Fig.44 M shows the absolute counts of myeloid lineage subsets from HSC to differentiated leukocytes in BM. Untreated mice were pooled together (grey bars), 4G8-treated FLT3 N399and AAVS1 BE mice are reported in pink and yellow, respectively. Mean ± SD. Absolute counts in the CAR-treated group (FLT3 N399 Fold changes of 4G8 CAR-treated FLT3 N399 FDR adjusted p-values ​​for comparisons to AAVS1 BE conditions (p<0.05 in bold).

[0177] Fig.44 N is a representative FACS plot showing the composition of lineage-CD34+38-10- progenitor cells. Stem cells (HSC) are defined as CD45RA-90+, multipotent progenitor cells (MPP) are defined as CD45RA-90-, and lymphoid primed MPP (LMPP) are defined as CD45RA+90-.

[0178] Fig.44 O is a bar graph showing LMPP% within lin-CD34+38-. Mean ± SD.

[0179] Fig.44 P shows the absolute counts of lymphoid lineage subsets from HSC to differentiated leukocytes in BM. preB / NK is defined as CD33 / 66b-19-56-34+38+10+, B prolymphocytes are defined as CD33 / 66b-19-56-34-10+, pro-B cells are defined as CD33 / 66b-19+10+34+, pre-B cells are defined as CD33 / 66b-19+10+34-, and mature B cells are defined as CD33 / 66b-19+10-34-. Untreated mice were pooled together (grey bars), 4G8-treated FLT3 N399 and AAVS1 BE mice are reported in pink and yellow, respectively. The absolute counts of the CAR-treated group (FLT3 N399 Fold changes of 4G8 CAR-treated FLT3 cells were reported. N399 FDR adjusted p-values ​​for comparisons to AAVS1 BE conditions (p<0.05 in bold).

[0180] Fig.45 A shows the use of AAVS1 at 8 weeks BE and FLT3 N399 Peripheral blood lineage composition of HSPC xenografted NBSGW mice. Mean ± SD. AAVS1 BE N=13, FLT3 N399 N = 18. Statistical comparisons were performed by unpaired t-test.

[0181] Fig.45 B shows that lineage-negative CD34+ progenitor cells were depleted by 4G8CAR-T in vivo and FLT3 N399 Edit protection (from Fig.44 Representative flow cytometry plots of lineage-negative cells (mNeonGreen-CD3-19-14-11c-56-) with CD34+ progenitor gating (percentages reported within the gate).

[0182] Fig.45 C shows the percentage of lin-CD34+ cells within hCD45+3-mNeonGreen-BM cells. Mean ± SD. Comparison was performed by one-way ANOVA.

[0183] Fig.45 D shows the Fig.44 Relative composition of BM lin-CD34+ in mice. Mean ± SD. Two-way ANOVA with multiple comparisons (only AAVS1 and FLT3 are reported) N399 HSC, hematopoietic stem cell; MPP, multipotent progenitor cell; LMPP, lymphoid preconditioning multipotent progenitor cell; CMP, common myeloid progenitor cell; GMP, granulomonocytic progenitor cell; MEP, megaloerythroid progenitor cell.

[0184] Fig.45 E shows the expression (MFI) of FLT3 on myeloid (left) and lymphoid (right) BM subsets at the end point. BE LMPP, MPP, and HSC under different conditions were not evaluable (NE). Mean ± SD. Statistical differences were reported by multiple unpaired t-test.

[0185] Fig.45 F shows the Fig.44 Phenotype of CAR cells by flow cytometry in mouse BM. CD45RA+62L+, naive; CD45RA-62L+, central memory, CM; CD45RA-62L-, effector memory, EM; CD45RA+62L, terminally differentiated EM cells that re-express CD45RA and EMRA.

[0186] Fig.45 G is a bar graph reporting (from left to right) the percentage of EGFRt+ in BM CD3+ cells, the percentage of PD1(CD279) MFI on BM CD8+CAR T cells, and the percentage of PD1(CD279) MFI on BM CD4+CAR T cells. Mean ± SD. AAVS1 by one-way ANOVA is reported.BE FLT3 N399 Comparison between conditions.

[0187] Fig.45 H shows the expression of AAVS1 at 10 weeks BE and CD123 S59 Peripheral blood lineage composition of HSPC xenografted NBSGW mice (from Fig.46 Experiments). Mean ± SD (N = 11). Statistical comparisons by unpaired t-test are reported.

[0188] Fig.45 I shows that lineage-negative CD34+ progenitor cells are depleted in vivo by CSL362 CAR-T (from Fig.46 On the left, a representative flow cytometric plot of lineage negative cells (mNeonGreen-CD3-19-14-11c-56-) gated on CD34+ progenitors. On the right, a representative flow cytometric plot of lin-CD34+38-10- cells gated on HSC (CD45RA-90+), MPP (CD45RA-90-), and LMPP (CD45RA+90-) subsets.

[0189] Fig.45 J shows the Fig.46 Relative composition of BM lin-CD34+ in mice. Mean ± SD. Two-way ANOVA with multiple comparisons (only AAVS1 and CD123 are reported) S59 HSC, hematopoietic stem cell; MPP, multipotent progenitor cell; LMPP, lymphoid preconditioning multipotent progenitor cell; CMP, common myeloid progenitor cell; GMP, granulomonocytic progenitor cell; MEP, megaloerythroid progenitor cell.

[0190] Fig.46 A was co-transplanted with AML PDX-1 and treated with 5M CSL362 CAR - CD123 for T cell therapy S59 Schematic representative diagram of xenotransplantation and analysis of AAVS1BE or AAVS1BE HSPCs.

[0191] Fig.46 B shows CD123 base editing measured on total blood cells (weeks 8, 10) and sorted CD33+ and CD19+ myeloid (BM) cells at the end point of mice treated or untreated with CSL362 CAR-T cells. S59 N = 6, AAVS1 BE N = 5. Mean ± SD. Statistical comparisons were performed by multiple unpaired t-test.

[0192] Fig.46C shows representative flow cytometry images of BM samples from mice implanted with CD34+HSPC+AML PDX-1, treated or untreated with CSL362 CAR-T, and implanted with AML PDX-1 alone. The image is pre-gated for total human CD45+; CAR-T cells are identified by CD3 staining, while AML PDX cells are mNeonGreen+.

[0193] Fig.46 D is a bar graph showing the percentage of AML PDX cells within hCD45+CD3- BM cells. Mean ± SD.

[0194] Fig.46 E is a bar graph showing the percentage of CD3+ cells within hCD45+mNeonGreen-BM cells. Mean ± SD.

[0195] Fig.46 F is a bar graph showing the absolute counts of total hCD45+3-mNeonGreen- cells in BM. Mean ± SD.

[0196] Fig.46 G is a bar graph showing the percentage of pro-B cells (CD19+10-34-) in human CD45+3-mNeonGreen-BM cells. Mean ± SD. CD123 S59 Statistical comparisons were made with the AAVS1 BE condition.

[0197] Fig.46 H on the left shows the CD123 S59 Representative FACS plots showing depletion of BM myeloid cells (CD33 / 66b+19-, highlighted by orange gating) by CSL362CAR-T in mice transplanted with or AAVS1 BE HSPCs; and the right side shows depletion of granulocytes (PMN, CD33 / 66b+19-14-SSC high , orange gated) representative FACS images

[0198] Fig.46 I, 46J and 46K show total myeloid cells (CD33 / 66b+19- in hCD45+ cells) (46I), PMN (CD33 / 66b+19- in CD33 / 66b+19- cells) (46J), immature PMN (CD33 / 66b+19- in CD33 / 66b+19- cells) (46J), high Bar graph of the percentage of (46K). Mean ± SD. CD123 was analyzed by one-way ANOVA S59Statistical comparisons were made with the AAVS1 BE condition.

[0199] Fig.46 L is shown in CD123 S59 Representative flow cytometry plots of dendritic cell (DC) subset loss by CSL362 CAR-T in mice transplanted with AAVS1 BE HSPC or AAVS1 BE HSPC. Left: conventional DC (cDC, CD33 / 66b+14-11c+FLT3+SSC low ), the figure shows CD33 / 66b+14-SSC low Cell gating. Right: plasmacytoid DC (pDC, CD33 / 66b+14-11c-FLT3+CD123 high SSC low ), the figure shows CD33 / 66b+14-11c-SSC low Cell gating.

[0200] Fig.46 M and 46N are bar blots showing the percentage of cDCs and pDCs within hCD45+3-mNeonGreen- cells, respectively.

[0201] Fig.46 O shows the percentage of lineage-CD34+ progenitor cells within hCD45+3-mNeonGreen- cells. Mean ± SD. CD123 S59 Statistical comparisons were made with the AAVS1 BE condition.

[0202] Fig.46 P and 46Q show the absolute counts of myeloid (P) and lymphoid (Q) lineage subsets from HSC to differentiated leukocytes in BM. Untreated mice were pooled together (grey bars), while CD123 S59 and AAVS1 BE mice are reported in pink and blue, respectively. The absolute counts of CAR-treated groups (CD123 S59 Fold changes of 4G8 CAR-treated CD123 cells were reported. S59 FDR adjusted p-values ​​for comparisons to AAVS1 BE conditions (p<0.05 in bold).

[0203] Fig.47 A shows CD123 expression (MFI) on myeloid (left) and lymphoid (right) BM subsets at endpoint. Mean ± SD. Statistical differences by multiple unpaired t-test are reported.

[0204] Fig.47B shows that 4G8CAR T cells deplete PDX-1 in vivo but cannot eradicate PDX-2.NSBGW female mice were xenotransplanted with AML PDX cells and treated with 4G8 CAR-T cells 10 days later.The experimental endpoint was 14 days after CAR-T administration.From left to right, the bar graph shows the percentage of AML PDX cells in total CD45+ cells in bone marrow (BM), the percentage of AML PDX cells in total CD45+ cells in spleen (SP), the absolute count of BM T cells, the FLT3 MFI of surviving AML cells in BM, and the FLT3 MFI of surviving AML cells in SP.Mean ± SD.Compared by one-way analysis of variance.

[0205] Fig.47 C shows that 4G8CAR T cells deplete PDX-1 in vivo but fail to deplete AAVS1 BE and FLT3 N399 PDX-2 was eradicated in HSPC-pre-implanted mice. NBSGW mice were xenografted with edited HSPCs and injected with PDX-1 or PDX-2 cells 11 weeks later. After 10 days, mice were treated with 2.5M 4G8 CAR-T cells and the results were assessed after 2 weeks. The percentage of AML cells within total BM hCD45+ cells is reported in the bar graph. Mean ± SD. Comparisons were made by one-way ANOVA.

[0206] Fig.47 D shows that the CAR-T cell combination has an improved effect on PDX-2 in vivo. NBSGW mice were xenotransplanted with 0.75MPDX-2 cells, and after 10 days, treated with 2.5M 4G8 CAR or 4G8+CSL362, 4G8+Fab79D or CSL362+Fab79DCAR T cell combination (each 2.5M). The results were evaluated two weeks later. The bar graph shows the percentage of AML cells in total BM hCD45+ cells. Mean ± SD. Multiple comparisons by one-way ANOVA with no treatment.

[0207] Fig.47 E shows the use of AAVS1 at 9 weeks BE and double-edited FLT3 N399 / CD123 S59 Peripheral blood lineage composition of HSPC xenografted NBSGW mice (from Fig.49 D experiments). Statistical comparisons were performed by unpaired t-test. Mean ± SD.

[0208] Fig.48 A is for mice xenografted with edited HSPCs and / or AML PDX (from Fig.46Representative flow cytometry gating strategy for bone marrow analysis of experiments with CAR. Cells were pre-gated with single state, live and physical parameters. Populations: 1. Human CD45+; 2. T cells (CAR); 3. mNeonGreen+ (AML PDX); 4. Human CD45+ w / o CAR or AML; 5. Total CD19+; 6. Total myeloid cells (CD33 / 66b+); 7. Granulocytes + mast cells; 8. Monocytes; 9. Mast cells; 10. Total granulocytes; 11. Mature granulocytes (CD10+ / 11c+); 12. Immature granulocytes (CD10- / 11c-); 13. Classical dendritic cells, cDC; 14. pro-B cells; 15. pre-B cells; 16. Mature B cells; 17. Natural killer cells, NK; 18. Prolymphocytes; 19. Myeloid blasts; 20. lin-CD34+ (CD33 / 66+lin-CD34+ and CD33 / 66-lin-CD34+ are pooled for downstream gating); 21.Lin-CD34+38+; 22.Lin-CD34+38-; 23.Pre-B / NK; 24.GMP; 25.CMP; 26.MEP; 27.HSC; 28.MPP; 29.LMPP; 30.Bead gate; 31.Mouse CD45+; 32.Plasmacytoid DC; 33.MLP. First, CountBead is gated in single state as FSC-A low PI high , and then gated using two additional fluorescence parameters (plotted in the lower left corner).

[0209] Fig.48 B is a representative flow cytometry gating strategy for T cell panels on bone marrow and spleen. Cells were pre-gated with single state, live and physical parameter gates. Human CD45+ cells were divided into CD3+ (T cells) and CD3-, with residual AML gated as mNeonGreen+. CAR+ cells were identified by EGFR staining. T cell phenotype was assessed by CD45RA and CD62L with gated CD8+ and CD4+ cells.

[0210] Fig.49 A shows FLT3 alone measured on either autologous cells or FACS sorted CD90+ primitive progenitor cells N399 or with KIT H378R The efficiency of combined CD34+ HSPC base editing was reported from Fig.41 C's KIT H378R Single edits were used for comparison. Mean ± SD.

[0211] Fig.49 B is a representative flow cytometry graph of dual FLT3 / CD123 reporter K562 cells showing loss of recognition by 4G8 and 7G3 mAbs after multiple epitope editing.

[0212] Fig.49 C shows that the edited cells in each quadrant of B were FACS sorted and then co-cultured with bispecific FLT3 / CD123 CAR-T cells. The percentage of live target cells (left), T cell activation (CD69 expression, middle) and degranulation (CD107a surface expression, right), the median fluorescence intensity (MFI) of CellTrace markers on T cells, and the FLT3 and CD123 surface expression (MFI) on target cells are reported in different E: T ratios. Mean ± SD (N = 4). Statistical comparison was performed by two-way ANOVA.

[0213] Fig.49 D is a double FLT3 tumor co-transplanted with AML PDX-2 and treated with a 1:1 pool of 4G8 and CSL362 CAR-T cells. N399 / CD123 S59 Schematic representation of xenotransplantation and analysis of epitope-edited or AAVS1 BE HSPCs.

[0214] Fig.49 E shows PDX from CD34+HSPC, CD34+HSPC+AML - Representative flow cytometry plots of BM samples from mice transplanted with 4G8 / CSL362 CAR or CD34+HSPC+AML PDX-2. The plots are pre-gated with total human CD45+; CAR T cells are identified by CD3 staining, and AML PDX cells are mNeonGreen+.

[0215] Fig.49 F is a bar graph showing the percentage of AMIPDX cells within hCD45+CD3- BM cells. Mean ± SD. Statistical comparisons were performed by one-way ANOVA.

[0216] Fig.49 G shows FLT3 (left) and CD123 (right) base editing measured on total blood cells (weeks 9, 10) and sorted CD33+ and CD19+ BM cells at the end point of mice from D. Mean ± SD. Statistical comparisons were performed by multiple unpaired t-tests.

[0217] Fig.49H shows the absolute counts of myeloid (left) and lymphoid (right) lineage subsets in BM from HSCs to differentiated leukocytes. Untreated mice were pooled together (grey bars), CAR-treated FLT3 N399 +CD123 S59 Mice are reported in pink and CAR-treated AAVS1 BE Mice are reported in blue. Absolute counts of CAR-treated groups (FLT3 N399 +CD123 S59 Fold changes of 4G8 CAR-treated FLT3 cells were reported. N399 / CD123 S59 FDR-adjusted p-values ​​for comparisons with AAVS1 BE conditions (p<0.05 in bold). DETAILED DESCRIPTION

[0218] Identifying suitable proteins for targeted cancer therapy is a major challenge. Many potential target proteins are present both on the cell surface of cancer cells and on the cell surface of normal non-cancerous cells, and the target proteins may be required or critically involved in the development and / or survival of the subject. Many target proteins contribute to the function of such essential cells. Therefore, therapies targeting these proteins may cause harmful effects on the subject, such as significant toxicity and / or other side effects. In addition, resistance to CAR-T therapy remains a challenge for the treatment of hematopoietic malignancies such as acute myeloid leukemia (AML), which escape CAR-T therapy due to the conversion of cancer antigens on cancer cells.

[0219] Therefore, the present disclosure provides methods, cells, compositions and kits for solving at least the above problems. The methods, cells, compositions and kits described herein provide safe and effective treatment for hematological malignancies, and the treatment allows targeting to be present not only on cancer cells but also on cells that are essential for the development and / or survival of the subject. One or more cell surface proteins. In some cases, genetically engineered hematopoietic cells such as hematopoietic stem cells (HSPC) with genetic editing in one or more genes encoding cell surface proteins (e.g., FLT3, CD123 and / or KIT) are described herein; Methods for producing such cells, for example, via CRISPR methods using specific guide RNAs; Methods for treating hematopoietic malignancies using engineered hematopoietic cells alone or in combination with one or more cytotoxic agents (e.g., CAR-T cells), the one or more cytotoxic agents can target wild-type cell surface antigens but not target those antigens encoded by the genes edited in engineered hematopoietic cells; and kits comprising engineered hematopoietic cells.

[0220] I. Genetically Engineered Hematopoietic Cells

[0221] In some embodiments, the genetically engineered hematopoietic cell has the FLT3 gene, CD123 gene or KIT gene edited.In some cases, one or more of these genes mutate.In some cases, the FLT3 gene, CD123 gene or KIT gene mutated include mutation or disappearance of one or more non-essential epitopes, to retain the biological activity of (all or part of) FLT3 gene, CD123 gene or KIT gene.

[0222] i. Hematopoiesis

[0223] In some embodiments, hematopoietic cells described herein are hematopoietic stem cells.Hematopoietic stem cells / progenitor cells (HSPC) can produce myeloid progenitor cells and lymphoid progenitor cells, and these progenitor cells further produce myeloid cells (e.g., monocytes, macrophages, neutrophils, basophils, dendritic cells, erythrocytes, platelets, etc.) and lymphocytes (e.g., T cells, B cells, NK cells) respectively.HSPC is characterized by the expression of cell surface marker CD34 (e.g., CD34+), which can be used for the identification and / or separation of HSPC.

[0224] In some embodiments, HSPC is obtained from a subject (such as a mammalian subject). In some embodiments, the mammalian subject is a non-human primate, a rodent (such as a mouse or a rat), a cow, a pig, a horse or a domestic animal. In some embodiments, HSPC is obtained from a human patient (such as a human patient with a hematopoietic malignancy). In some embodiments, HSPC is obtained from a healthy donor. In some embodiments, HSPC is obtained from a subject to which genetically engineered HSPC will be subsequently administered. The HSPC administered to the same subject to obtain cells is referred to as autologous cells, and the HSPC obtained from a subject different from the subject to which cells will be administered is referred to as allogeneic cells (the method for reducing the incidence of rejection is standard and well known in the art).

[0225] HSPC can be obtained from any suitable source using conventional means known in the art. In some embodiments, HSPC can be obtained from a sample (such as a bone marrow sample or a blood sample) of a subject (or donor). Alternatively or in addition, HSPC can be obtained from the umbilical cord (i.e., umbilical cord blood cells). In some embodiments, HSPC is from bone marrow, umbilical cord blood cells, or peripheral blood mononuclear cells (PBMC). In general, bone marrow cells can be obtained from the iliac crest, femur, tibia, spine, ribs, or other bone marrow cavities of a subject (or donor). Bone marrow can be removed from the patient and separated by various separation and washing procedures known in the art. An exemplary procedure for separating bone marrow cells comprises the following steps: a) extracting a bone marrow sample; b) centrifuging the bone marrow suspension into three parts and collecting the middle part or buffy coat; c) separating the buffy coat part in step (b) in a separation fluid (usually Ficoll TM ) and collecting the middle portion containing the bone marrow cells; and d) washing the portion collected in step (c) to recover the bone marrow cells that can be re-transfused.

[0226] HSPC is usually present in the bone marrow, but can be mobilized into the circulating blood by administering a mobilizing agent so as to obtain HSPC from the peripheral blood. In some embodiments, a mobilizing agent, such as granulocyte colony stimulating factor (G-CSF), is administered to the subject (or donor) from which HSPC is obtained. The number of HSPCs collected after mobilization using a mobilizing agent is generally greater than the number of cells obtained without the use of a mobilizing agent.

[0227] In some embodiments, a sample is obtained from a subject (or donor) and then the desired cell type (e.g., CD34+, CD34+CD38-, CD133+, CD90+, CD49f+) is enriched. For example, PBMC and / or CD34+ hematopoietic cells can be separated from blood as described herein. Cells can also be separated from other cells, for example, by separating and / or activating antibodies that bind to epitopes on the cell surface of the desired cell type. Another method that can be used includes negative selection using antibodies against cell surface markers to selectively enrich for specific cell types without the need for activating cells by receptor binding.

[0228] II mutated cell surface antigen

[0229] In some embodiments, hematopoietic stem cells (HSPC) described herein may contain a gene encoded in a mutant form (mutant or variant, used interchangeably herein) for editing one or more cell surface proteins of interest (e.g., FLT3, CD123, KIT), which is reduced or not combined with a cytotoxic agent as described herein (e.g., anti-FLT3 antibody, anti-CD123 antibody, anti-KIT antibody). Mutants may carry one or more mutations of cytotoxic agent binding epitopes, so that compared with natural or wild-type cell surface protein counterparts, their combination with cytotoxic agents is reduced or eliminated. Such mutants preferably maintain biological activity substantially similar to that of wild-type counterparts.

[0230] As used herein, the term "combination reduction" refers to a reduction of at least 25% in combination. The binding level can refer to the binding amount of cytotoxic agents and hematopoietic stem cells or the binding amount of cytotoxic agents and cell surface proteins compared to wild-type (i.e., non-engineered, non-mutated) proteins. In some embodiments, the binding is reduced by at least 25%, 30%, 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%. In some embodiments, the binding is reduced so that there is substantially no detectable binding in conventional determinations. As used herein, "no binding" refers to substantially no binding, such as no detectable binding or only the baseline binding as determined in conventional binding determinations.

[0231] In some cases, the variant contains one or more amino acid residue substitutions (e.g., 2, 3, 4, 5 or more) within the epitope of interest, so that the cytotoxic agent does not bind to the mutated epitope or the binding to the mutated epitope is reduced. The binding affinity of such mutants to cytotoxic agents can be significantly reduced (e.g., having a binding affinity of at least 40%, 50%, 60%, 70%, 80% or 90% less than its wild-type counterpart). In some examples, such variants can eliminate the binding activity to cytotoxic agents. In other cases, the mutant contains a deletion of a region containing an epitope of interest. Such a region can be encoded by an exon. In some embodiments, the region is a domain of a cell surface protein of interest encoding an epitope. In one example, the variant simply lacks an epitope. The length of the missing region can be 3-60 amino acids, such as 5-50, 5-40, 10-30, 10-20, etc.

[0232] The mutation or deletion in the cell surface antigen mutant may be located within or around a non-essential epitope, such that the mutation or deletion does not substantially affect the biological activity of the protein.

[0233] As used herein, the term "epitope" refers to an amino acid sequence (linear or conformational) of a protein (such as a cell surface antigen) to which the CDR of an antibody binds. In some embodiments, a cytotoxic agent binds to one or more (e.g., at least 2, 3, 4, 5 or more) epitopes of a cell surface antigen. In some embodiments, a cytotoxic agent binds to more than one epitope of a cell surface antigen, and the hematopoietic cells are manipulated so that each epitope is absent and / or cannot be bound by the cytotoxic agent.

[0234] In some embodiments, the genetically engineered HSPC described herein has one or more edited genes of cell surface antigens, so that the edited gene expresses a mutant cell surface antigen with one or more non-essential epitope mutations. "Non-essential epitopes" (or fragments comprising such non-essential epitopes) refer to domains within cell surface proteins / antigens, wherein mutations are unlikely to significantly affect the biological activity of cell surface proteins. For example, hematopoietic cells comprising a deletion or mutation of a non-essential epitope of a cell surface antigen, such hematopoietic cells can proliferate and / or undergo erythropoiesis differentiation to a level similar to that of hematopoietic cells expressing wild-type cell surface antigens.

[0235] The method for identifying and / or verifying the non-essential epitope in the cell surface antigen is known and recognized by those of ordinary skill in the art, and is also within the scope of the present disclosure. In addition, the method for evaluating the functionality of cell surface antigens and hematopoietic cells is known in the art, and includes, for example, proliferation assays, differentiation assays, colony formation, expression analysis (for example, gene and / or protein), protein localization, intracellular signal transduction, functional assays, and humanized mouse models in vivo.

[0236] iii. Preparation of genetically engineered hematopoietic cells

[0237] Any genetically engineered hematopoietic cell such as HSPC carrying the edited gene of one or more cell surface antigens can be prepared by conventional methods or methods described herein. In some embodiments, genetic engineering is performed using genome editing. As used herein, "genome editing" refers to a method for modifying the genome (including any protein encoding or non-coding nucleotide sequence) of an organism to change the expression of a target gene. In general, genome editing methods involve the use of endonucleases capable of cleaving genomic nucleic acids, such as at targeted nucleotide sequences. In some cases, genome editing methods involve the use of dead nucleases or nucleases that are nickases. Double-strand breaks in the genome can be repaired by introducing mutations and / or exogenous nucleic acids are inserted into targeted sites. In some cases, genome editing methods involve the use of catalytically inactivated or partially inactivated endonucleases fused to functional domains (e.g., in terms of base editors, adenine or cytidine deaminase domains). Other functional domains include lead editors, CRISPR-Cas activators or inhibitors, etc.

[0238] Genome editing methods are generally classified based on the type of endonuclease involved in generating double-strand breaks in the target nucleic acid. These methods include the use of zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), meganucleases, and CRISPR / Cas systems.

[0239] In one aspect of the present disclosure, replacement of cancer cells by a modified normal cell population is performed using normal cells that have been manipulated so that the cells will not bind to a cytotoxic agent. Such modifications can include deletion or mutation of specific cell surface protein epitopes using a CRISPR-Cas system, wherein the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas system is an engineered, non-naturally occurring CRISPR-Cas system.

[0240] The CRISPR system encodes RNA-guided endonucleases that are essential for bacterial adaptive immunity. CRISPR-associated (Cas) nucleases can be easily programmed to cleave target DNA sequences for a variety of genome editing. One class of nucleases is called the Cas9 protein, which is complexed with two short RNAs: crRNA and trans-activating crRNA (tracrRNA). The most commonly used Cas9 ortholog, SpCas9, uses a crRNA with 20 nucleotides (nt) at the 5′ end that are complementary to the “protospacer” region of the target DNA site. Effective cleavage also requires SpCas9 to recognize the protospacer adjacent motif (PAM). The crRNA and tracrRNA are usually combined into a single guide RNA (gRNA) of about 100 nt that directs the DNA cleavage activity of SpCas9. A Cas protein called Cpf1 has been identified that can also be programmed to cleave target DNA sequences. Unlike SpCas9, Cpf1 only requires a single 42nt crRNA with 23nt at the 3′ end that are complementary to the protospacer of the target DNA sequence.

[0241] In some embodiments, the Cas endonuclease is a Cas9 nuclease or a variant thereof. The Cas9 endonuclease cleaves the double-stranded DNA of the target nucleic acid to produce a blunt end. In some embodiments, the Cas endonuclease is a Cpf1 nuclease or a variant thereof. Cleavage with a Cpf1 nuclease results in staggered nucleic acid ends.

[0242] Cas9

[0243] In some embodiments, the Cas endonuclease is a Cas9 enzyme or a variant thereof. In some embodiments, the Cas9 endonuclease is derived from Streptococcus pyogenes (SpCas9) or Staphylococcus aureus (SaCas9).

[0244] The wild-type sequence of SpCas9 is as follows (SEQ ID NO: 1):

[0245]

[0246]

[0247] The wild-type sequence of SaCas9 is as follows (SEQ ID NO: 2):

[0248]

[0249]

[0250] Generally, the 3' or 5' side of the target nucleic acid is flanked by a protospacer adjacent motif (PAM), which can interact with the endonuclease and is further involved in targeting the endonuclease activity to the target nucleic acid. It is generally believed that the PAM sequence flanking the target nucleic acid depends on the endonuclease and the source from which the endonuclease is derived. For example, for the Cas9 endonuclease derived from Streptococcus pyogenes, the PAM sequence is NGG, although the PAM sequences NAG and NGA can be recognized with lower efficiency. For the Cas9 endonuclease derived from Staphylococcus aureus, the PAM sequence is NNGRRT (SEQ ID NO: 3).

[0251] Therefore, in some cases, the endonuclease is engineered / modified so that it can recognize one or more PAM sequences. In some embodiments, the endonuclease has been engineered / modified to recognize one or more PAM sequences different from the PAM sequence recognized by the unengineered / modified endonuclease. In some embodiments, the endonuclease has been engineered / modified to reduce the off-target activity of the enzyme. In some embodiments, the nucleotide sequence encoding the endonuclease is modified to change the PAM recognition of the endonuclease. For example, a Cas endonuclease (e.g., SpCas9) has a mutation at one or more of the following positions: A61, L1111, D1135, S1136, G1218, E1219, N1317, A1322, R1333, R1335, T1337. See, e.g., International Patent Application Publication Nos. WO 2016 / 141224 and WO 2017 / 040348, U.S. Patent Application Publication No. 2021 / 0284978A1, all of which are incorporated herein by reference.

[0252] In some embodiments, the Cas9 endonuclease is a wild-type version of the nuclease. For example, the Cas9 endonuclease is a SpCas9 endonuclease having a sequence of SEQ ID NO: 1 as shown above. In some embodiments, the SpCas9 endonuclease is at least 80%, such as at least 85%, 90% or 95% identical to the amino acid sequence of SEQ ID NO: 1, for example, having a difference of up to 5%, 10%, 15% or 20% with the residues of SEQ ID NO: 1, for example, substituted with conservative mutations. In preferred embodiments, the endonuclease retains the desired activity of the parent, such as nuclease activity (unless the parent is a nickase or dead Cas9), and / or the ability to interact with guide RNA and target DNA. In other cases, the Cas9 endonuclease is a SaCas9 endonuclease having a sequence of SEQ ID NO: 2 as shown above. In some embodiments, the SaCas9 endonuclease is at least 80%, such as at least 85%, 90% or 95% identical to the amino acid sequence of SEQ ID NO: 2, for example, having up to 5%, 10%, 15% or 20% difference from the residues of SEQ ID NO: 2, for example, substituted with conservative mutations. In preferred embodiments, the endonuclease retains the desired activity of the parent, such as nuclease activity (unless the parent is a nickase or dead Cas9), and / or the ability to interact with guide RNA and target DNA.

[0253] In some embodiments, the Cas9 endonuclease is a catalytically inactive Cas9. For example, the dCas9 contains a mutation at a catalytically active residue (D10, E762, D839, H983, or D986; and / or H840 or N863) and does not have nuclease activity. For example, the mutation is: (i) D10A or D10N, and / or (ii) H840A, H840N, or H840Y.

[0254] In some embodiments, the Cas9 endonuclease comprises a mutation at K918. For example, the mutation is K918N.

[0255] In some embodiments, the nucleotide sequence encoding the Cas9 endonuclease is further modified to alter the activity of the protein. In some embodiments, the Cas9 endonuclease has been modified to inactivate one or more catalytic residues of the endonuclease. In some embodiments, the Cas9 endonuclease has been modified to inactivate one of the catalytic residues of the endonuclease, referred to as a "nickase" or "Cas9n". The Cas9 nickase endonuclease cleaves one DNA strand of the target nucleic acid.

[0256] In some cases, the endonuclease is a NG-SpCas9 nickase and has the following mutations: D10A, L1111R, D1135V, G1218R, E1219F, A1322R, R1335V, T1337R (relative to wild-type SpCas9). In some cases, the endonuclease is a SpRY-Cas9 nickase and has the following mutations: D10A, A61R, L1111R, D1135L, S1136W, G1218K, E1219Q, N1317R, A1322R, R1333P, R1335Q, T1337R (relative to wild-type SpCas9).

[0257] Cpf1(Cas12a)

[0258] In some embodiments, the Cas endonuclease is a Cpf1 nuclease or a variant thereof. The Cpf1 endonuclease generally recognizes a PAM sequence located at the 5′ end of the target nucleic acid. For the Cpf1 nuclease, the PAM sequence is TTTN. Those skilled in the art will appreciate that the Cas endonuclease Cpf1 nuclease may also be referred to as Cas12a. In some embodiments, the host cell expresses a Cpf1 nuclease derived from a bacterium of the family Lachnospiraceae (LbCpf1), a certain aminoacid coccus (AsCpf1), or Francisella tularensis (FnCpf1). Each wild-type sequence is shown below.

[0259] Type V CRISPR-associated protein Cpf1 [Lachnospiraceae ND2006], GenBank accession number WP_051666128.1 (SEQ ID NO: 4)

[0260]

[0261]

[0262] Type V CRISPR-associated protein Cpf1 [Aminococcus sp. BV3L6], NCBI reference sequence: WP_021736722.1 (SEQ ID NO: 5)

[0263]

[0264]

[0265] Type V CRISPR-associated protein Cpf1 [Franciscoides tularensis], GenBank accession number WP_003040289.1 (SEQ ID NO: 6)

[0266]

[0267]

[0268] In some embodiments, the Cpf1 endonuclease is a wild-type version of the nuclease. For example, the Cpf1 endonuclease is a Cpf1 endonuclease having a sequence of SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6 as shown above. In some embodiments, the Cpf1 endonuclease is at least 80%, such as at least 85%, 90%, or 95% identical to the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6, for example, having up to 5%, 10%, 15%, or 20% difference from the residues of SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6, for example, substituted with conservative mutations. In preferred embodiments, the endonuclease retains the desired activity of the parent, such as nuclease activity (unless the parent is a nickase or dead Cas9), and / or the ability to interact with the guide RNA and the target DNA.

[0269] The catalytically inactive variant of Cpf1 (Cas12a) may be referred to as dCas12a. Thus, in some embodiments, for AsCpf1, catalytic activity-destroying mutations are made at D908 and E993, such as D908A and E993A; for LbCpf1, catalytic activity-destroying mutations are made at D832 and E925, such as D832A and E925A; and for FnCpf1, catalytic activity-destroying mutations are made at D917A and E1006A.

[0270] Functional domain

[0271] Alternatively or in addition, Cas endonucleases (i.e., Cas9 or Cas12a) can be fused with another protein or part thereof (e.g., heterologous functional domains). In some embodiments, the heterologous functional domain is a transcriptional activation domain (e.g., VP64 or NF-KB p65). In some embodiments, the heterologous functional domain is a transcriptional silencer or a transcriptional repression domain (e.g., wherein the transcriptional repression domain is a Krueppel-associated box (KRAB) domain, an ERF repressor domain (ERD), or an mSin3A interaction domain (SID); wherein the transcriptional silencer is heterochromatin protein 1 (HP1)). In some embodiments, the heterologous functional domain is an enzyme that modifies the DNA methylation state (e.g., DNA methyltransferase (DNMT) or TET protein (such as, TET1)). In some embodiments, the heterologous functional domain is an enzyme that modifies a histone subunit (e.g., histone acetyltransferase (HAT), histone deacetylase (HDAC), histone methyltransferase (HMT) or histone demethylase). In some embodiments, the heterologous functional domain is a biological tether (e.g., MS2, Csy4 or λN). In some embodiments, the heterologous functional domain is FokI.

[0272] In some embodiments, the heterologous functional domain is a base editor, such as a deaminase that modifies cytosine DNA bases, for example, a cytidine deaminase from the apolipoprotein B mRNA editing enzyme catalytic polypeptide-like (APOBEC) family of deaminases, including APOBEC1, APOBEC2, APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3D / E, APOBEC3F, APOBEC3G, APOBEC3H, APOBEC4, activation-induced cytidine deaminase (AID), cytosine deaminase 1 (CDA1) and CDA2, and cytosine deaminase acting on tRNA (CDAT). Specific examples include evoAPOBEC1-BE4max, eA3A-BE5, and EA-BE4max.

[0273] In some embodiments, the heterologous functional domain is a deaminase that modifies adenosine DNA bases, for example, the deaminase is adenosine deaminase 1 (ADA1), ADA2; adenosine deaminase 1 (ADAR1), ADAR2, ADAR3 acting on RNA; adenosine deaminase 1 (ADAT1), ADAT2, ADAT3 acting on tRNA; and naturally occurring or engineered tRNA-specific adenosine deaminase (TadA). For example, ABE8e-TadA-8e. In some embodiments, the TadA adenosine deaminase domain comprises a V106W substitution.

[0274] In some embodiments, the heterologous functional domain is an enzyme, domain, or peptide that inhibits or enhances an endogenous DNA repair or base excision repair (BER) pathway, e.g., a uracil DNA glycosylase inhibitor (UGI), which inhibits uracil DNA glycosylase (UDG, also known as uracil N-glycosylase, or UNG)-mediated uracil excision to initiate BER; or a DNA end-binding protein, such as Gam from bacteriophage Mu.

[0275] In some embodiments, the endonuclease is a base editor. The base editor endonuclease generally includes a catalytically inactive Cas endonuclease fused to a base editor. For example, the endonuclease is SpCas9, which has a mutation at D10, E762, D839, H983, or D986; and / or has a mutation at H840 or N863 and is fused to a base editor, such as those mentioned above.

[0276] In some cases, the endonuclease (Cas9 or Cas12a) is fused to one or more of a nuclear localization sequence, a cell penetrating peptide sequence, an affinity tag, and / or a fluorescent protein. For example, the nuclear localization sequence is a SV40 large T antigen nuclear localization sequence (PKKKRKV; SEQ ID NO: 82), a nuclear plasmid nuclear localization sequence (KRPAATKKAGQAKKKK; SEQ ID NO: 83) or a c-Myc nuclear localization sequence (PAAKRVKLD; SEQ ID NO: 84). For example, the nuclear localization sequence is fused to the N-terminus and / or C-terminus of Cas9 or Cas12a protein. In some embodiments, when a heterologous functional domain is fused to the N-terminus and / or C-terminus of a Cas9 or Cas12a protein, the nuclear localization sequence is fused to the N-terminus and / or C-terminus of a heterologous functional domain-Cas protein complex or inserted between the heterologous functional domain and the Cas protein.

[0277] The sequences of exemplary Cas endonucleases are provided below:

[0278] SEQ ID NO: 7 (amino acid sequence of SpRY-ABE8e-V106W 3xNLS adenine base editor):

[0279]

[0280] SEQ ID NO: 85 (amino acid sequence of SpRY-ABE8e 3xNLS adenine base editor):

[0281]

[0282] SEQ ID NO: Amino acid sequence of 8-SpRY-evoAPOBEC1-BE4 3xNLS adenine base editor

[0283]

[0284] SEQ ID NO: 9-SpRY-K918N-ABE8e-V106W amino acid sequence of 3xNLS adenine base editor

[0285]

[0286] SEQ ID NO: 10-SpRY-ABE8e-V106W 3xNLS adenine base editor nucleotide sequence:

[0287]

[0288]

[0289]

[0290] SEQ ID NO: 11 - Nucleotide sequence of SpRY-evoAPOBEC1-BE4 3xNLS adenine base editor:

[0291]

[0292]

[0293]

[0294]

[0295] SEQ ID NO: 12-SpRY-K918N-ABE8e-V106W nucleotide sequence of 3xNLS adenine base editor

[0296]

[0297]

[0298]

[0299] gRNA

[0300] The terms "gRNA", "guide RNA" and "CRISPR guide sequence" are used interchangeably throughout the text and refer to nucleic acids containing sequences that determine the specificity of the Cas DNA binding protein of the CRISPR / Cas system. The gRNA hybridizes with a target nucleic acid sequence in the host cell genome (partially or completely complementary to it). In some cases, gRNA refers to crRNA and tracrRNA collectively (for example, when using Cas9 nuclease-in those cases, the guide RNA can be referred to as a single guide RNA, i.e., sgRNA). In other cases, gRNA refers only to crRNA (for example, when using Cpf1 endonuclease). The length of the gRNA or part thereof hybridized with the target nucleic acid can be 15-25 nucleotides, 18-22 nucleotides, or 19-21 nucleotides. In some embodiments, the gRNA sequence length hybridized with the target nucleic acid is 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides. In some embodiments, the gRNA sequence length hybridized with the target nucleic acid is 10-30 nucleotides, or 15-25 nucleotides. In some embodiments, the gRNA sequence is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or at least 100% complementary to the target nucleic acid.

[0301] Table 1 below provides exemplary guide RNAs for editing FLT3, CD123 and KIT. It will be apparent to one of ordinary skill in the art that the selection of gRNA sequences may depend on factors such as the number of predicted on-target and / or off-target binding sites. In some embodiments, gRNA sequences are selected to maximize potential on-target sites and minimize potential off-target sites.

[0302]

[0303]

[0304]

[0305] In some embodiments, multiple gRNAs are introduced into cells (e.g., one for FLT3 and one for CD123). In some embodiments, two or more guide RNAs are transfected into cells in equimolar amounts. In some embodiments, two or more guide RNAs are provided in unequal molar amounts. In some embodiments, two or more guide RNAs are provided in optimized amounts so that the editing of each target occurs at the same frequency. In some embodiments, two or more guide RNAs are provided in optimized amounts so that the editing of each target occurs at an optimal frequency.

[0306] Template donor sequence

[0307] In some embodiments, "template" donor sequences are provided herein. The template donor sequence includes 100-500 nucleotides (e.g., 200 nucleotides) long single-stranded oligodeoxynucleotides (ssODNs), which serve as donor templates for homology-directed repair (HDR), so that the desired mutations are introduced into a specific gene. Each donor template additionally includes selected silent mutations in bystander amino acids to reduce the risk of being re-cut by the CRISPR-Cas ribonucleoprotein nuclease complex after successful DNA repair.

[0308] Table 2 below provides exemplary template donor sequences for introducing mutation N399D in FLT.

[0309] Table 2: ssODN 200 bp long oligonucleotide donor serves as template for introduction of FLT3 N399D by CRISPR-Cas nuclease homology-directed repair

[0310]

[0311]

[0312] iv. Genetically engineered hematopoietic cells

[0313] Provided herein is a method for producing a genetically engineered hematopoietic cell as described herein, the genetically engineered hematopoietic cell carrying a gene for expressing the editing of one or more cell surface antigens in a mutant form.Such methods may involve providing cells and introducing cellular components of the CRISPR Cas system for genome editing.In some embodiments, a nucleic acid comprising a CRISPR-Cas guide RNA (gRNA) hybridized with a portion of a nucleotide sequence encoding a cell surface antigen or predicted to hybridize with it is introduced into the cell.In some embodiments, gRNA is introduced into the cell on a vector.In some embodiments, a Cas endonuclease is introduced into the cell.In some embodiments, a Cas endonuclease is introduced into the cell in the form of a nucleic acid encoding a Cas endonuclease.In some embodiments, a nucleotide sequence encoding a Cas endonuclease and a gRNA are introduced into the cell on the same nucleic acid (e.g., the same vector).In some embodiments, a Cas endonuclease is introduced into the cell in the form of a protein.In some embodiments, a Cas endonuclease and a gRNA are preformed in vitro and introduced into the cell in the form of a ribonucleoprotein complex.

[0314] v. Mutant FLT3

[0315] In some embodiments, the cell surface protein is FLT3. The amino acid sequence of wild-type FLT3 is as follows:

[0316] SEQ ID NO: 48 (FLT3 wild-type amino acid sequence)

[0317]

[0318] In some embodiments, the methods described herein relate to genetically engineering hematopoietic cell groups using Cas nucleases (or their variants). In some embodiments, the methods described herein relate to genetically engineering genes encoding cell surface antigens in hematopoietic cell groups using Cas nucleases or their variants (e.g., SpCas9 or AsCpf1). In some embodiments, the methods described herein relate to genetically modifying or editing FLT3 genes, or genetically modifying or editing CD123 genes, or genetically modifying or editing KIT genes, or genetically modifying or editing FLT3 genes and CD123 genes in hematopoietic cell groups using Cas nucleases.

[0319] In some embodiments, the methods described herein involve genetically engineering a mutant FLT3 gene in a hematopoietic cell population using a Cas nuclease or a variant thereof. In some embodiments, the methods described herein involve genetically engineering a mutation in exon 9 of FLT3 in a hematopoietic cell population using a Cas nuclease or a variant thereof (e.g., resulting in a mutation at position N399 in the encoded polypeptide). In some embodiments, the methods described herein involve genetically engineering a mutant FLT3 gene in a hematopoietic cell population using a Cas nuclease or a variant thereof and a guide sequence provided by any one of SEQ ID NOs: 13-23. In some embodiments, a template donor DNA sequence is also provided. For example, a template donor DNA sequence is provided by any one of SEQ ID NOs: 40-43.

[0320] In some embodiments, the genetically engineered FLT3 gene encodes a protein that is reduced in combination with the treatment of anti-FLT3 antibodies. In some cases, the genetically engineered FLT3 gene includes at least one mutation in exon 9 of the FLT3 gene. In some cases, at least one mutation in exon 9 of the genetically engineered FLT3 gene results in a polypeptide with a mutation at position N399. In some cases, the mutation at position N399 is N399D or N399G. An exemplary amino acid sequence of genetically engineered FLT3 is provided below:

[0321] SEQ ID NO: 49 FLT3 N354S, S356Q, D358E, Q363P, E366K, Q378R, T384I, R387Q, K389A, K395R, D398E, N399D, N408D, H411N, Q412K, H419Y; FLT3-ECD4 variant (with 16 amino acid substitutions within extracellular domain 4 that reduce binding of clone 4G8, including N399D)

[0322]

[0323] SEQ ID NO: 50 FLT3 N354S, S356Q, D358E, Q363P, E366K, Q378R, T384I, R387Q, K389A, K395R, D398E, N399D (FLT3 exon 9 mutation)

[0324]

[0325] SEQ ID NO: 51 (FLT3 N399D variant amino acid sequence)

[0326]

[0327]

[0328] SEQ ID NO: 52 (FLT3 N399G variant amino acid sequence)

[0329]

[0330] In some embodiments, provided herein is a polypeptide sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence shown in SEQ ID NO: 51, wherein the polypeptide sequence comprises a mutation at N399D, and wherein the polypeptide sequence has reduced binding to a therapeutic anti-FLT3 antibody. Also provided herein is a nucleic acid encoding the polypeptide sequence.

[0331] In some embodiments, provided herein is a polypeptide sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence shown in SEQ ID NO: 52, wherein the polypeptide sequence comprises a mutation at N399G, and wherein the polypeptide sequence has reduced binding to a therapeutic anti-FLT3 antibody. Also provided herein is a nucleic acid encoding the polypeptide sequence.

[0332] vi. Mutant CD123

[0333] In some embodiments, the cell surface protein is CD123. The amino acid sequence of wild-type CD123 is as follows:

[0334] SEQ.ID NO: 53 (CD123 wild-type amino acid sequence)

[0335]

[0336] In some embodiments, the methods described herein relate to genetically engineering mutant CD123 genes in hematopoietic cell populations using Cas nucleases or their variants. In some embodiments, the methods described herein relate to genetically engineering mutations in exon 2 of CD123 (e.g., resulting in mutations in position S59 in the encoded polypeptide) or mutations in exon 3 of CD123 (e.g., resulting in mutations in position P88 in the encoded polypeptide) in hematopoietic cell populations using Cas nucleases or their variants. In some embodiments, the methods described herein relate to genetically engineering mutant CD123 genes in hematopoietic cell populations using guide sequences provided by any one of SEQ ID NO:24-35.

[0337] In some embodiments, the genetically engineered HSPC includes a genetically engineered CD123 gene, wherein the genetically engineered CD123 gene encodes a protein that is reduced in combination with treatment anti-CD123 antibodies. In some cases, the genetically engineered FLT3 gene includes at least one mutation in exon 2 or exon 3 of the CD123 gene. In some cases, at least one mutation in exon 2 of the genetically engineered CD123 gene results in a polypeptide with a mutation at position S59. In some cases, the mutation at position S59 is S59P or S59F. In some cases, at least one mutation in exon 3 of the genetically engineered CD123 gene results in a polypeptide with a mutation at position P88. In some cases, the mutation at position P88 is P88L or P88S. An exemplary amino acid sequence of genetically engineered CD123 is provided below:

[0338] SEQ ID NO: 54 (CD123 S59P variant amino acid sequence)

[0339]

[0340] SEQ ID NO: 55 (CD123 Y58H S59P variant amino acid sequence)

[0341]

[0342] SEQ ID NO: 56 (CD123 S59F variant amino acid sequence)

[0343]

[0344] SEQ ID NO: 57 (CD123 P88S variant amino acid sequence)

[0345]

[0346] SEQ ID NO: 58 (CD123 P88L variant amino acid sequence)

[0347]

[0348] The nucleotide sequence is as follows:

[0349] CD123 exon 2 wild-type sequence (SEQ.ID NO: 59)

[0350]

[0351] CD123 exon 2 sequence with base editing induced by IL3RA_gRNA_N or IL3RA_gRNA_R and SpRY_ABE8e_V106W (I variant) (SEQ.ID NO: 60)

[0352]

[0353] CD123 exon 2 sequence with base editing induced by IL3RA_gRNA_N or IL3RA_gRNA_R and SpRY_ABE8e_V106W (II variant) (SEQ.ID NO: 61)

[0354]

[0355] CD123 exon 2 sequence with base editing induced by IL3RA_gRNA_N or IL3RA_gRNA_R and SpRY_ABE8e_V106W (III variant) (SEQ.ID NO: 62)

[0356]

[0357] CD123 exon 2 sequence with base editing induced by IL3RA_gRNA_N or IL3RA_gRNA_R and SpRY_ABE8e_V106W (IV variant) (SEQ.ID NO: 63)

[0358]

[0359] CD123 exon 2 sequence with base editing induced by IL3RA_gRNA_N or IL3RA_gRNA_R and SpRY_ABE8e_V106W (V variant) (SEQ.ID NO: 64)

[0360]

[0361] CD123 exon 2 sequence with base editing induced by IL3RA_gRNA_N or IL3RA_gRNA_R and SpRY_ABE8e_V106W (VI variant) (SEQ.ID NO: 65)

[0362]

[0363] In some embodiments, provided herein is a polypeptide sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence shown in SEQ ID NO: 54, wherein the polypeptide sequence is included in the mutation at S59P, and wherein the polypeptide sequence is reduced in combination with the treatment of anti-CD123 antibodies. Also provided herein is a nucleic acid encoding the polypeptide sequence.

[0364] In some embodiments, provided herein is a polypeptide sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence shown in SEQ ID NO: 55, wherein the polypeptide sequence comprises a mutation at Y58H and S59P, and wherein the polypeptide sequence is reduced in combination with treatment of anti-CD123 antibodies. Also provided herein is a nucleic acid encoding the polypeptide sequence. Also provided herein is a nucleic acid encoding the polypeptide sequence.

[0365] In some embodiments, provided herein is a polypeptide sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence shown in SEQ ID NO: 56, wherein the polypeptide sequence is included in the mutation at S59F, and wherein the polypeptide sequence is reduced in combination with therapeutic anti-CD123 antibodies. Also provided herein is a nucleic acid encoding the polypeptide sequence.

[0366] In some embodiments, provided herein is a polypeptide sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence shown in SEQ ID NO: 57, wherein the polypeptide sequence is included in the mutation at P88S, and wherein the polypeptide sequence is reduced in combination with the treatment of anti-CD123 antibodies. Also provided herein is a nucleic acid encoding the polypeptide sequence.

[0367] In some embodiments, provided herein is a polypeptide sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence shown in SEQ ID NO: 58, wherein the polypeptide sequence is included in the mutation at P88L, and wherein the polypeptide sequence is reduced in combination with treatment of anti-CD123 antibodies. Also provided herein is a nucleic acid encoding the polypeptide sequence.

[0368] vii. Mutant KIT

[0369] In some embodiments, the cell surface protein is KIT. The amino acid sequence of wild-type KIT is shown below:

[0370] SEQ ID NO: 66 (KIT wild-type amino acid sequence)

[0371]

[0372] In some embodiments, the methods described herein involve genetically engineering a mutant KIT gene in a hematopoietic cell population using a Cas nuclease or a variant thereof. In some embodiments, the methods described herein involve genetically engineering a mutation in exon 7 of KIT (e.g., mutation position H378) in a hematopoietic cell population using a Cas nuclease or a variant thereof. In some embodiments, the methods described herein involve genetically engineering a mutant KIT gene in a hematopoietic cell population using a Cas nuclease or a variant thereof and a guide sequence provided by any one of SEQ ID NOs: 36-47.

[0373] In some embodiments, the genetically engineered HSPC comprises a genetically engineered KIT gene, wherein the genetically engineered KIT gene encodes a protein with reduced binding to a therapeutic anti-KIT antibody. In some cases, the genetically engineered KIT gene comprises at least one mutation in exon 6 and / or exon 7 of the KIT gene. In some cases, at least one mutation in exon 7 of the genetically engineered KIT gene results in a polypeptide with a mutation at position H378. In some cases, the mutation at position H378 is H378R or H378S or H378P or H378A or H378F or H378K or H378G or H378L or H378M. In some cases, the mutation in exon 6 of KIT results in an encoded polypeptide having one or more of the following mutations: F316S, M318V, I319K, V323I, I334V, E360K, P363V, E366D. In some cases, an exon 7 mutation of KIT results in a polypeptide having a mutation at E376Q and / or H378R.

[0374] An exemplary amino acid sequence of a genetically engineered KIT is provided below:

[0375] SEQ ID NO: 67 KIT F316S, M318V, I319K, V323I, I334V, E360K, P363V, E366D, E376Q, H378R (KIT-ECD4 variant amino acid sequence)

[0376]

[0377]

[0378] SEQ ID NO: 68 (KIT H378R variant amino acid sequence)

[0379]

[0380] In some embodiments, provided herein is a polypeptide sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 67, wherein the polypeptide sequence comprises mutations at F316S, M318V, I319K, V323I, I334V, E360K, P363V, E366D, E376Q, and H378R, and wherein binding of the polypeptide sequence to a therapeutic anti-KIT antibody is reduced. Also provided herein is a nucleic acid encoding the polypeptide sequence.

[0381] In some embodiments, provided herein is a polypeptide sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence shown in SEQ ID NO: 68, wherein the polypeptide sequence comprises a mutation at H378R, and wherein binding of the polypeptide sequence to a therapeutic anti-KIT antibody is reduced. Also provided herein is a nucleic acid encoding the polypeptide sequence.

[0382] viii. Genetically engineered hematopoietic cells expressing mutant FLT3, CD123 and / or KIT genes

[0383] In some embodiments, the cell surface proteins are FLT3 and CD123. In some embodiments, the cell surface proteins are FLT3 and KIT. In some embodiments, the cell surface proteins are KIT and CD123. In some embodiments, two or more guides are transfected simultaneously with each other. In some embodiments, two or more guides are provided sequentially or continuously, i.e., provided in two or more separate transfections. For example, FLT3 guide RNA (SEQ ID NO: any one of 13-23), CD123 guide RNA (SEQ ID NO: any one of 24-35), KIT guide RNA (SEQ ID NO: any one of 36-47).

[0384] In some embodiments, the genetically engineered HSPC includes a genetically engineered FLT3 gene, wherein the genetically engineered FLT3 gene encodes a protein that is reduced in combination with treatment anti-FLT3 antibodies. In some cases, the genetically engineered FLT3 gene includes at least one mutation in exon 9 of the FLT3 gene. In some cases, at least one mutation in exon 9 of the genetically engineered FLT3 gene results in the production of a polypeptide with a mutation at position N399. In some cases, the mutation at position N399 is N399D or N399G. The exemplary amino acid sequence of the genetically engineered FLT3 is as shown above (see SEQ ID NO: 49-52).

[0385] In some embodiments, genetically engineered HSPC includes genetically engineered CD123 genes, wherein genetically engineered CD123 genes encode proteins that are reduced in combination with treatment anti-CD123 antibodies. In some cases, genetically engineered CD123 genes include at least one mutation in exon 2 or exon 3 of CD123 genes. In some cases, mutations in exon 2 of genetically engineered CD123 genes result in polypeptides with mutations at position S59. In some cases, mutations at S59 positions are S59P or S59F. In some cases, mutations are S59P and Y58H. In some cases, at least one mutation in exon 3 of genetically engineered CD123 genes results in polypeptides with mutations at position P88. In some cases, mutations at P88 positions are P88L or P88S. The exemplary amino acid sequences of genetically engineered CD123 are as shown above (see SEQ ID NO: 54-58).

[0386] In some embodiments, the genetically engineered HSPC comprises a genetically engineered KIT gene, wherein the genetically engineered KIT gene encodes a protein with reduced binding to a therapeutic anti-KIT antibody. In some cases, the genetically engineered KIT gene comprises at least one mutation in exon 6 and / or exon 7 of the KIT gene. In some cases, at least one mutation in exon 7 of the genetically engineered KIT gene results in a polypeptide with a mutation at position H378. In some cases, the mutation at position H378 is H378R or H378S or H378P or H378A or H378F or H378K or H378G or H378L or H378M. In some cases, the mutation in exon 6 of KIT results in an encoded polypeptide having one or more of the following mutations: F316S, M318V, I319K, V323I, I334V, E360K, P363V, E366D. In some cases, a mutation in exon 7 in KIT results in a polypeptide having a mutation at one or more of E376Q and H378R. Exemplary amino acid sequences of genetically engineered KIT are provided as shown above (see SEQ ID NOs: 67-68).

[0387] II. Immunotherapeutic Agents Specific for Cell Surface Antigens

[0388] Cytotoxic agents targeting cells (e.g., cancer cells) expressing cell surface antigens can be used in conjunction with genetically engineered hematopoietic cells as described herein. As used herein, the term "cytotoxic agent" refers to any agent that can directly or indirectly induce cytotoxicity of target cells (e.g., target cancer cells) expressing specific cell surface antigens. Such cytotoxic agents may include protein binding fragments that bind to and target specific cell surface antigen epitopes.

[0389] i. Therapeutic Antibodies / Antibody-Drug Conjugates

[0390] In some cases, cytotoxic agents include therapeutic antibodies, which can be conjugated to a drug (e.g., an anticancer drug) to form an antibody-drug conjugate (ADC). In some embodiments, the agent is an antibody-drug conjugate. In some embodiments, the antibody-drug conjugate comprises an epitope binding fragment and a toxin or drug that induces cytotoxicity in a target cell.

[0391] In some embodiments, the anti-FLT3 antibody for treatment is an anti-FLT3 clone 4G8 antibody. In some embodiments, the anti-CD123 antibody for treatment is a clone 7G3 antibody or its humanized counterpart CSL362 ("Talacotuzumab"). In some embodiments, the anti-CD123 antibody for treatment is an anti-CD123 clone 6H6 antibody or an anti-CD123 clone S18016F antibody. In some embodiments, the anti-KIT antibody for treatment is an anti-KIT clone Fab79D antibody.

[0392] Toxins or drugs suitable for use in antibody-drug conjugates are well known in the art and will be apparent to one of ordinary skill in the art. See, e.g., Peters et al. Biosci. Rep. (2015) 35(4): e00225, Beck et al. Nature Reviews Drug Discovery (2017) 16: 315-337; Marin-Acevedo et al. J. Hematol. Oncol. (2018) 11: 8; Elgundi et al. Advanced Drug Delivery Reviews (2017) 122: 2-19. In some embodiments, the antibody-drug conjugate may also include a linker (e.g., a peptide linker, such as a cleavable linker or a non-cleavable linker) that attaches the antibody and drug molecules. Examples of antibody-drug conjugates include, but are not limited to, brentuximab vedotin, glembatumumab vedotin / CDX-011, depatuxizumab mafodotin / ABT-414, PSMA ADC, polatuzumab vedotin / RG7596 / DCDS4501A, denintuzumab mafodotin / SGN-CD19A, AGS-16C3F, CDX-014, RG7841 / DLYE5953A, RG7882 / DMUC406A, RG7986 / DCDS0780A, SGN-LIV1A, enfortumab vedotin / RG7596 / DCDS4501A, denintuzumab mafodotin / SGN-CD19A, AGS-16C3F, CDX-014, RG7841 / DLYE5953A, RG7882 / DMUC406A, RG7986 / DCDS0780A, SGN-LIV1A, enfortumab vedotin / RG7596 / DCDS4501A, vedotin / ASG-22ME, AG-15ME, AGS67E, telisotuzumab vedotin / ABBV-399, ABBV-221, ABBV-085, GSK-2857916, tisotumab vedotin / HuMax-TF-ADC, HuMax-Axl-ADC, pinatuzumab veodtin / RG7593 / DCDT2980S, lifastuzumab vedotin / RG7599 / DNIB0600A, indusatumab vedotin / MLN-0264 / TAK-264, vandortuzumab vedotin / RG7593 / DCDT2980S Vedotin) / RG7450 / DSTP3086S, Vedotin-sofituzumabvedotin / RG7458 / DMUC5754A、RG7600 / DMOT4039A、RG7336 / DEDN6526A、ME1547、PF-06263507 / ADC 5T4、trastuzumab emtansine / T-DM1、mirvetuximab soravtansine / IMGN853、coltuxi mab ravtansine / SAR3419、naratuximab emtansine / IMGN529、indatuximab ravtansine / BT-062、anetumab ravtansine / BAY 94-9343, SAR408701, SAR428926, AMG 224, PCA062, HKT288, LY3076226, SAR566658, lorvotuzumab mertansine / IMGN901, cantuzumab mertansine / SB-408075, cantuzumab ravtansine / IMGN242, laprituximab emtansine / IMGN289, IMGN388, bivatuzumab mertansine, AVE9633, BIIB015, MLN2704, AMG 172, AMG 595, LOP 628、vadastuximab talirine / SGN-CD33A、SGN-CD70A、SGN-CD19B、SGN-CD123A、SGN-CD352A、rovalpituzumab tesirine / SC16LD6.5、SC-002、SC-003、ADCT-301 / HuMax-TAC-PBD、ADCT-402、MEDI3726 / ADC-401、IMGN779、IMGN632、gemtuzumabozogamicin、inotuzumab ozogamicin / CMC-544、PF-06647263、CMD-193、CMB-401、trastuzumabduocarmazine / SYD985, BMS-936561 / MDX-1203, sacituzumab govitecan / IMMU-132, labetuzumab govitecan / IMMU-130, DS-8201a, U3-1402, milatuzumab doxorubicin / IMMU-110 / hLL1-DOX, BMS-986148, RC48-ADC / hertuzumab-Vc-MMAE, PF-06647020, PF-06650808, PF-06664178 / RN927C, adin-lupartumab In one example, the antibody-drug conjugate is oga-gemtuzumab.

[0393] In some embodiments, the combination of antibody-drug conjugates and epitopes of cell surface proteins induces the internalization of antibody-drug conjugates, and drugs (or toxins) can be released intracellularly. In some embodiments, the combination of antibody-drug conjugates and epitopes of cell surface proteins induces the internalization of toxins or drugs, which allows toxins or drugs to kill cells (target cells) expressing cell surface proteins. In some embodiments, the combination of antibody-drug conjugates and epitopes of cell surface proteins induces the internalization of toxins or drugs, which can regulate the activity of cells (target cells) expressing cell surface proteins. The type of toxins or drugs used in antibody-drug conjugates described herein is not limited to any specific type.

[0394] In some embodiments, two or more (e.g., 2, 3, 4, 5 or more) epitopes of a cell surface antigen have been modified so that two or more (e.g., 2, 3, 4, 5 or more) different cytotoxic agents (e.g., two ADCs) can target the two or more epitopes. In some embodiments, the toxins carried by the ADCs can work synergistically to enhance efficacy (e.g., death of target cells). In some embodiments, two or more (e.g., 2, 3, 4, 5 or more) epitopes of a cell surface protein have been modified so that two or more (e.g., 2, 3, 4, 5 or more) different cytotoxic agents (e.g., two ADCs) can target the epitopes of the two or more cell surface antigens. In some embodiments, one or more (e.g., 1, 2, 3, 4, 5 or more) epitopes of a cell surface antigen have been modified, and one or more (e.g., 1, 2, 3, 4, 5 or more) epitopes of an additional cell surface protein have been modified, so that two or more (e.g., 2, 3, 4, 5 or more) different cytotoxic agents (e.g., two ADCs) can target an epitope of a cell surface antigen and an epitope of an additional cell surface antigen. In some embodiments, targeting more than one cell surface antigen or one cell surface antigen and one or more additional cell surface proteins / antigens can reduce the recurrence of hematopoietic malignancies.

[0395] In some embodiments, the methods described herein involve administering an ADC targeting a cell surface epitope that is mutated in a genetically engineered hematopoietic cell population. In some embodiments, the methods described herein involve administering an ADC targeting a cell surface epitope that is mutated in a genetically engineered hematopoietic cell population and one or more additional cytotoxic agents that can target one or more additional cell surface proteins. In some embodiments, the agents can work synergistically to enhance efficacy by targeting more than one cell surface protein.

[0396] The ADCs described herein can be used as follow-up treatment for a subject who has already received a combination therapy as described herein.

[0397] In some embodiments, the methods described herein relate to administering to a subject a genetically engineered cell population lacking a non-essential epitope in a cell surface antigen and one or more immunotherapeutic agents (e.g., ADC) targeting cells expressing cell surface antigens. In some embodiments, the methods described herein relate to administering to a subject a genetically engineered cell population lacking a non-essential epitope in a type 1 cell surface antigen and one or more immunotherapeutic agents (e.g., ADC) targeting cells expressing cell surface antigens. In some embodiments, the methods described herein relate to administering to a subject a genetically engineered cell population lacking a non-essential epitope in a type 2 cell surface antigen and one or more immunotherapeutic agents (e.g., ADC) targeting cells expressing cell surface antigens. In any embodiments described herein, for example, if a hematopoietic malignancy recurs, one or more additional immunotherapeutic agents (e.g., targeting one or more additional epitopes and / or antigens) may be further administered to the subject.

[0398] ii. Immune cells expressing chimeric antigen receptors

[0399] In some embodiments, the cytotoxic agent targeting a specific cell surface antigen epitope as described herein is an immune cell expressing a chimeric receptor, which comprises an epitope binding fragment (e.g., a single-chain antibody) capable of binding to a cell surface protein (e.g., FLT3, CD123, or KIT) epitope. Recognition of a target cell (e.g., a cancer cell) having a specific protein epitope on the cell surface by an epitope binding fragment of a chimeric receptor transduces an activation signal to a signaling domain (e.g., a co-stimulatory signaling domain and / or a cytoplasmic signaling domain) of the chimeric receptor, which can activate effector functions in immune cells expressing chimeric receptors.

[0400] In some embodiments, immune cells express more than one chimeric receptor (e.g., 2, 3, 4, 5 or more), referred to as bispecific or multispecific immune cells. In some embodiments, immune cells express more than one chimeric receptor, at least one of which targets an epitope of a cell surface antigen. In some embodiments, immune cells express more than one chimeric receptor, each of which targets an epitope of a specific cell surface antigen. In some embodiments, immune cells express more than one chimeric receptor, at least one of which targets an epitope of a cell surface antigen, and at least one of which targets an epitope of an additional cell surface antigen. In some embodiments, targeting more than one cell surface protein or one cell surface protein and one or more additional cell surface proteins can reduce the recurrence of hematopoietic malignancies. In some embodiments, immune cells express chimeric receptors targeting more than one epitope (e.g., more than one epitope of an antigen or more than one epitope of an antigen), referred to as bispecific chimeric receptors.

[0401] In some embodiments, the cytotoxic agent targets the epitope of two or more lineage-specific cell surface proteins. In some embodiments, two or more chimeric receptors are expressed in the same immune cell, such as a bispecific chimeric receptor. Such cells can be used in any of the methods described herein. In some embodiments, cells expressing chimeric receptors are "pooled", i.e., two or more groups of cells express two or more different chimeric receptors. In some embodiments, two or more cells expressing different chimeric antigen receptors are administered simultaneously. In some embodiments, two or more cells expressing different chimeric antigen receptors are administered sequentially. In some embodiments, the cytotoxic agent targets the epitope of FLT3, CD123 and / or KIT. In some embodiments, chimeric receptors targeting FLT3, CD123 and / or KIT are expressed in the same immune cell (i.e., bispecific immune cells). Such cells can be used in any of the methods described herein. In some embodiments, cells expressing chimeric receptors targeting FLT3, CD123 and / or KIT are "pooled", i.e., two or more groups of cells express two or more different chimeric receptors. In some embodiments, two or more groups of cells expressing chimeric receptors targeting FLT3, CD123 and / or KIT are administered simultaneously. In some embodiments, two or more groups of cells expressing chimeric receptors targeting FLT3, CD123 and / or KIT are administered sequentially.

[0402] As used herein, a chimeric receptor refers to a non-naturally occurring molecule that can be expressed on the surface of a host cell, and the chimeric receptor comprises a binding domain that provides chimeric receptor specificity (e.g., an epitope binding fragment that binds to an epitope of a cell surface lineage-specific protein). In general, a chimeric receptor comprises at least two domains derived from different molecules. In addition to the epitope binding fragments described herein, a chimeric receptor may also include one or more of the following: a hinge domain (e.g., a CD28 hinge, an IgG4 hinge, or a CD8α hinge), a transmembrane domain (e.g., CD28 TM, CD8α TM, 4-1BB TM), a costimulatory domain (e.g., CD28z, 4-1BB, ICOS, OX40), a cytoplasmic signaling domain (e.g., CD3z) and combinations thereof.

[0403] In some embodiments, the chimeric receptors described herein comprise one or more hinge domains. In some embodiments, the hinge domain can be located between the epitope binding fragment and the transmembrane domain. The hinge domain is an amino acid segment generally present between two domains of a protein, and it can allow flexibility of the protein and movement of one or two domains relative to each other. Any amino acid sequence that provides such flexibility and movement of the epitope binding fragment relative to another domain of the chimeric receptor can be used.

[0404] The hinge domain can contain about 10-200 amino acids, such as 15-150 amino acids, 20-100 amino acids, or 30-60 amino acids. In some embodiments, the hinge domain can be about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200 amino acids in length.

[0405] In some embodiments, the hinge domain is a hinge domain of a naturally occurring protein. The hinge domain of any protein known in the art comprising a hinge domain is suitable for chimeric receptors described herein. In some embodiments, the hinge domain is at least a portion of the hinge domain of a naturally occurring protein and imparts chimeric receptor flexibility. In some embodiments, the hinge domain is CD8α or CD28. In some embodiments, the hinge domain is a part of a CD8α hinge domain, such as a fragment containing at least 15 (e.g., 20, 25, 30, 35, or 40) consecutive amino acids of a CD8α or CD28 hinge domain.

[0406] The hinge domain of an antibody (such as IgG, IgA, IgM, IgE or IgD antibody) is also suitable for chimeric receptors described herein. In some embodiments, the hinge domain is a hinge domain connecting the constant domains CH1 and CH2 of an antibody. In some embodiments, the hinge domain is an antibody, and it comprises the hinge domain of an antibody and one or more constant regions of an antibody. In some embodiments, the hinge domain comprises the hinge domain of an antibody and the CH3 constant region of an antibody. In some embodiments, the hinge domain comprises the hinge domain of an antibody and the CH2 constant region and CH3 constant region of an antibody. In some embodiments, the antibody is an IgG, IgA, IgM, IgE or IgD antibody. In some embodiments, the antibody is an IgG antibody. In some embodiments, the antibody is an IgG1, IgG2, IgG3 or IgG4 antibody. In some embodiments, the hinge region comprises the hinge region of an IgG1 antibody and the CH2 constant region and the CH3 constant region. In some embodiments, the hinge region comprises the hinge region and the CH3 constant region of an IgG1 antibody.

[0407] In some embodiments, the chimeric receptors described herein comprise one or more transmembrane domains. The transmembrane domain used in the chimeric receptor can be any form known in the art. As used herein, "transmembrane domain" refers to any protein structure that is thermodynamically stable in a cell membrane (preferably, a eukaryotic cell membrane). Transmembrane domains suitable for use in chimeric receptors used herein can be obtained from naturally occurring proteins. Alternatively, the transmembrane domain can be a synthetic, non-naturally occurring protein segment, for example, a hydrophobic protein segment that is thermodynamically stable in a cell membrane.

[0408] Transmembrane domains are classified based on the transmembrane domain topology, which includes the number of times the transmembrane domain passes through the membrane and the orientation of the protein. For example, a single transmembrane protein passes through the cell membrane once, and multiple transmembrane proteins pass through the cell membrane at least twice (for example, 2, 3, 4, 5, 6, 7 times or more). In some embodiments, the transmembrane domain is a single transmembrane domain. In some embodiments, the transmembrane domain is a single transmembrane domain that directs the N-terminus of the chimeric receptor to the extracellular side of the cell and directs the C-terminus of the chimeric receptor to the intracellular side of the cell. In some embodiments, the transmembrane domain is obtained from a single transmembrane protein. In some embodiments, the transmembrane domain is CD28 or 4-1BB or CD8α.

[0409] In some embodiments, the chimeric receptor described herein comprises one or more co-stimulatory signaling domains. As used herein, the term "co-stimulatory signaling domain" refers to at least a portion of a protein that mediates intracellular signaling to induce an immune response (such as an effector function). The co-stimulatory signaling domain of the chimeric receptor described herein can be a cytoplasmic signaling domain from a co-stimulatory protein that transduces signals and regulates responses mediated by immune cells (such as T cells, NK cells, macrophages, neutrophils, or eosinophils).

[0410] In some embodiments, the chimeric receptor comprises more than one (at least 2, 3, 4 or more) co-stimulatory signaling domains. In some embodiments, the chimeric receptor comprises more than one co-stimulatory signaling domain obtained from different co-stimulatory proteins. In some embodiments, the chimeric receptor does not comprise a co-stimulatory signaling domain.

[0411] In general, in addition to the stimulation of antigen-specific signals, many immune cells also need costimulation to promote cell proliferation, differentiation and survival, as well as the effector function of activated cells. The activation of the costimulatory signaling domain in host cells (e.g., immune cells) can induce cells to increase or reduce the production and secretion of cytokines, phagocytic properties, proliferation, differentiation, survival and / or cytotoxicity. The costimulatory signaling domain of any costimulatory protein can be applied to chimeric receptors described herein. The type of costimulatory signaling domain is based on factors such as immune cell types (e.g., primary T cells, T cell lines, NK cell lines) expressing chimeric receptors and desired immune effector functions (e.g., cytotoxicity) and other factors to select. The example of the costimulatory signaling domain for chimeric receptors can be the cytoplasmic signaling domain of costimulatory proteins, including but not limited to CD27, CD28ζ (CD28z), 4-1BB, OX40, CD30, ICOS, CD2, CD7, LIGHT, NKG2C, B7-H3.

[0412] In some embodiments, the chimeric receptors described herein comprise one or more cytoplasmic signaling domains. Any cytoplasmic signaling domain can be used for the chimeric receptors described herein. In general, the cytoplasmic signaling domain transmits a signal, such as the interaction of an extracellular ligand binding domain with its ligand, to stimulate a cellular response, such as inducing an effector function (e.g., cytotoxicity) of the cell. In some embodiments, the cytoplasmic signaling domain is from CD3ζ (CD3z).

[0413] In some embodiments, provided herein is a chimeric receptor construct targeting FLT3, CD123, FLT3+CD123, KIT, FLT3+KIT or KIT+CD123. The construct may also include at least one hinge domain (e.g., from CD28, CD8α or antibody), a transmembrane domain (e.g., from CD28), one or more costimulatory domains (one or more from CD28z) and a cytoplasmic signaling domain (e.g., from CD3z) or a combination thereof. In certain embodiments, the methods described herein relate to administering to a subject a genetically engineered hematopoietic cell population (engineered to have mutant FLT3, CD123, FLT3+CD123, KIT, FLT3+KIT or CD123+KIT) and expressing an immune cell targeting a chimeric receptor of FLT3, CD123, FLT3+CD123, KIT, FLT3+KIT or CD123+KIT, respectively, the chimeric receptor may also include at least one hinge domain (e.g., from CD28, CD8α or antibody), a transmembrane domain (e.g., from CD28), one or more costimulatory domains (one or more from CD28z) and a cytoplasmic signaling domain (e.g., from CD3z) or a combination thereof. In some embodiments, the immunotherapy product administered is a combination of immune cells expressing a single chimeric receptor targeting FLT3, CD123 and / or KIT.

[0414] Any chimeric receptor described herein can be prepared by conventional methods, such as recombinant techniques. Methods for preparing chimeric receptors herein involve generating nucleic acids encoding polypeptides comprising each domain of a chimeric receptor, including an epitope binding fragment and optionally a hinge domain, a transmembrane domain, at least one co-stimulatory signaling domain, and a cytoplasmic signaling domain. In some embodiments, nucleic acids encoding components of a chimeric receptor are linked together using recombinant techniques.

[0415] In addition, any chimeric receptor can be expressed in immune cells and applied to subjects (e.g., human subjects) by conventional methods. For example, T cells can be derived from T cells in the subject's own blood (autologous), or from T cells of another healthy donor (allogeneic). Once separated from the subject, these T cells are genetically engineered to express specific CARs, so that they are programmed to target antigens present on the surface of the tumor. CAR-T cells are then infused into the subject by convention.

[0416] In some embodiments, the CAR is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of any one of SEQ ID NO: 69, 71, 73, 75, 77, 79, 86 or 87, wherein the CAR retains its ability to bind to its corresponding cell surface lineage-specific protein (e.g., KIT, CD123, FLT3 or a combination thereof).

[0417] In some embodiments, the cell surface lineage-specific protein is KIT, and the epitope binding fragment comprises the following CDR sequences: GFNISVYMMH (SEQ ID NO: 88), SIYPYSGYTYYADSVKG (SEQ ID NO: 89), ARYVYHALDY (SEQ ID NO: 90), RASQRGLRNVAVA (SEQ ID NO: 91), SASSLYS (SEQ ID NO: 92), and QQWAVHSLIT (SEQ ID NO: 93). In some cases, the epitope-binding fragment comprises a sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to GFNISVYMMHWVRQAPGKGLEWVASIYPYSGYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARYVYHALDY (SEQ ID NO:94), wherein the epitope-binding fragment retains its ability to bind to its corresponding KIT epitope. In some cases, the epitope-binding fragment comprises a sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to RASQRGLRNVAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQWAVHSLIT (SEQ ID NO:95), wherein the epitope-binding fragment retains its ability to bind to its corresponding KIT epitope. In some cases, the epitope binding fragment comprises a sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 94 and comprises a sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 95. In some embodiments, the epitope binding fragment comprises SEQ ID NOs 94 and 95.

[0418] In some embodiments, the cell surface lineage-specific protein is FLT3, and the epitope binding fragment comprises the following CDR sequences: GYTFTSYWMH (SEQ ID NO: 96), EIDPSDSYKDYNQKFK (SEQ ID NO: 97), RAITTTPFDF (SEQ ID NO: 98), RASQSISNNLH (SEQ ID NO: 99), YASQSIS (SEQ ID NO: 100), and QQSNTWPYT (SEQ ID NO: 101). In some cases, the epitope binding fragment comprises a sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to GYTFTSYWMHWVRQRPGHGLEWIGEIDPSDSYKDYNQKFKDKATLTVDRSSNTAYMHLSSLTSDDSAVYYCARAITTTPFDF (SEQ ID NO: 102), wherein the epitope binding fragment retains its ability to bind to its corresponding FLT3 epitope. In some cases, the epitope binding fragment comprises a sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to RASQSISNNLHWYQQKSHESPRLLIKYASQSISGIPSRFSGSGSGTDFTLSINSVETEDFGVYFCQQSNTWPYT (SEQ ID NO: 103), wherein the epitope binding fragment retains its ability to bind to its corresponding FLT3 epitope. In some cases, the epitope binding fragment comprises a sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 102 and comprises a sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 103. In some embodiments, the epitope binding fragment comprises SEQ ID NOs 102 and 103.

[0419] In some embodiments, the cell surface lineage-specific protein is CD123, and the epitope binding fragment comprises the following CDR sequences: GYSFTDYYMK (SEQ ID NO: 104), DIIPSNGATFYNQKFKG (SEQ ID NO: 105), ARSHLLRASWFAY (SEQ ID NO: 106), SQSLLNSGNQKNYLT (SEQ ID NO: 107), WASTRES (SEQ ID NO: 108), and QNDYSYPYT (SEQ ID NO: 109). In some cases, the epitope binding fragment comprises a sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to GYSFTDYYMKWARQMPGKGLEWMGDIIPSNGATFYNQKFKGQVTISADKSISTTYLQWSSLKASDTAMYYCARSHLLRASWFAY (SEQ ID NO: 110), wherein the epitope binding fragment retains its ability to bind to its corresponding CD123 epitope. In some cases, the epitope binding fragment comprises a sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ESSQSLLNSGNQKNYLTWYQQKPGQPPKPLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPYT (SEQ ID NO: 111), wherein the epitope binding fragment retains its ability to bind to its corresponding CD123 epitope. In some cases, the epitope binding fragment comprises a sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 110 and comprises a sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 111. In some embodiments, the epitope binding fragment comprises SEQ ID NOs 110 and 111.

[0420] In some embodiments, the cell surface lineage-specific proteins are FLT3 and CD123, and the epitope binding fragment comprises the following CDR sequences: GYTFTSYWMH (SEQ ID NO: 96), EIDPSDSYKDYNQKFK (SEQ ID NO: 97), RAITTTPFDF (SEQ ID NO: 98), RASQSISNNLH (SEQ ID NO: 99), YASQSIS (SEQ ID NO: 100), QQSNTWPYT (SEQ ID NO: 101), GYSFTDYYMK (SEQ ID NO: 104), DIIPSNGATFYNQKFKG (SEQ ID NO: 105), ARSHLLRASWFAY (SEQ ID NO: 106), SQSLLNSGNQKNYLT (SEQ ID NO: 107), WASTRES (SEQ ID NO: 108), and QNDYSYPYT (SEQ ID NO: 109). In some cases, the epitope binding fragment comprises a sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to GYTFTSYWMHWVRQRPGHGLEWIGEIDPSDSYKDYNQKFKDKATLTVDRSSNTAYMHLSSLTSDDSAVYYCARAITTTPFDF (SEQ ID NO: 102), wherein the epitope binding fragment retains its ability to bind to its corresponding FLT3 epitope. In some cases, the epitope binding fragment comprises a sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to RASQSISNNLHWYQQKSHESPRLLIKYASQSISGIPSRFSGSGSGTDFTLSINSVETEDFGVYFCQQSNTWPYT (SEQ ID NO: 103), wherein the epitope binding fragment retains its ability to bind to its corresponding FLT3 epitope. In some cases, the epitope binding fragment comprises a sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to GYSFTDYYMKWARQMPGKGLEWMGDIIPSNGATFYNQKFKGQVTISADKSISTTYLQWSSLKASDTAMYYCARSHLLRASWFAY (SEQ ID NO: 110), wherein the epitope binding fragment retains its ability to bind to its corresponding CD123 epitope.In some cases, the epitope binding fragment comprises a sequence that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to ESSQSLLNSGNQKNYLTWYQQKPGQPPKPLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPYT (SEQ ID NO: 111), wherein the epitope binding fragment retains its ability to bind to its corresponding CD123 epitope. In some cases, the epitope-binding fragment comprises a sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 102, a sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 103, a sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 110, and a sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: NO: 111 is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence. In some embodiments, the epitope binding fragment comprises all four of SEQ ID NOs 102, 103, 110 and 111.

[0421] In some embodiments, the cell surface lineage-specific protein is CD123, and the epitope binding fragment comprises the following CDR sequences: DIIPSNGATFYNQKFKG (SEQ ID NO: 105), SQSLLNSGNQKNYLT (SEQ ID NO: 107), WASTRES (SEQ ID NO: 108), and QNDYSYPYT (SEQ ID NO: 109).

[0422] Exemplary CAR sequences are provided below:

[0423] SEQ ID NO:69—Fab79D-CAR targeting KIT domain 4, variant 1 (CD28 hinge, CD28 TM, CD28z, CD3z) amino acid sequence (epitope binding regions are italicized, CDRs are bold)

[0424]

[0425] SEQ ID NO: 70—Fab79D-CAR targeting KIT domain 4, variant 1 (CD28 hinge, CD28 TM, CD28z, CD3z) nucleotide sequence

[0426]

[0427] SEQ ID NO:71 - Fab79D-CAR targeting KIT domain 4, variant II (CD28 hinge, CD28 TM, CD28z, CD3z) amino acid sequence (epitope binding regions are italicized, CDRs are bold)

[0428]

[0429] SEQ ID NO: 72—Fab79D-CAR targeting KIT domain 4, variant II (CD28 hinge, CD28 TM, CD28z, CD3z) nucleotide sequence

[0430]

[0431] SEQ ID NO:73—4G8-CAR targeting FLT3 domain 4 (IgG4 hinge, CD28 TM, CD28z, CD3z) amino acid sequence (epitope binding regions are italicized; CDRs are bold)

[0432]

[0433] SEQ ID NO: 74 - 4G8-CAR targeting FLT3 domain 4 (IgG4 hinge, CD28 TM, CD28z, CD3z) nucleotide sequence

[0434]

[0435] SEQ ID NO: 75 - CSL362-CAR targeting CD123 N-terminal domain (CD8a hinge, CD28 TM, CD28z, CD3z) amino acid sequence (epitope binding regions are italicized, CDRs are bold)

[0436]

[0437] SEQ ID NO: 76 - CSL362-CAR (CD8a hinge, CD28 TM, CD28z, CD3z) nucleotide sequence targeting CD123 N-terminal domain

[0438]

[0439] SEQ ID NO: 77—4G8-CSL362-bispecific CAR targeting FLT3 and CD123, variant I (CD8a hinge, CD28 TM, CD28z, CD3z) amino acid sequence (epitope binding regions are italicized, CDRs are bold)

[0440]

[0441] SEQ ID NO: 78 - 4G8-CSL362-bispecific CAR targeting FLT3 and CD123, variant 1 (CD8a hinge, CD28 TM, CD28z, CD3z) nucleotide sequence

[0442]

[0443]

[0444] SEQ ID NO: 79—4G8-CSL362-bispecific CAR targeting FLT3 and CD123, variant II (CD8a hinge, CD28 TM, CD28z, CD3z) amino acid sequence (epitope binding regions are italicized, CDRs are bold)

[0445]

[0446] SEQ ID NO: 80—4G8-CSL362-bispecific CAR targeting FLT3 and CD123, variant II (CD8a hinge, CD28 TM, CD28z, CD3z) nucleotide sequence

[0447]

[0448]

[0449] SEQ ID NO: 86 - CSL362-CAR variant 2 targeting CD123 N-terminal domain (IgG4 hinge, CD28TM, CD28z, CD3z) amino acid sequence (CDRs are in bold)

[0450]

[0451] SEQ ID NO: 87 - CSL362-CAR variant 3 targeting CD123 N-terminal domain (IgG4 hinge, CD28TM, CD28z, CD3z) amino acid sequence (CDRs are in bold)

[0452]

[0453] III. Methods of Treating Subjects

[0454] Genetically engineered hematopoietic cells (such as HSC) can be administered to a subject in need of treatment alone or in combination with one or more cytotoxic agents targeting one or more cell surface antigens as described herein. Since hematopoietic cells are genetically edited in the genes of one or more cell surface antigens, hematopoietic cells and / or their progeny cells will express one or more cell surface antigens in a mutant form (e.g., but functional), so that they can escape being targeted by cytotoxic agents (e.g., CAR-T cells).

[0455] Therefore, the present disclosure provides a method for treating hematopoietic malignancies, the method comprising administering to a subject in need (i) a genetically engineered hematopoietic cell population as described herein, and optionally (ii) a cytotoxic agent (such as a CAR-T cell) targeting a cell surface antigen, whose gene is genetically edited in the hematopoietic cell so that the cytotoxic agent does not target the hematopoietic cell or its progeny cell. (i) and (ii) administration can be performed simultaneously or in any order. In some embodiments, the cytotoxic agent and / or hematopoietic cells can be mixed with a pharmaceutically acceptable carrier to form a pharmaceutical composition, which is also within the scope of the present disclosure.

[0456] As used herein, "subject," "individual," and "patient" are used interchangeably and refer to a vertebrate, preferably a mammal such as a human. Mammals include, but are not limited to, human primates, non-human primates, or murine, bovine, equine, canine, or feline species. In some embodiments, the subject is a human patient suffering from a hematopoietic malignancy.

[0457] In order to implement the methods described herein, an effective amount of genetically engineered hematopoietic cells can be administered to a subject in need of treatment. Optionally, hematopoietic cells can be used in conjunction with cytotoxic agents as described herein. As used herein, the term "effective amount" can be used interchangeably with the term "therapeutically effective amount", and refers to the amount of a cytotoxic agent, a hematopoietic cell group or a pharmaceutical composition (e.g., a composition comprising a cytotoxic agent and / or hematopoietic cells), which is sufficient to produce the desired activity after being administered to a subject in need. In the context of the present disclosure, the term "effective amount" refers to the amount of a compound, a cell group or a pharmaceutical composition that is sufficient to delay manifestation, prevent progression, alleviate or mitigate at least one symptom of a disorder treated by the methods of the present disclosure. Please note that when a combination of active ingredients is administered, the effective amount of the combination may include or exclude the amount of each component that is effective when administered alone.

[0458] As will be appreciated by those skilled in the art, the effective amount varies, depending on the particular disorder being treated, the severity of the disorder, individual patient parameters (including age, physical condition, size, sex, and weight), duration of treatment, the nature of concurrent therapy (if any), the specific route of administration, and similar factors within the knowledge and expertise of the health care personnel. In some embodiments, the effective amount alleviates, relieves, improves, increases, reduces symptoms, or delays the progression of any disease or condition of the subject. In some embodiments, the subject is a human. In some embodiments, the subject is a human patient suffering from a hematopoietic malignancy.

[0459] As described herein, the hematopoietic cells and / or immune cells expressing chimeric receptors can be subject autologous, that is, cells are obtained from subjects in need of treatment, and the cells are operated so that they do not bind to cytotoxic agents and are then applied to the same subject. Compared with the use of non-autologous cells, the use of autologous cells to subjects can cause the rejection of host cells to be reduced. For example, HSPC is obtained from a biological sample of a subject, HSPC is genetically engineered, and the genetically engineered HSPC is applied to the same subject. In some cases, HSPC is obtained from a biological sample, and the biological sample is CD34+ hematopoietic stem cells and progenitor cells derived from bone marrow cells, blood, umbilical cord blood cells or mobilized peripheral blood.

[0460] Alternatively, the host cells are allogeneic cells, i.e., cells obtained from a first subject, genetically engineered, and then administered to a second subject that is different from the first subject but of the same species. For example, allogeneic immune cells can be derived from a human donor and administered to a human recipient that is different from the donor. In some embodiments, the hematopoietic cells have been further genetically engineered to reduce the host-versus-graft effect. For example, in some embodiments, immune cells and / or hematopoietic cells can be subjected to gene editing or gene silencing methods to reduce or eliminate the expression of one or more proteins involved in inducing a host immune response.

[0461] A typical amount of cells (ie, immune cells or hematopoietic cells) administered to a mammal (eg, a human) may be, for example, about 10 6 Up to 10 11 In some embodiments, less than 10 cells are administered to a subject. 6 In some embodiments, less than 10 cells are administered to a subject. 11 In some embodiments, one or more doses of cells include about 10 6 cells to about 10 11 cells, about 10 7 cells to about 10 10 cells, about 108 cells to about 10 9 cells, about 10 6 cells to about 10 8 cells, about 10 7 cells to about 10 9 cells, about 10 7 cells to about 10 10 cells, about 10 7 cells to about 10 11 cells, about 10 8 cells to about 10 10 cells, about 10 8 cells to about 10 11 cells, about 10 9 cells to about 10 10 cells, about 10 9 cells to about 10 11 cells or about 10 10 cells to about 10 11 cells.

[0462] In some embodiments, the methods described herein involve administering to a subject a population of genetically engineered hematopoietic cells and administering one or more immunotherapeutic agents (e.g., cytotoxic agents). One of ordinary skill in the art will appreciate that the immunotherapeutic agents can be of the same or different types (e.g., therapeutic antibodies, immune cell populations expressing chimeric antigen receptors, and / or antibody-drug conjugates).

[0463] In some embodiments, a cytotoxic agent comprising an epitope-binding fragment that binds to an epitope of a cell surface protein is administered prior to administration of hematopoietic cells (e.g., an immune cell expressing a chimeric receptor as described herein). In some embodiments, an agent comprising an epitope-binding fragment that binds to an epitope of a cell surface protein (e.g., an immune cell expressing a chimeric receptor as described herein) is administered prior to administration of hematopoietic cells for at least about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 3 months, 4 months, 5 months, 6 months or longer.

[0464] Alternatively, in some embodiments, hematopoietic cells are administered prior to a cytotoxic agent comprising an epitope-binding fragment that binds to an epitope of a cell surface protein (e.g., an immune cell expressing a chimeric receptor as described herein). In some embodiments, a hematopoietic cell population is administered prior to administration of a cytotoxic agent comprising an epitope-binding fragment that binds to an epitope of a cell surface protein for at least about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 3 months, 4 months, 5 months, 6 months or longer.

[0465] In some embodiments, the cytotoxic agent targeting the cell surface protein and the hematopoietic cell population are administered substantially simultaneously. In some embodiments, the cytotoxic agent targeting the cell surface protein is administered and the patient is evaluated for a period of time, and then the hematopoietic cell population is administered. In some embodiments, the hematopoietic cell population is administered and the patient is evaluated for a period of time, and then the cytotoxic agent targeting the cell surface protein is administered.

[0466] Multiple administrations (e.g., dosages) of cytotoxic agents and / or hematopoietic cell populations are also within the scope of the present disclosure. In some embodiments, cytotoxic agents and / or hematopoietic cell populations are administered to a subject once. In some embodiments, cytotoxic agents and / or hematopoietic cell populations are administered to a subject more than once (e.g., at least 2, 3, 4, 5 or more times). In some embodiments, cytotoxic agents and / or hematopoietic cell populations are administered to a subject at regular intervals (e.g., every six months).

[0467] Examples of routes of administration include intravenous, infusion, intradermal, subcutaneous, oral (eg, inhalation), transdermal (topical), transmucosal, and rectal administration.

[0468] Any of the methods described herein can be used to treat a subject's hematological malignancy. As used herein, the term "treat" or "treatment" or "treating" or "to treat" refers to a therapeutic measure intended to alleviate a pathological disorder or condition, slow its progression, alleviate its symptoms, and / or stop its progression. Therefore, people in need of treatment include those who already have a condition. For example, in some cases, treating cancer means stabilizing the progression of cancer. In some cases, treating cancer means slowing the progression of cancer. In some cases, treating cancer means stopping the progression of cancer. In some cases, treating cancer means reducing the size of cancer. In some cases, treating cancer means improving the overall survival rate of subjects diagnosed with cancer. Methods of evaluating cancer progression are known in the art and include, for example, assessment of target lesions using imaging (e.g., X-ray, computed tomography, magnetic resonance imaging, caliper measurement, or positron emission tomography), cytology or histology, or expression of tumor markers (see, e.g., Eisenhauer et al., 2009, European Journal of Cancer 45:228-247 and Schwartz et al., 2016, European Journal of Cancer 62:132-137; each of which is incorporated herein by reference in its entirety).

[0469] In some embodiments, the subject is a human subject suffering from a hematopoietic malignancy. As used herein, a hematopoietic malignancy refers to a malignant abnormality involving hematopoietic cells (e.g., blood cells, including progenitor cells and stem cells). Examples of hematopoietic malignancies include, but are not limited to, Hodgkin's lymphoma, non-Hodgkin's lymphoma, leukemia, or multiple myeloma. Exemplary leukemias include, but are not limited to, acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia or chronic lymphoblastic leukemia and chronic lymphocytic leukemia.

[0470] In some embodiments, cells related to hematopoietic malignancies are resistant to conventional or standard therapeutic agents for treating malignancies. For example, cells (e.g., cancer cells) may be resistant to chemotherapeutic agents and / or CART cells for treating malignancies.

[0471] In some instances, the hematopoietic malignancy comprises: B-lymphoblastic leukemia (B-ALL), acute myeloid leukemia (AML), T-cell acute lymphoblastic leukemia (T-ALL), or blastic plasmacytoid dendritic cell leukemia (BPCDN).

[0472] IV. Compositions and Kits

[0473] Any immune cell expressing the chimeric receptor described herein can be administered as a pharmaceutical composition in a pharmaceutically acceptable carrier or excipient.

[0474] The phrase "pharmaceutically acceptable" as used in conjunction with the compositions and / or cells of the present disclosure refers to the fact that the molecular entities and other components of such compositions are physiologically tolerable and generally do not produce adverse reactions when applied to mammals (e.g., humans). Preferably, as used herein, the term "pharmaceutically acceptable" means approved by federal regulatory agencies or state governments or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeias for use in mammals and more specifically in humans. "Acceptable" means that the carrier is compatible with the active ingredients (e.g., nucleic acids, vectors, cells, or therapeutic antibodies) of the composition and does not negatively affect the subject to whom the composition is administered. Any pharmaceutical composition and / or cell used in the present method may include a pharmaceutically acceptable carrier, excipient, or stabilizer in the form of a lyophilized formulation or an aqueous solution.

[0475] Pharmaceutically acceptable carriers, including buffers, are well known in the art and may include phosphates, citrates and other organic acids; antioxidants including ascorbic acid and methionine; preservatives; low molecular weight polypeptides; proteins such as serum albumin, gelatin or immunoglobulins; amino acids; hydrophobic polymers; monosaccharides; disaccharides; and other carbohydrates; metal complexes; and / or nonionic surfactants. See, for example, Remington: The Science and Practice of Pharmacy 20th Edition (2000) Lippincott Williams and Wilkins, ed. KE Hoover.

[0476] Kits for treating hematopoietic malignancies are also within the scope of the present disclosure. Such kits may include genetically engineered hematopoietic cells such as HSPC, and optionally one or more cytotoxic agents targeting cell surface antigens, the genes of which are edited in hematopoietic cells. Such kits may include a container comprising a first pharmaceutical composition comprising any genetically engineered hematopoietic cells as described herein, and optionally one or more additional containers comprising one or more cytotoxic agents targeting cell surface antigens as described herein (e.g., immune cells expressing chimeric receptors as described herein).

[0477] In some embodiments, the kit may include instructions for any method described herein. The included instructions may include a description of the administration of genetically engineered hematopoietic cells, and optionally a description of administering one or more cytotoxic agents to a subject to achieve the desired activity in the subject. The kit may also include a description of selecting a subject suitable for treatment based on identifying whether the subject needs treatment. In some embodiments, the instructions include a description of administering genetically engineered hematopoietic cells and optionally one or more cytotoxic agents to a subject in need of treatment.

[0478] Instructions related to the use of genetically engineered hematopoietic cells and optional cytotoxic agents described herein generally include information about the dosage, dosing schedule, and route of administration for the intended treatment. The container can be a unit dose, bulk packaging (e.g., multi-dose packaging), or a subunit dose. The instructions provided in the kit of the present disclosure are typically written instructions on a label or package insert. The label or package insert indicates that the pharmaceutical composition is used to treat a disease or condition of a subject, delay its onset, and / or alleviate it.

[0479] The medicine boxes provided herein all adopt suitable packaging. Suitable packaging includes but is not limited to vials, bottles, jars, soft packaging, etc. It is also envisioned that the packaging used in combination with a specific device (such as an inhaler, a nasal application device, or an infusion device) can be used. The medicine box can have a sterile access port (for example, the container can be an intravenous solution bag or a vial with a stopper that can be pierced by a hypodermic injection needle). The container can also have a sterile access port. At least one active agent in the pharmaceutical composition is a chimeric receptor variant as described herein.

[0480] The kit may optionally provide additional components, such as buffers and interpretive information. Typically, the kit includes a container and a label or package insert on or associated with the container. In some embodiments, the disclosure provides an article of manufacture comprising the contents of the above kit.

[0481] Example

[0482] The following examples are provided to better illustrate the claimed invention and should not be construed as limiting the scope of the invention. With regard to specific materials, they are merely for illustrative purposes and are not intended to limit the present invention. Those skilled in the art can develop equivalent means or reactants without using creative ability and without departing from the scope of the present invention.

[0483] Example 1: General protocol used in the following examples

[0484] Plasmid cloning

[0485] WT-Cas9 and NG-Cas9 base editor plasmids were obtained through Addgene (plasmid numbers 138495, 138491). SpRY-ABE8e-V106W 3xNLS and other base editor variants (see full list below) were cloned using NEB HiFi assembly master mix and synthetic dsDNA inserts (IDT gBlock). Single amino acid changes (ie, K918N) or deletions (Blackjack variants) were introduced by standard site-specific mutagenesis techniques. When needed, sgRNAs were cloned into pLentiguide-Puro backbones (Addgene) or pLKO-mTagBFP2 backbones (cloned) using BsmBI restriction enzymes and annealed and phosphorylated DNA oligonucleotides with the desired spacer sequences. Purify plasmids using Mackarey Nagel NucleoBondXtra Maxi kits to extract (maxiprep).

[0486] Table 3:

[0487]

[0488]

[0489] Flow cytometry ligand affinity assay

[0490] In order to evaluate the binding affinity of mutant receptors to their ligands, a fluorescent ligand binding assay was developed. Human SCF and FLT3L (Peprotech) were conjugated with Alexa Fluor 488 antibody labeling kit (Invitrogen catalog number A20181) according to the manufacturer's recommendations. Cells expressing FLT3 or KIT variants were incubated with FcR blocking reagent (Miltenyi 130-059-901), LIVE / DEAD fixable yellow dead cell stain (Invitrogen L34967), control antibodies (KIT104D2 PE-Cy7, Biolegend, or FLT3 BV10A4 PE-Cy7, Biolegend) and the corresponding AF488-conjugated ligand for 15 min at room temperature. Samples were washed with PBS+2% FBS and analyzed with a BD Fortessa flow cytometer.

[0491] Reporter cell lines for FLT3 and CD123 editing

[0492] Since K562 cells do not constitutively express FLT3 or CD123, these cells were engineered to overexpress FLT3, CD123, KIT, or any combination of the three genes from their endogenous genomic loci to serve as a model for gene editing methods for these genes. To obtain constitutive strong expression of these genes, the fully human EF1α promoter was integrated upstream of the transcription start site of the FLT3, CD123, or KIT gene by CRISPR-Cas9 (FLT3, KIT) or CRISPR-AsCas12a (CD123) gene editing strategy ( Figure 8 ). A dsDNA linear donor with a 50 bp long homology arm for the region to be targeted was prepared by PCR on the Sleeping Beauty plasmid encoding the EF1α promoter. Wild-type K562 cells were electroporated using the Lonza 4D-Nucleofector system, in which Cas9 (FLT3, KIT) or Cas12a (CD123) RNP had a gRNA targeting the promoter region of the corresponding gene. 5 to 10ug of dsDNA linear donors with matching homology arms were included in the electroporation reaction to serve as a template for homology-directed repair integration. Cells were stained with FLT3 BV10A4 PE-Cy7 (Biolegend), KIT 104D2 PE-Cy (Biolegend) or CD123 9F5 BV421 and CD123 7G3 BV711 (BD) and evaluated by flow cytometry. FLT3, CD123 or KIT-high populations were FACS sorted and single clones were isolated by limiting dilution ( Figure 8 The clones with the highest MFI for FLT3 (clone AH11) and CD123 (clone 3D5) by flow cytometry were selected for expansion.

[0493] Western blotting

[0494] K562 cells overexpressing FLT3 / CD123 variants or NIH-3T3 cells or HEK-293T cells overexpressing KIT were cultured overnight in FBS-free culture medium (serum starvation), and then 1 million cells under each condition were stimulated or not stimulated (for 5') at 37°C with 100ng / mL FLT3L, IL3 or SCF (depending on the receptor assessed). Cells were then washed 3 times with ice-cold PBS, lysed and proteins were extracted for western blot (cell extraction buffer, ThermoFisher FNN0011 + 1mM PMSF). After quantification with BCA assay, protein extracts were mixed with Laemmli loading dye (Biorad 161-0747) and run on Novex Tris-Glycine gel (Invitrogen). After transfer, the membrane was blocked with 5% w / v BSA in TBST and incubated overnight at 4° C. with primary antibodies recognizing pKIT (Y719, Cell Signaling 3391T) or pFLT3 (Tyr589 / 591 clone 30D4, Cell Signaling 3464S). After washing, the membrane was incubated with anti-rabbit IgG, HRP-linked antibody (Cell Signaling 7074) for 1 hour at room temperature, then incubated with SuperSignalWest Femto chemiluminescent HRP substrate (Thermo Scientific 34096) and analyzed with ImageQuantLAS4000. The same membrane was then incubated with Restore (ThermoScientific #21059) stripping buffer at room temperature for 20 minutes and secondary stained with anti-KIT (clone 1C5, Invitrogen MA5-15894) or anti-FLT3 (clone OTI7D6, Origene TA808157) primary antibodies in the same steps as above. Secondary antibody staining was performed with anti-rabbit or anti-mouse IgG HRP-conjugated antibodies according to the primary antibody, and the membrane was developed and acquired as described above. Anti-actin staining was used as an internal control for loading normalization.

[0495] Flow cytometry analysis (in vitro experiments)

[0496] Edited cell lines were evaluated by flow cytometry 72 hours after editing and stained with antibody clones binding to therapeutic epitopes or irrelevant epitopes to serve as control antibodies for surface expression of edited proteins. For FLT3 editing, cells were incubated with FcR blocking reagent (Miltenyi 130-059-901) 2 / 100uL, LIVE / DEAD fixable yellow dead cell stain (Invitrogen L34967) 1 / 1000, FLT3 BV10A4 PE-Cy7 2 / 100 (Biolegend 313314) and FLT3 4G8 BV711 (BD 563908). For CD123 editing, cells were incubated with FcR blocking reagent (Miltenyi130-059-901) 2 / 100uL, LIVE / DEAD Fixable Yellow Dead Cell Stain (Invitrogen L34967) 1 / 1000, CD123 9F5 PE or BV421 (BD 555644) 1 / 100, CD123 7G3 BV711 or BV421 (BD 740722) 1 / 100. For KIT editing, cells were incubated with FcR blocking reagent (Miltenyi 130-059-901) 2 / 100uL, LIVE / DEAD fixable yellow dead cell stain (Invitrogen L34967) 1 / 1000, KIT 104D2 PE-Cy7 or BV711 2 / 100 (Biolegend 313212), KIT Fab79D AF488 or PE (Creative Biolabs) 2 / 100. Staining was performed at 4°C for 30 minutes at 100uL / sample volume. To evaluate the stem cell phenotype of cultured human CD34+ HSPCs, cells were harvested, resuspended in 100uL PBS, and stained with FcR blocking reagent (Miltenyi 130-059-901) 2 / 100uL, LIVE / DEAD fixable yellow dead cell stain (Invitrogen L34967) 1 / 1000, CD34 BV421 (Biolegend) 1.5 / 100, CD90 APC (BD) 3.5 / 100, CD45RA APC-Cy7 (Biolegend) 3.5 / 100, CD133 / 2PE (Miltenyi) 4 / 100. Staining was performed at 100uL / sample volume for 30 minutes at 4°C. Samples were analyzed on a 4 or 5 laser BD Fortessa flow cytometer.

[0497] Flow cytometric analysis (in vivo experiments)

[0498] Peripheral blood from xenografted NSG mice was collected into 1.5 mL Eppendorf tubes with 10 uL 0.5 M EDTA and stained with FcR blocking reagent (Miltenyi 130-059-901) 2 / 100 uL, LIVE / DEAD fixable yellow dead cell stain (Invitrogen L34967) 1 / 1000, human CD45 BV786 (Biolegend) 1.5 / 100, mouse CD45 BV570 (Biolegend), CD34 BV421 (Biolegend) 1.5 / 100, CD19 BV650 (Biolegend) 3 / 100, CD3 BV711 (Biolegend) 2 / 100, CD33 BB515 (BD) 2 / 100 for 15 minutes at room temperature. Blood samples were then lysed with ACK reagent (StemCell Technologies) for 5 minutes at room temperature and washed twice in PBS + 2% FBS. Samples were analyzed on a 4-laser BD Fortessa flow cytometer.

[0499] Bone marrow from xenografted mice was obtained by crushing hind limb bones in a mortar, filtering through a 40-um cell strainer, and resuspending cells in Miltenyi MACS running buffer. A portion of the cells were stained for flow cytometry analysis: FcR blocking reagent (Miltenyi 130-059-901) 2 / 100uL, 7-AAD (BD Pharmigen) 3 / 100, human CD45 BV786 (Biolegend) 1.5 / 100, mouse CD45 BV570 (Biolegend), CD34 BV421 (Biolegend) 1.5 / 100, CD19 BV650 (Biolegend) or CD19 BV605 (Biolegend) 3 / 100, CD3 BV711 (Biolegend) or CD3 PE-Cy7 (Biolegend) 2 / 100CD33 BB515 (BD), CD38 BV480 (BD) 1.5 / 100 or CD38 BUV396 (BD) 2 / 100, FLT3 BV10A4 PE-Cy7 (Biolegend), CD123 9F5 PE (BD), CD90 APC (BD) 3.5 / 100, CD45RA APC-Cy7 (Biolegend) 3 / 100 for 30 minutes at 4° C. Spleens were triturated on a 40 um cell strainer and resuspended in Miltenyi MACS running buffer. The recovered cells were stained with FcR blocking reagent (Miltenyi 130-059-901) 2 / 100uL, LIVE / DEAD fixable yellow dead cell stain (Invitrogen L34967) 1 / 1000, human CD45 Pacific Blue (Biolegend) 1.5 / 100, mouse CD45 BV570 (Biolegend), CD3 BV711 (Biolegend) 2 / 100, EGFR AF488 (R&D) 1.5 / 100, CD62L PE (BD) 2 / 100, CD4 APC (BD) 2 / 100, CD8 BV750 (Biolegend) 2 / 100, CD45RA APC-Cy7 (Biolegend) 3 / 100, and CD69 PerCP-Cy5.5 (Biolegend) 3 / 100 at 4°C for 30 minutes. Samples were analyzed on a 4-laser BD Fortessa flow cytometer.In some experiments, BM cells were stained with hCD45 BV786, mCD45 PerCP-Cy5.5, CD3 PE-Cy5, CD7 AF700, CD10 BUV737, CD11c BUV661, CD14 BV510, CD19 BV605, CD33 PE-Cy7, CD38 BUV396, CD45RA APC-Cy7, CD56 BUV496, CD90 APC, FLT3 PE or BV711, and KIT BV711 or CD123 PE antibodies, and 50 uL / sample Brilliant staining buffer (BD catalog number 659611) was added.

[0500] gDNA extraction, PCR amplification and Sanger sequencing

[0501] Genomic DNA was extracted from dry pellet samples using Qiagen DNeasy Blood & Tissue Kit or Lucigen QuickExtract reagent, quantified by Nanodrop 8000, and the sequences of interest were amplified by PCR using Promega GoTaq G2 and corresponding primers. PCR products were purified using Promega SV Wizard Gel and PCR Clean-Up systems and sent for Sanger sequencing by Genewiz. Base editing efficiencies were calculated from Sanger trajectories using custom scripts for high-throughput sample analysis and deconvolution using the EditR R package.

[0502] Colony formation assay

[0503] Unless otherwise stated, colony forming unit (CFU) determination is by paving 1000 CD34+ cells / well in in vitro CD34+HSPC experiment, or paving 25000 total bone marrow cells / well in xenotransplantation BM derived determination. Cells are resuspended in Methocult H4034 culture medium (StemCell catalog number 04034), and paved in SmartDish without meniscus 6-well plate. StemCell STEMvision system is used to image the hole after 2 weeks. For flow cytometry analysis, methylcellulose culture medium is softened with warm PBS before analysis, collected and washed twice.

[0504] Example 2: Receptor variant design

[0505] To design mutant receptor variants that will not be recognized by the selected monoclonal antibody clone, epitopes targeted by different mAbs are identified based on information available in the literature or by screening individual mutant receptor variants or mutant libraries. The overall goal is to identify minimally modified target variants that retain surface expression, gene regulation, and signal transduction functions but lack recognition by the selected therapeutic antibody clone ( Figure 1 Cells bearing such modified surface targets are conferred selective resistance when exposed to immunotherapies directed against target molecules (including but not limited to naked monoclonal antibodies, toxin-conjugated antibodies, bispecific antibody constructs, and chimeric antigen receptor cells).

[0506] FLT3 epitope engineering:

[0507] FLT3 is a type III tyrosine kinase receptor consisting of the following parts: i) an extracellular ligand binding domain characterized by the presence of five immunoglobulin-like domains; ii) a single transmembrane region; iii) an intracellular portion containing a split tyrosine kinase domain. The first three extracellular domains are involved in binding to its dimeric ligand, FLT3-ligand (FLT3L), and this interaction induces receptor dimerization. After dimerization, FLT3 activation is mediated by the intracellular tyrosine kinase domains being closely positioned to each other, which facilitates their subsequent transphosphorylation.

[0508] The alignment showed that mouse and human FLT3 / FLT3L were 85.5% identical at the amino acid level, and mouse and human FLT3 IgG-like domain 4 were 82% identical (95.5% similar) at the amino acid level ( Figure 3 ). In addition, the mouse and human FLT3 / FLT3L pairs are cross-reactive with each other. The anti-human FLT3 therapeutic antibody clone 4G8 specifically recognizes human FLT3, and the epitope is located within the extracellular domain 4. The lack of recognition of other orthologous variants (i.e., mouse Flt3) by clone 4G8 was confirmed by staining of K562 cells overexpressing wild-type human or mouse FLT3 using the Sleeping Beauty transposon system, in which human FLT3 or mouse Flt3 cDNA sequences were cloned downstream of the constitutive EF1a promoter ( Figure 2 ). The mCherry fluorescent reporter gene encoded by the Sleeping Beauty transposon was used to identify transduced cells. Based on this evidence, 16 residues located in the extracellular domain 4 (which are relatively rare in orthologous sequences) were added ( Figure 3 ) were replaced with the corresponding murine amino acids, and the resulting variant (eFLT3-01, SEQ ID NO: 49) could not be recognized by clone 4G8 ( Figure 2 The generated variants still retained surface expression (confirmed using control anti-FLT3 clone BV10A4 that binds extracellular domain 2), FLT3L binding (see Figure 4A and 4B ) and intracellular signaling properties. (See Figure 4C ).

[0509] In a second step, the 16 mutations introduced to generate eFLT3-01 (SEQ ID NO: 49) were divided into two mutant pools by their genomic location within FLT3 exon 9 or exon 10 (collectively encoding FLT3 extracellular domain 4). Overexpression of these two FLT3 variants showed that mutations restricted to FLT3 exon 9 (SEQ ID NO: 50) were sufficient to eliminate anti-FLT3 clone 4G8, similar to SEQ ID NO: 49. FLT3 variants with mutations restricted to exon 10 did not eliminate clone 4G8 binding.

[0510] To identify the key residues involved in the recognition of the anti-FLT3 antibody FLT3 4G8 clone in the FLT3 extracellular domain 4, a combinatorial library with all 16 previously identified residues (wild type or mutant) was designed and cloned into the Sleeping Beauty transposon transfer vector under the EF1α promoter (GeneScript- Figure 5 ).Antense boxes expressing mCherry and puromycin resistance under RPBSA promoter serve as transduction markers and selection methods.K562 cells are electroporated using Lonza 4D-Nucleofector system with 5,10 or 100ng transfer vector and 500ngSB100x transposase expression plasmid.Cells of nuclear transfection are selected for 7 days with 1ug / mL puromycin and then evaluated by flow cytometry.FACS sorting is performed using BD Aria II sorter to control antibodies (FLT3 BV10A4 PE-Cy7) positive and negative cells for therapeutic antibodies (FLT3 4G8 BV711), and amplified in vitro.The FLT3 library area integrated is amplified by PCR from the gDNA samples of cells that are not sorted, single positive sorting and double positive sorting, and part of Illumina adapters are added to amplicon and submitted to NGS on Illumina platform (GeneWiz). By comparing the three samples, only one codon (N399) showed differential mutation enrichment in single-positive cells versus double-positive cells ( Figure 5 ). Validation of the candidate mutation (N399D) in the Sleeping Beauty overexpression system confirmed that it was sufficient to eliminate 4G8 clone binding ( Figure 5 ). Incubation of K562 cells overexpressing the FLT3 N399D variant with AF488-conjugated fluorescent FLT3L showed ligand binding comparable to that of wild-type FLT3 ( Figure 5 ).

[0511] KIT epitope engineering:

[0512] Based on available literature, the anti-KIT antibody clone Fab79D recognizes a putative amino acid contact point in the extracellular domain 4 of KIT ( Figure 3 ). Therefore, by replacing the 10 predicted contact amino acids that were retained less in the orthologous sequence, a KIT variant (eKIT-01) that could not be recognized by the anti-KIT antibody clone Fab79D was generated ( Fig. 6A This variant retains affinity for human stem cell factor (SCF) ( Figure 6B ) and intracellular domain phosphorylation after SCF stimulation ( Figure 6C To identify the specific amino acid basis to which cloned Fab79D binds, each single amino acid change was cloned individually into a Sleeping Beauty transfer vector co-expressing mCherry and Puromycin resistance. 293T cells were electroporated using the Lonza 4D-Nucleofector system in SF solution with 100 ng of transfer vector and 500 ng of a plasmid expressing SB100x transposase ( Fig.6D ). Cells were selected with puromycin (2ug / mL) and analyzed by flow cytometry staining with KIT Fab79D and KIT 104D2 control antibodies. Mutations with the lowest Fab79D MFI compared to KIT expression by clone 104D2 staining (KIT H378R) were selected as candidate variants for base editing strategy development ( Fig.6D ).

[0513] To extend these findings, a comprehensive library approach was designed to further define alternative codons involved in Fab79D binding. A degenerate library in which each codon within the KIT extracellular domain 4 consisted of a degenerate base (NNN) was cloned into a Sleeping Beauty transfer plasmid expressing human KIT cDNA, the mTagBFP reporter gene, and puromycin resistance ( Figure 7 ). HEK-293T cells were electroporated with library plasmid and pSB100X transposase plasmid to allow stable integration of transgenes. After puromycin selection, cells were FACS sorted to obtain single positive and double positive groups. PCR amplification and NGS sequencing were performed on the library region. The relative enrichment of amino acid variants in single positive and double positive groups was compared, and additional codons (M318, I319, V323, D332, E360, Y362, E376) involved in Fab79D binding were identified in addition to H378.

[0514] CD123 epitope engineering:

[0515] For CD123 (CD123), it has been reported that the anti-CD123 antibody clone 7G3 and its humanized version CSL362 can recognize putative amino acid contact points within the CD123 N-terminal domain ( Fig. 9 ). Similarly, other commercially available clones 6H6 and S18016E have been reported to bind to the N-terminal domain, but there is limited information on their contact points with CD123. IL3 is a ligand for CD123, and CD123 residues important for IL3 binding have been mapped by Ala scanning or evolutionarily conserved amino acid changes ( Fig. 9 ).

[0516] In order to engineer the target epitope in the CD123 extracellular domain, a direct base editor screening method was used to design a group of sgRNAs targeting I50, E51, Y58, S59, R84, P88 or P89 in the CD123 N-terminal domain (Figure 10). These gRNAs were tested with cytidine or adenine base editors (evo-APOBEC1-BE4, ABE8e-V106W) on K562 cells overexpressing CD123. In brief, according to the manufacturer's instructions, 0.5M cells were electroporated in SF solution using the Lonza 4D-Nucleofector system. 500ng base editor expression plasmid and 300-360pmol sgRNA (Integrated DNA Technology) were included in the electroporation reaction. Cells were then cultured, and genomic DNA and flow cytometry analysis samples were harvested 72h after editing. sgRNAs that generated CD123 mutants that lacked recognition by several mAb clones (7G3 / CSL362, 6H6, S18016F) but retained surface expression by staining with control antibody clone 9F5 were selected for further development ( FIG. 10 , only the best performing candidate gRNAs are reported: SEQ ID NO: 24, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34).

[0517] A second round of sgRNA screening was performed, including additional sequences in close proximity to the sgRNAs identified in the previous round, and several BEs, including variants with relaxed PAM specificity, were tested (evo-APOBEC1-BE4, NG-EA-BE4max, NG-A3A-BE5, SpRY-evo-APOBEC1-BE4-SEQ ID NO: 8 and SEQ ID NO: 11, NG-ABE8e, SpRY-ABE8e-V106E-SEQ ID NO: 7 and SEQ ID NO: 10, LbCas12a-ABE8e- Fig.11). Using clone 9F5 as a normalizer for surface expression, the binding of clones 7G3, 6H6 and S18016E was evaluated by flow cytometry as previously described. gDNA under conditions showing the desired loss of recognition was extracted, and Sanger sequencing was performed on CD123 exon 2 and 3 regions to obtain amino acid changes associated with the observed phenotype. For antibody clone 7G3 or its humanized counterpart, CSL362, CD123 S59P (introduced by gRNA-N, gRNA-R and related variants with ABE) and S59F (introduced by gRNA-L and variants with CBE) are the best candidate variants. Due to the conversion of bystander adenine from A to G, the Y58H mutation was also introduced by gRNA-N and gRNA-R. To eliminate the binding of antibody clones 6H6 and S18016F, P88L / P89L (introduced by gRNA-F and related variants with CBE) is the best performing amino acid substitution. Additional gRNAs (gRNA-H and related variants) that introduced additional pools of amino acid substitutions (R84Q, V85M, V85I, A86T) by cytidine base editing were identified and resulted in reduced affinity for clones 7G3, 6H6, and S18016F ( Fig.11 ).

[0518] Example 3: FLT3 variants are resistant to CAR-T cells targeting FLT3

[0519] To test whether FLT3 variants are selectively resistant to FLT3-targeting CAR-T cells, an in vitro killing assay was performed.

[0520] CAR-T cell generation

[0521] The III generation lentiviral construct was cloned using synthetic dsDNA fragments (IDT gBlocks), and the construct was expressed under the constitutive hPGK promoter with the 2nd generation FLT3 specific 4G8 cloned chimeric antigen receptor of CD28 transmembrane region and CD28 costimulatory domain. The antisense box of the truncated variant of human EGFR cDNA expressed under the minimum CMV promoter was used to serve as a transduction marker and safety switch for in vivo depletion by using anti-EGFR antibody Cetuximab. According to the disclosed method, VSV-G pseudotype self-inactivation lentiviral particles were prepared by 5 plasmids (transfer vector, pMD2, pMDL-RRE, pREV and pAdvantage plasmid) in calcium phosphate transient cotransfection HEK-293T cells. The supernatant containing viral particles was concentrated 500 times by ultracentrifugation (20000rpm, 20°C, 2 hours), and resuspended in PBS. Concentrated LVs were titrated by transducing 293T cells at different concentrations and calculating transduction efficiency by flow cytometry or ddPCR.

[0522] Peripheral blood mononuclear cells (PBMC) were isolated from whole blood by polysucrose gradient separation. After estimating the T cell fraction by flow cytometry, freshly isolated or thawed PBMCs were incubated with CD3-CD28 Dynabeads at a 3:1 bead: T cell ratio (Gibco 11131D) at room temperature for 45 min with slow stirring, followed by magnetic separation (DynaMag-5 Magnet, Invitrogen 12303D). Positively selected cells were cultured with Dynabeads at a concentration of 1M / mL in IMDM containing 10% FBS, 1% P / S, human IL-7 5ng / mL (Peprotech) and human IL-15 5ng / mL (Peprotech). 48h after the start of Dynabead stimulation, T cells were transduced at MOI 5 to MOI10 according to the experiment of the lentiviral particles encoding the selected CAR. On the 7th day after the start of stimulation, Dynabead was removed from the culture by magnetic separation, and T cells were additionally expanded for 5-7 days in IMDM supplemented with 10% FBS, 1% P / S, human IL-7 5ng / mL (Peprotech) and human IL-15 5ng / mL (Peprotech). T cell phenotype and transduction efficiency (by EGFR surface staining) were regularly assessed by flow cytometry. Amplified CAR-T cells or untransduced T cells can be used for killing assays, in vivo administration or in vivo freezing 12-14 days after the start of stimulation.

[0523] K562 cells (unmodified, base-edited, or overexpressing receptor variants after Sleeping Beauty transduction) were plated in 96-well plates (25,000 target cells / well). Anti-FLT3 CAR-T cells were generated by transducing peripheral blood mononuclear cells (PBMCs) with a lentiviral vector encoding a second-generation 4G8-CAR construct with a CD28 co-stimulatory domain and co-expressing an EGFRt (truncated EGFR) safety switch (see the protocol above). 4G8 CAR-T cells targeting FLT3 or untransduced T cells were labeled with CellTrace yellow (Invitrogen C34567) according to the manufacturer's recommendations. 4G8 CAR-T cells targeting FLT3 or untransduced T cells were then co-plated in the same wells at different effector: target ratios (E: T ratios), typically 10, 5, 2.5, 1.25, 0.625, and incubated at 37°C in a humidified incubator with 5% CO2. After 4 hours, 50% of the culture volume was harvested for flow cytometry analysis by staining with FcR blocking reagent (Miltenyi 130-059-901) 2 / 100uL, LIVE / DEAD fixable yellow dead cell stain (Invitrogen L34967) 1 / 1000, FLT3 BV10A4 PE-Cy7 2 / 100 (Biolegend 313314), CD4 APC (BD) 2 / 100, CD8 BV750 (Biolegend) 2 / 100, CD107a BV711 (Biolegend) 2 / 100, CD69 PerCP-Cy5.5 (Biolegend) 2 / 100. The staining mixture included flow counting beads to normalize cell counts (Biolegend Precision Count Bead). The cells were then washed and resuspended in AnnexinV binding buffer (Biolegend) supplemented with AnnexinV FITC (Biolegend) 3 / 100. The samples were analyzed on a 4 or 5 laser BD Fortessa flow cytometer.48 hours after plating the remaining culture volume was assessed by flow cytometry staining with FcR blocking reagent (Miltenyi 130-059-901) 2 / 100uL, LIVE / DEAD fixable yellow dead cell stain (Invitrogen L34967) 1 / 1000, FLT3 BV10A4 PE-Cy7 2 / 100(Biolegend 313314), CD4 APC (BD) 2 / 100, CD8 BV750 (Biolegend) 2 / 100, CCR7 BV421 (Biolegend) 2 / 100, CD45RA APC-Cy7 (Biolegend) 3 / 100, CD33 PerCP-Cy5.5 (Biolegend). The cells were then washed and resuspended in AnnexinV binding buffer (Biolegend) supplemented with AnnexinV FITC (Biolegend) 3 / 100.

[0524] Fig. 12A Shown is the experimental design of the co-culture killing assay to evaluate the resistance of modified FLT3 variants to CAR-T cell-mediated killing. Fig. 12B Is a flow cytometry diagram showing the co-culture composition of live cells at 4 hours and 48 hours after incubation. The top row shows the FLT3 expression on WT or engineered K562 cells by flow cytometry. Cells expressing unmodified wild-type FLT3 are selectively killed, while engineered FLT3 (e9-FLT3) is spared. Fig. 12C Target cell viability obtained by AnnexinV and LiveDead Yellow staining 4 hours after incubation is shown. Fig.12D Selective T cell degranulation by CD107a surface staining at 4 hours was shown only for FLT3-CAR-T exposed to target cells expressing unmodified FLT3. Fig.12E Selective T cell proliferation by dye dilution (CellTrace yellow) is shown 48 hours after co-culture, only for FLT3-CAR--T exposed to target cells expressing unmodified FLT3. Unmodified K562: wild-type cells; WT FLT3 OE: K562 reporter cell line, whose endogenous promoter overexpresses FLT3 (see reporter cell line generation); "WT FLT3 OE (Sleeping Beauty)" and "e9 FLT3 OE (Sleeping Beauty)": K562 cells transduced with Sleeping Beauty transposon driving overexpression of FLT3 variants. The e9-FLT3 variant has 12 amino acid changes compared to WT-FLT3, including N399D (SEQ ID NO: 50).

[0525] Example 4: Homology-directed repair to introduce N399D into FLT3

[0526] To test whether FLT3 N399D can be introduced by homology-directed repair, a CRISPR Cas homology-directed repair (HDR) strategy was designed. SpCas9 or AsCas12a nucleases in combination with several gRNAs targeting the FLT3 exon 9 locus were tested in combination with 200nt long single-stranded oligodeoxynucleotides (ssODNs) as donor templates for HDR. Each donor template included selected silent mutations in bystander amino acids to reduce the risk of heavy cutting by the CRISPR-Cas9 RNP nuclease complex after successful DNA repair. The reverse complementarity of each ssODN donor (referred to as A, C, H, F) was also tested. The sequences of the ssODN template donors are reported as SEQ ID NOS: 40 to 43 (see Table 2 above). K562 reporter cells overexpressing FLT3 by targeted integration of the EF1-a promoter upstream of the endogenous FLT3 locus were electroporated using the Lonza 4D-Nucleofector system in SF solution supplemented with 50 pmol 3xNLS Cas9 nuclease (IDT) complexed with 62.5 pmol annealed trRNA:gRNA, or 50 pmol AsCas12aUltra (IDT) complexed with 62.5 pmol sgRNA, depending on the experimental conditions. Cas9 gRNA e9-4-NGG was tested in combination with ssODN-A and C and their reverse complements (final concentration of 5 uM). Cas12a gRNAs e9-15-TTTV and e9-16-TTTV were tested in combination with ssODN-H and F and their reverse complements (final concentration of 5 uM). IDT HDR Enhancer 0.2 uL / 20 uL (30 uM) was included in the electroporation reaction. The outcome of the editing procedure was assessed by flow cytometry 72 h after electroporation. Fig.13A (Top) Exon 9 of FLT3 with the N399 residue highlighted and its position relative to three gRNAs, one SpCas9 gRNA (e9-4-NGG) and two Cas12a gRNAs (e9-15-TTTV and e9-16-TTTV). The FLT3 exon 9 targeting gRNAs are reported as SEQ ID NOS: 13 to 16 (see Table 1 above). Fig.13A (Bottom) shows the insertion of the N399D (arrow) mutation by homology-directed repair using a single-stranded oligodeoxynucleotide donor template. Additional silent single nucleotide changes were included in the template design to reduce the rate of re-cleavage by the Cas9-gRNA complex (dark squares).

[0527] Fig. 13BFACS plots 72 hours after electroporation of K562 reporter cells stained with FLT3 clone 104D2 and clone 4G8 as normalizers for surface expression to assess the efficiency of the N399D mutation are shown. Successfully edited cells are highlighted by black rectangles, showing that the N399D mutation can be inserted into human cell lines by CRISPR-Cas homology-directed repair, resulting in loss of recognition by mAb clone 4G8.

[0528] Example 5: FLT3 mutations at position N399 can be introduced via CRISPR adenine base editor

[0529] In order to introduce the desired single codon changes at the FLT3 locus with high efficiency and low toxicity without introducing double-stranded DNA breaks, we tested CRISPR-Cas base editing. We designed a set of sgRNAs that predicted that N399D or N399G mutations would be introduced in combination with adenine base editors. The CRISPR-Cas9 base editor ABE8e (TadA-8e V106W) was selected to develop the editing strategy and was further optimized by mutating the Cas9 nickase protein to relax PAM specificity, allowing editing in the absence of conventional NGG PAM. To this end, NG-SpCas9 and SpRY-Cas9 variants of the base editor were cloned. To further improve efficiency, the third nuclear localization site (NLS) was fused to the C-terminal portion of the protein. Unless otherwise stated, base editing experiments were performed by electroporation of reporter K562 overexpressing the FLT3 gene with 500ng base editing plasmid and 300-360pmol sgRNA (Integrated DNA Technology). The cells were then cultured, and genomic DNA was harvested 72 h after editing and samples analyzed by flow cytometry.

[0530] A representative experiment illustrating the PAM requirements for N399 base editing is shown in Figure 14. Two SpCas9 sgRNAs with NG PAM (SEQ ID NO: 17 and SEQ ID NO: 18, see Table 1 above) were tested with WT-SpCas9 nickase (PAM requirement: NGG), NG-SpCas9 nickase (PAM requirement: NG), and SpRY-Cas9 nickase (PAM requirement: NRN), ABE constructs. Fig.14A The relative positions of sgRNA and N399 codon in the FLT3 gene are shown. Fig. 14B is the gRNA protospacer sequence with the target adenine underlined. Fig. 14CThe design of three adenine base editor constructs (wild-type Cas9, NG-Cas9, or SpRY-Cas9 variants linked to a TadA deaminase domain with or without a V106W mutation) is shown. The V106W mutation is associated with reduced RNA editing, a known adverse effect of adenine base editors. ABE8e-V106W and NG-ABE8e are also available through Addgene (catalog product numbers 138495 and 138491, respectively). The cloned SpRY-ABE8e-V106W (SEQ ID NO: 7 and SEQ ID NO: 8) contains an additional C-terminal nuclear plasmid nuclear localization sequence (NLS). Fig.14D FACS plots of base editing results 72h after electroporation are shown, where K562 cells were stained with anti-FLT3 clone BV10A4 (normalizer) and 4G8 (therapeutic antibody). The percentage of edited cells is reported in the lower right corner of the FACS plot for each condition. Only base editor variants with relaxed PAM specificity (NG-ABE8e and SpRY-ABE8e-V106W) showed efficient editing, with up to 41.1% of cells staining negative for clone 4G8.

[0531] To improve the base editing efficiency of the N399 codon, customized editing window positioning was achieved by screening additional sgRNAs in combination with near-PAM-free SpRY-Cas9 variants. Fig.15A The genomic context of FLT3 N399 and its position relative to five sgRNAs are shown, including two from the previous example (SEQ ID NO: 17 and SEQ ID NO: 18) and three additional gRNAs with NRN PAMs (SEQ ID NO: 19, SEQ ID NO: 20, and SEQ ID NO: 23). Fig. 15B is the sgRNA protospacer sequence with the target adenine underlined. Fig. 15C The following is a FACS plot of a base editing experiment in which 500 ng of base editor expression plasmid and 360 pmol of sgRNA were electroporated into K562 cells. The percentage of edited cells is reported in the lower right corner of the FACS plot for each condition. The combination of SpRY-ABE8e-V106W and sgRNA FLT3_e9_18 achieved the highest efficiency by flow cytometry, with up to 66.3% of edited cells unable to be recognized by clone 4G8.

[0532] Example 6: FLT3 mutations introduced by ABE preserve protein expression and ligand binding

[0533] Sanger sequencing of base-edited cells from Example 5 revealed A to G editing of two adenines within the N399 codon (sequence: AAC), likely generating N399D or N399G mutations. To further test whether FLT3 variants containing mutations at the N399 position still retain physiological FLT3L binding, a fluorescent ligand binding assay was performed. Fig.16A Shown are fluorescent ligand binding assays performed with K562 cells expressing various FLT3 variants: N339D (SEQ ID NO: 51), N399G (SEQ ID NO: 52), exon 9 mutation (SEQ ID NO: 50), or WT FLT3 (SEQ ID NO: 48). Each graph reports the fluorescence ratio between FLT3L AF488 and FLT3 BV10A4 PE-Cy7. Fig. 16B The distribution of fluorescence ratios between FLT3LAF488 and FLT3 BV10A4 PE-Cy7 for each variant is shown (histogram). The data show that the N399D and N399G variants generated by FLT3 adenine base editing retain physiological FLT3L binding affinity.

[0534] Example 7: Use of SpRY-ABE8e-V106W mRNA can lead to efficient base editing in human leukemia cell lines and human CD34+ HSPCs

[0535] In order to transfer base editing programs to primary cells, a suitable delivery method for base editors needs to be developed, as bacterial plasmid transfection has been reported to be toxic to stem cells.

[0536] We transformed the base editing protocol into human CD34+ HSPCs using base editor mRNA generated by in vitro transcription. The base editor mRNA was expressed using the MEGAscript T7 transcription kit (Invitrogen AM1333) or the NEB T7 HiScribe kit (E2040S) and a custom plasmid (SEQ ID NO: 81; see Fig.17A Functional mRNA encoding an adenine base editor (SpRY-ABE8e-V106W 3xNLS or SpRY-K918N-ABE8e-V106W3xNLS) was generated by in vitro transcription (IVT) of a template encoding the base editor reading frame downstream to a T7 promoter sequence, a minimal 5′UTR, and downstream to 2 copies of HBB (hemoglobin B) 3′UTR and a polyA sequence (60-120 bp in length). Fig. 17BAn example of an in vitro transcription workflow for generating co-transcriptional 5′-capped and 3′-polyadenylated mRNA for base editing of primary human CD34+ is shown. Co-transcriptional capping was achieved by replacing 80% of the GTP with 3′-O-Me-m7G(5′)ppp(5′)G RNA cap structure analog (NEB S1411). IVT reaction products were purified using Qiagen RNAesy mini kit or NEB Monarch mRNA CleanUp (T2050L), quantified by Nanodrop and quality controlled by Agilent fragment analyzer analysis (typical electropherograms are shown in Figure 2). Fig. 17C shown.

[0537] SEQ ID NO: 81 - pmRNA plasmid for in vitro transcription of SpRY_ABE8e_V106W adenine base editor, including 5′UTR, HBB 3′UTRx2 and 120 bp long polyA tail

[0538]

[0539]

[0540]

[0541]

[0542]

[0543]

[0544] Fig.18 An example of a base editing experiment performed on K562 reporter cells using electroporated IVT SpRY-ABE8e-V106W 3xNLS base editor mRNA at different doses (0.5 to 5ug in 20uL electroporation volume) and 180 or 360pmol FLT3-e9-18sgRNA. Edited cells were stained with 4G8 clone (targeting antibody) and BV10A4 clone for expression normalization ( Fig.18 A) The percentage of edited cells by flow cytometry is reported in the lower right corner of each graph. Fig.18 B shows the relationship between mRNA / gRNA dosage and editing efficiency by flow cytometry. Fig.18 C shows the relationship between mRNA / gRNA dose and cell viability by flow cytometry (LiveDead yellow staining). Heat map shows the relationship between mRNA / gRNA dose and cell viability by flow cytometry (LiveDead yellow staining). Fig.19ABase editing efficiency of Sanger sequencing of PCR-amplified gDNA of experimental samples in . Sanger traces were deconvoluted using the EditR package to calculate the efficiency of A to G conversion. gRNA and mRNA doses are reported on the left, while the number of target adenines within the gRNA sequence is reported in columns (PAM corresponds to positions 21-23). Fig.19B The relationship between editing efficiency obtained by flow cytometry (4G8-cells) and Sanger sequencing is reported.

[0545] To confirm the feasibility of FLT3 base editing on primary human CD34+ hematopoietic stem and progenitor cells, in vitro base editing and expansion culture experiments were performed. Mobilized peripheral blood-derived CD34+ HSPCs were thawed and cultured at 0.5-0.75 million / mL in StemCell SFEMII medium supplemented with 1% penicillin / streptomycin, SCF 100ng / mL (Peprotech), FTL3L 100ng / mL (Peprotech), TPO 50ng / mL (Peprotech), Stemregenin-1 0.75uM (StemCell Technology), UM171 35nM (Selleckhem). 48 hours after thawing, 0.15-0.25 million (M) HSPCs were electroporated in P3 electroporation solution (Lonza) using the Lonza 4D-Nucleofector system, supplemented with 2.5-7.5ug base editor mRNA (SpRY-ABE8e-V106W) and sgRNA (Integrated DNA Technology) 250-450pmol per 20uL reaction. The cells were cultured in the above medium for 5-7 days. In order to test the specific resistance to CAR-T cell killing, the edited or unedited CD34+ cells were expanded in vitro for 3 days after editing and then co-cultured with anti-FLT3 CAR-T cells or untransduced T cells.

[0546] Fig. 20A The experimental layout and timeline for the in vitro expansion culture and FLT3 base editing of mobilized peripheral blood-derived CD34+ HSPCs are shown. Cells were electroporated with 1, 2.5 or 5ug of SpRY-ABE8e-V106W 3xNLS mRNA and 180 or 360pmol of FLT3-e9-18 sgRNA. Fig. 20B An example of the gating strategy for flow cytometric immunophenotyping of CD34+ cells during in vitro expansion culture is shown. Fig. 20C In vitro fold expansion of CD34+ cells relative to different base editing conditions is shown, indicating limited toxicity of the base editing procedure compared to untreated controls. Fig.20DThe composition of cultured CD34+ cells by flow cytometry at days 3 and 6 post-editing was summarized, showing that there was no bias in stem and progenitor cell subsets after electroporation and mRNA base editing.

[0547] Fig.21A Editing efficiencies by Sanger sequencing are reported on day 6 after electroporation. gRNA and mRNA doses are reported on the left, while the number of adenines targeted within the gRNA sequence is reported in columns (PAM corresponds to positions 21-23). Fig. 21B The relationship between base editing efficiency and different gRNA x mRNA doses in human CD34+ HSPCs is reported as a scatter plot.

[0548] Example 8: FLT3 base editing of human FLT3-expressing leukemia cell lines or human CD34+ HSPCs using SpRY-ABE8e-V106W mRNA confers resistance to 4G8 CAR-T cells

[0549] To test from Fig.18 To investigate whether the base-edited cells obtained in the experiments performed in were resistant to 4G8 CAR-T cells, a previously reported co-culture experiment was performed. Fig.22A Flow cytometry plots of surviving cells after 4 hours of co-culture at different effector: target ratios are reported. Edited cells (editing efficiency of approximately 89%) were protected from CAR-T cell killing and remained viable at higher E:T ratios. Fig. 22B Target cell (unedited or FLT3 base-edited K562) viability by Annexin V and LiveDead Yellow staining 4 h after coculture with 4G8 anti-FLT3CAR-T cells or untransduced T cells is reported, highlighting the selective killing of unmodified cells. Fig. 22C CAR-T / T cell degranulation by surface CD107a staining when co-cultured with unedited or FLT3 base-edited K562 cells for 4 hours was reported. Only CAR-T cells exposed to unmodified cells showed significant degranulation.

[0550] Similarly, to test whether base-edited human hematopoietic stem and progenitor cells are resistant to FLT3-targeted immunotherapy, the edited CD34+ cells in the experiment performed in Figure 20 were co-cultured with 4G8 CAR-T cells or untransduced T cells. Figure 23 shows a CAR-T cell co-culture experiment using unmodified or FLT3 base-edited mPB CD34+ cells (editing efficiency of approximately 46%) cultured on day 3 of the experiment in Figure 20. Fig.23A Flow cytometry plots of surviving cells when co-cultured with 4G8 anti-FLT3CAR-T cells or untransduced T cells at different effector:target ratios for 48 h are reported. Fig. 23B Specific killing of CD34+ cells co-cultured with 4G8 anti-FLT3 CAR-T cells or untransduced T cells at different effector:target ratios was reported. Fig.23C Specific killing of the stem cell-enriched CD34+90+ subset was reported. Although the differences in CAR-T-mediated killing were less pronounced compared to experiments performed on cell lines, due to the relatively low expression of FLT3 when cultured CD34+ HSPCs were exposed to FLT3L, the modified HSPCs showed resistance conferred by FLT3 editing, and the differences were greater in CD90+ cells, which are more stem cell-enriched.

[0551] Example 9: FLT3-edited HSPCs are protected from CAR-T cell-mediated killing in vivo

[0552] To further confirm the protective effect against on-target killing mediated by anti-FLT3 CAR-T cells, an in vivo xenograft experiment in immunodeficient NSG mice was performed ( Fig.24A The experimental design is shown). Human mobilized peripheral blood derived CD34+HSPCs were edited as previously described and transplanted by tail vein injection at 1 million per mouse 24h after sublethal irradiation (2.5Gy). Mice xenografted with unedited HSPCs served as a control group. Each group was further divided into two treatment subgroups, vehicle (PBS) or 4G8-CAR T cells, 1.5 million cells per mouse at week 7 after transplantation. Mice were euthanized at week 8 (one week after CAR-T cell treatment). Fig. 24B Human bone marrow engraftment (percentage of human CD45+ cells excluding CD3+ cells) and human absolute CD45+ cell counts by flow cytometry are reported. CD3+ were excluded from human engraftment because they were derived from the injected CAR - More severe depletion of human engraftment was observed in mice transplanted with unedited cells. Fig.24C Human engraftment composition on the bone marrow (excluding CD3+ cells) was reported, indicating multi-lineage engraftment generated by edited HSPCs.

[0553] Fig.25A The frequency (CD34+CD38-) and absolute abundance of hematopoietic stem and progenitor cells in the bone marrow at the time of sacrifice are reported, demonstrating the protective effect of FLT3 base editing against CAR-T-mediated killing. Fig.25D (gating strategy) and Fig.25E (Fraction of Lineage-CD34+38-persistent cells) Exemplary flow cytometry plots generated from pooled events analyzed from bone marrow of mice from each group are reported. Fig.25BThe CAR-T cell activation in the spleen of treated mice was shown to be relatively high by surface CD69 staining. - T cells were identified by staining for EGFR, which is co-expressed with CAR as a marker and safety switch. Fig.25C The phenotype of CAR-T cells expressed by CD62L and CD45RA in the spleen of treated mice is reported. Naive: CD45RA+CD62L+, central memory (CM): CD45RA-CD62L+; effector memory (EM): CD45RA-CD62L-; terminally differentiated effector memory (TEMRA): CD45RA+CD62L-. In treated mice xenografted with unedited HSPCs, a relative bias toward effector subsets was evident.

[0554] To further evaluate the protective effect of FLT3 base editing of N399 on CD34+HSPC from CAR-T cell killing, a second in vivo experiment was performed in NBSGW mice, which allows xenotransplantation and implantation of human HSPCs without irradiation, and due to the suballelic Kit mutation (homozygous W41 allele) in murine HSPCs, the level of human hematopoietic reconstruction is higher. Figure 32 reports the experimental setting and FLT3 base editing efficiency of transplanted human cells at week 8 bleeding. The treatment group received 2.5 million 4G8 CAR-T cells at week 11 after transplantation, and the treatment group was euthanized at week 13 after transplantation. This experimental setting allows for improved evaluation of myeloid progenitor cells and lineage protection conferred by FLT3 base editing. Fig.33A The relative abundance of granulocytes (polymorphonuclear cells, PMNs) in the bone marrow at the time of sacrifice, as measured by flow cytometry, is shown, with protection evident in mice transplanted with FLT3-edited HSPCs compared to cells edited by the AAVS1 control. Since mature granulocytes do not express FLT3, this suggests a degree of protection at the progenitor cell level. Consistent with this hypothesis, granulocyte monocytic progenitors (GMPs), defined as lineage-CD34+CD38+FLT3+CD45RA+, were selectively depleted by FLT3 CAR-T cells only in mice xenotransplanted with mock-edited HSPCs ( Fig.33A ). Fig.33B The efficiency of FLT3 base editing at several time points in the 4G8-CAR treated or untreated groups is reported. After 4G8-CAR administration, progressive negative selection of unmodified cells resulted in the selection of FLT3 edited cells (which was more evident in progeny derived from colony forming unit assays plated with bone marrow samples from treated mice). Fig.34 Representative FACS plots showing granulocytes, myelomonocytic progenitors (GMPs) and HSPC (Lineage-CD34+CD38-CD90+CD45RA-) populations are reported.

[0555] Example 10: CD123 base editing is feasible in human CD34+ HSPCs using SpRY-ABE8e-V106W mRNA and can be multiplexed with FLT3 base editing

[0556] Similar to the FLT3 base editing experiments, we introduced the S59P mutation using SpRY-ABE8e-V106W mRNA and CD123 gRNA-N in human CD34+ HSPCs, either alone or in combination with FLT3 N399 base editing. Mobilized peripheral blood-derived CD34+ HSPCs were thawed and cultured at 0.5-0.75 million / mL in StemCell SFEMII medium supplemented with 1% penicillin / streptomycin, SCF 100 ng / mL (Peprotech), FTL3L 100 ng / mL (Peprotech), TPO 50 ng / mL (Peprotech), Stemregenin-1 0.75 uM (StemCell Technologies), UM171 35 nM (Selleckhem). 48 hours after thawing, 0.15-0.25 million (M) HSPCs were electroporated using the Lonza 4D-Nucleofector system in P3 electroporation solution (Lonza), supplemented with 5-7.5ug base editor mRNA (SpRY-ABE8e-V106W) and sgRNA (Integrated DNA Technology) 420-450pmol per 20uL reaction. The cells were cultured in the above medium for 7 days. Fig.26A The experimental layout and media composition are illustrated. Fig.26B shows the in vitro expansion of cultured CD34+ HSPCs, while Fig.26C Loss of 7G3 clone binding to successfully base edited CD34+ HSPCs is shown. Flow cytometry graphs are gated on the stem cell enriched CD90+ subpopulation, showing CD123 base editing of HSPCs by loss of 7G3 staining when normalized with clone 9F5 staining. Fig. 27 Editing efficiencies under FLT3 single editing, CD123 single editing, and FLT3+CD123 dual base editing conditions are reported. Although introduction of the S59P mutation by base editing is feasible, the efficiency obtained in our setting is relatively low (up to 29.3%) compared to FLT3 N399 (>64%).

[0557] Example 11: CD123 base editing efficiency can be improved by optimizing sgRNA position and introducing K918N substitution in the Cas9 protein of adenine base editor

[0558] To see if the editing efficiency of the CD123 S59 codon could be improved, a Cas9 protein containing the K918N mutation, which is associated with increased Cas9 catalytic activity, was tested in combination with our SpRY-ABE8e design. Fig.28A As shown, the introduction of the K918N mutation resulted in a sequence-specific effect on editing efficiency, with CD123-gRNA-N editing being enhanced and FLT3-gRNA-18 editing being slightly reduced. Fig.28A The results of base editing by flow cytometry on the third day after 500ng of base editor expression plasmid and 360pmol sgRNA were electroporated into K562 reporter cells are shown. For CD123, the edited cells were stained with 7G3 (targeting antibody) plus 9F5 clone (normalization). gRNA CD123-N (CD123_gRNA_N, SEQ ID NO: 24) was tested in combination with SpRY-ABE8e-V106W-3xNLS BE (as described in the previous experiment), or in combination with SpRY-K3918N-ABE8e-V106W-3xNLS (SEQ ID NO: 9 and SEQ ID NO: 12, sequences see above). The percentage of edited cells by flow cytometry is reported in the lower right corner of each figure.

[0559] To further improve CD123 editing efficiency, two additional sgRNAs (CD123-gRNA-R and its 21 bp long version CD123-gRNA-R21) were cloned into the pHKO-mTagBFP2 plasmid under the human U6 promoter together with the benchmark CD123-gRNA-N and FLT3-gRNA-18. Fig.28B The relative position and sequence of the CD123 S59 targeting gRNA are reported. In addition, additional adenine base editor designs were cloned and tested with SpRY-ABE8e-V106W ( Fig.28C): SpRY-K918N-ABE8e-V106W, SpRY-HF1-ABE8e-V106W, SpRY-HF1-BlackJack-ABE8e-V106W, SpRY-BlackJack-ABE8e-V106W, SpRY-Sniper-ABE8e-V106W SpRY-Sniper-BlackJack-ABE8e-V106W. HF1 variant includes N497A, R661A, Q695A, Q926A substitutions associated with lower tolerance to mismatched bases in the gRNA spacer and lower off-target editing (high fidelity). Sniper variant includes F539S, M763I, K890N substitutions, which can produce another higher fidelity SpCas9 variant that retains on-target efficiency. BlackJack is a Cas9 variant designed to tolerate 21-bp and longer sgRNAs, which is relatively more important for higher fidelity variants. For all combinations of sgRNAs (CD123-gRNA-N, CD123-gRNA-R, CD123-gRNA-R21, FLT3-gRNA-18), 500 ng of base editor plasmid and 500 ng of sgRNA expression plasmid were co-electroporated in K562 reporter cells, and the results were evaluated by flow cytometry 72 h after editing. Fig.28D The results of the screening program are summarized, which highlight improved combinations of CD123 S59 base editing. Specifically, excluding the HF1 variant, the average efficiency of CD123-gRNA-R is 1.42-fold higher than that of CD123-gRNA-N, while its 21bp long counterpart (CD123-gRNA-R21) is only 1.21-fold higher in efficiency. The introduction of the K918N mutation can improve CD123 editing by 1.08-fold for gRNA-R and 1.05-fold for gRNA-N. In combination with the Sniper mutation, K918N increased the efficiency of gRNA-R by 1.22-fold and gRNA-N by 1.16-fold. In summary, switching to CD123-gRNA-R and introducing the K918N mutation will partially compensate for the lower efficiency observed for CD123 editing compared to FLT3, which seems to be relatively unaffected by the K918N substitution.

[0560] Example 12: Improving duplex base editing efficiency in CD34+ HSPCs using SpRY-K918N-ABE8e-V106W mRNA

[0561] By optimizing multiple parameters (mRNA preparation, K918N mutation introduction, sgRNA selection), the efficiency of CD34+HSPC base editing of FLT3 and CD123 loci was improved using SpRY-K918N-ABE8e-V106W in vitro transcribed mRNA. Figure 29 reports an exemplary experiment. Fig.29A Summarizing the experimental design, Fig.29B reported a gating strategy for CD123 editing assessment by flow cytometry, whereas Fig.29C Similar expansion of FLT3+CD123 base-edited cells was demonstrated compared to untreated (electroporation only) controls. Sanger sequencing revealed up to 85% editing efficiency at FLT3 N399 and 41% editing efficiency at CD123 S59 ( Fig.30 ).

[0562] Example 13: KIT H378R mutation can be introduced into CD34+ HSPCs by adenine base editing

[0563] Using the same experimental setup as in Example 12, we tested whether the H378R mutation could be introduced in human CD34+ HSPCs by base editing. By electroporation of SpRY-K918N-ABE8e-V106W in vitro transcribed mRNA (4ug / 20uL electroporation volume) and KIT-gRNA-Y (SEQ ID NO: 37), an editing efficiency of up to 60% was achieved.

[0564] Example 14: Generation of anti-FLT3 and CD123 bispecific chimeric antigen receptors

[0565] Rationally designed anti-FLT3 and CD123 bispecific chimeric antigen receptors should produce potent anti-leukemic efficacy. Fig.29A Schematic representation of a putative second generation bispecific chimeric antigen receptor targeting FLT3 domain 4 and CD123 N-terminal domain. Fig.29B It is the design of the second generation monospecific CAR targeting CD123 (CSL362 clone, SEQ ID NO: 75-76) and FLT3 (4G8 clone, SEQ ID NO: 73-74) and bispecific chimeric antigen receptors with different oriented scFv domains and / or different extracellular linkers, transmembrane domains, and intracellular co-stimulatory domains (SEQ ID NO: 77-80).

[0566] Example 15: Base editing to generate invisible receptors

[0567] As targets for our epitope engineering strategy, we selected the cytokine receptors FLT3, KIT, and CD123 (IL3RA). Fms-like tyrosine kinase 3 (FLT3, CD135) and the proto-oncogene c-KIT (KIT, CD117) are class III receptor tyrosine kinases that are expressed in 93% and 85% of AML cases as wild-type (WT) or mutant forms, respectively. 32-37 CD123 is the α subunit of the IL-3 receptor (IL3RA), which is present on the surface of >75% of AML cases and is expressed in leukemic stem cells. 38-40 Overexpression of type I cytokine receptors on the surface. These genes are present at all stages of normal hematopoietic development, and their overexpression on AML cells is associated with a poor prognosis in both adult and pediatric patients. 33,36,41-43 In the context of AML, the incidence of relapse after HSCT is high and the overall survival is low. To develop our approach, we selected a monoclonal antibody (mAb) currently being evaluated for development of anti-AML immunotherapies: clone 4G8 22,44 (FLT3), Fab-79D 21,45 (KIT) and 7G3 46-48 Previous studies have reported that 4G8 recognizes FLT3 extracellular domain (ECD) 4, whereas clone BV10A4 recognizes an unrelated epitope within ECD2 and thus could serve as a marker for evaluating FLT3 surface expression. 44 Since 4G8 was generated by immunizing BALB / c mice with a cell line transfected with human FLT3, we reasoned that 4G8 would recognize human-specific epitopes, although human and mouse FLT3 49 There is a high degree of homology (85.8% identity and 91.5% similarity) and cross-reactivity with FLT3 ligand (FLT3L).

[0568] We first demonstrated that chimeric human FLT3 with ECD4 replaced by the murine ortholog (16 codon changes) resulted in loss of 4G8 binding but did not affect FLT3L binding and intracellular kinase phosphorylation ( Fig.36 A, 36B left, 36C top). To identify the minimum number of residues involved in 4G8 binding, we designed a Sleeping Beauty transposon-based combinatorial library with either human or mouse codons at each of the 16 mismatched positions within ECD4 ( Fig.36 D, upper left). Flow cytometric analysis of K562 cells transduced with this library showed that the cell population was positive for a control antibody (BV10A4) and negative for 4G8 ( Fig.36D, upper right). The relative abundance of human codons versus mouse codons at each position was measured by targeted deep sequencing of sorted single (BV10A4+4G8-) and double-positive (BV10A4+4G8+) cells, revealing enrichment of a single amino acid substitution (N399D; Fig.36 D, bottom and FIG. 37A ). To validate this result, we transduced K562 cells with the FLT3 N399D variant and confirmed that the surface expression level of FLT3 was comparable to the wild type, but 4G8 binding was lost ( FIG. 37B ).

[0569] Next, we evaluated gene editing strategies to introduce N399D substitutions. In order to easily evaluate the results of our genome engineering procedures for cells that do not rely on FLT3 signaling, we generated K562 reporter cells, which express FLT3 from its endogenous locus by integrating the upstream targeted EF1α constitutive promoter into the transcription start site (Figure 37C). We then confirmed that N399D mutations can be inserted by homology-directed repair (HDR) using SpCas9 or AsCas12a nucleases and 200-bp ssODN donor templates, and successfully edited cells show 4G8 binding loss while retaining FLT3 surface expression (Figure 37D). Nevertheless, the use of nucleases carries the inherent risk of genotoxicity associated with DNA double-strand breaks (DSBs) and gene knockouts, which occurs in most unedited cells (Figure 37D).

[0570] Since epitope engineering can be achieved by introducing single point mutations, we reasoned that base editing (BE) could be a suitable and safer option for epitope editing by avoiding the need for DSBs. The asparagine at position 399 is encoded by an AAC codon, which can be converted to GAC (aspartic acid) or GGC (glycine) by adenine base editing (ABE). We tested this hypothesis by electroporating FLT3 reporter cells with several sgRNAs (in a 1 bp staggered manner, targeting adenines at positions 3 to 9 of the protospacer) in combination with the new generation TadA-8e deaminase, which is conjugated to the SpCas9 nickase (NGG PAM) or Cas9 variants with relaxed PAM specificity (NG-SpCas9n and SpRY-Cas9n, Fig.36 Evaluation by flow cytometry showed successful epitope editing with loss of 4G8 recognition, with SpRY-ABE8e in combination with FLT3-sgRNA-18 achieving the highest efficiency (66.3%, Fig.36F). In contrast to the HDR-based strategy, both base-edited and non-base-edited cells retained normal surface FLT3 expression with no apparent gene knockout. As both N399D and N399G are potential outcomes of our editing strategy, we included this mutation in all further validation analyses.

[0571] A similar strategy was also applied to epitope mapping of Fab-79D, a mAb targeting KIT that was reported to bind to KIT ECD4 and block ligand-induced dimerization. 45 We first confirmed the loss of Fab-79D binding by introducing 10 amino acid changes (from KIT orthologs) at positions previously predicted as potential contact points with KIT ECD4 (F316S, M318V, I319K, V323I, I334V, E360K, P363V, E366D, E376Q, H378R) and verified the retention of stem cell factor (SCF) binding and intracellular kinase phosphorylation ( Fig.36 B right, 36C bottom). To comprehensively screen for interactions between ECD4 mutations and cloned Fab-79D, we performed a screen using a degenerate codon library in which every position of KIT ECD4 was substituted with a random amino acid ( Fig.36 E left). We transduced HEK-293T cells with the library and sorted cells with reduced binding to Fab-79D but retained KIT expression and cells that retained Fab-79D staining ( Fig.36 E right). NGS sequencing of the library region and comparison of specific codon enrichment at each position within single positive cells revealed several mutations that reduced the affinity of Fab-79D ( Fig.36 E bottom). To validate these findings, we cloned 20 amino acid substitutions individually by selecting mutations replicated by adenine or cytidine base editing at 10 positions identifiable by the library (M318, I319, V323, D332, I334, D357, E360, E376, and H378), and selected H378R for further development because it showed the highest reduction in Fab-79D binding when normalized to a KIT control Ab (clone 104D2) while retaining binding to SCF (Figure 37E). In addition, similar to FLT3 N399D, H378R can be inserted by ABE, allowing potential combinatorial and dual epitope engineering. As done for FLT3, we screened 3 different sgRNAs with editing windows against H378 (target A at position 5, 6, or 7) in combination with SpRY-ABE8e on K562 cells and identified KIT-Y as the most efficient combination (Figure 37C, F).

[0572] For CD123, the epitopes and amino acid substitutions affecting the binding of therapeutic clone 7G3 (or its humanized counterpart CSL362-Talacotuzumab) have been previously reported. 48 To develop our epitope editing strategy, we designed a targeted BE screen for K562 reporter cells by testing sgRNAs targeting positions E51, Y58, S59, R84, P88, and P89 of the CD123 N-terminal domain ( Figure 37E ), and combined them with CBEs (evo-APOBEC1-BE4 with NGG, NG, and SpRY Cas variants) and ABEs (ABE8e, NG, and SpRY variants, Fig.36 G) Rational combination. Although several combinations introduced mutations that reduced the affinity of 7G3 for CD123, only the combination of gRNA CD123-N and CD123-R with SpRY-ABE8e and the combination of gRNA CD123-L with SpRY-evo-APOBEC1-BE4 completely abolished 7G3 binding ( Fig.36 G and Figure 37H). Sequencing of edited cells revealed that ABE and CBE resulted in S59P and S59F substitutions, respectively. By adenine base editing, a bystander mutation (Y58H) with higher efficiency with gRNA CD123-R than with CD123-N can also be introduced, and is therefore included in further validation. Due to the possibility of editing multiple epitopes in combination with FLT3 and KIT ABE, we chose S59P introduced by gRNA CD123-R with ABE for further development. Finally, by testing our base-edited CD123 reporter cells with two additional mAbs targeting CD123, we found that cytidine base editing of P88 / P89 resulted in a combination of P88S / P89S or P88L / P89L) resulted in almost complete loss of recognition of clones 6H6 and S18016E, thereby expanding the mAb pool with potential applications in combination with epitope-engineered cells (Figure 37I).

[0573] To precisely quantify the loss of affinity of our selected Abs for the epitope-engineered receptors, we transduced K562 cells with each receptor variant (FLT3 WT, N399D, N399G; KIT WT, H378R; CD123 WT, S59P, and Y58H-S59P) via Sleeping Beauty transposase and observed that at mAb saturation concentrations (>5000 ng / mL) for the WT receptor, Fig.36H), all tested variants also showed almost complete absence of recognition. Notably, FLT3 N399G (introduced by editing two adenines in the AAG codon at position 399) was no different from N399D in its ability to reduce 4G8 binding. Similarly, adding the Y58H bystander mutation to CD123 S59P showed a similar reduction in 7G3 binding without affecting CD123 expression on the cell membrane.

[0574] In summary, we conclude that epitope engineering of FLT3, KIT, and CD123 is feasible and can be achieved efficiently without DSBs by selecting appropriate gRNA and base editing enzyme combinations.

[0575] Example 16: Epitope editing preserves receptor function

[0576] Since the targets chosen are essential cytokine / growth factor receptors expressed on human HSPCs and have relevant roles in stem cell maintenance and lineage differentiation, we rigorously evaluated whether our engineering procedures would alter receptor function. Using fluorescently conjugated FLT3L, SCF, and IL-3 ligands, we demonstrated that FLT3L, SCF, and IL-3 expression was altered at all tested concentrations (1 to >1000 ng / mL; Fig.36 I) with their respective WT or epitope engineered receptors have comparable binding. CD123 variants are co-expressed with common β subunits (CSF2RB / CD131) to form heterodimeric IL-3 receptors and allow signal transduction, because by flow cytometry, K562 cells do not express CSF2RB (Figure 37J). Activation of the intracellular signaling cascade of FLT3 and KIT was confirmed by Western blotting, which showed comparable and dose-dependent kinase phosphorylation after ligand binding ( Fig.38 A, B). For CD123, we confirmed ligand-mediated receptor activation by measuring phosphorylation of the downstream STAT5 signal transducer, which was equally activated in WT and epitope-engineered variants at all IL-3 concentrations tested ( Fig.38 C). Finally, to confirm the full retention of the ligand-dependent proliferative response, we performed a kinase complementation assay on BaF3 cells, a murine IL-3-dependent lymphoblastoid cell line that requires signaling through the STAT5 pathway for proliferation and survival. 50 We demonstrated comparable and dose-dependent rescue of cell proliferation by WT and epitope-engineered receptor variants following exposure to human FLT3L, SCF, and human IL-3 during murine IL-3 starvation ( Fig.38 D).

[0577] Example 17: Stealth receptors are resistant to CAR-T cells

[0578] Recent studies have shown that the anti-FLT3 clone 4G8 22 , anti-KIT Fab-79D 21 or anti-CD123 CSL362 (clone 7G3 48,51 CAR-T cells generated by using humanized variants of 4G8-mAb have significant efficacy against human AML cells. To evaluate the resistance of epitope-engineered cells to targeted CAR-T therapy, we cloned 4G8, Fab79D, and CSL362 single-chain variable fragments (scFv) in a second-generation CAR construct with a CD28 costimulatory domain and co-expressed the optimized 4G8-mAb using a lentiviral vector with a bidirectional promoter. 52 Truncated EGFR selection / depletion marker (tEGFR; Fig.39 A) For the generation of CAR-T cells, we used a culture protocol based on CD3-CD28 bead stimulation in the presence of IL-7+IL-15, which expanded with a T stem cell memory phenotype 53 Cells ( Fig.39 A. Fig.40 A, B). We achieved high CAR transduction efficiency (>85% by tEGFR staining) and in vitro expansion >20-fold compared to the start of culture ( Fig.39 B).

[0579] By performing in vitro killing assays on K562 reporter cells, we found that although most cells overexpressing WT FLT3, KIT, or CD123 were cytotoxic to their respective specific CARs, - T (<2% surviving cells at E:T=10 compared to E:T=0), but K562 cells expressing the epitope-engineered variants were resistant to CAR-T cell killing (absolute counts and cell viability) at different effector:target ratios (E:T 0.625 to 10) and survived until the termination of the experiment ( Fig.39 CE and Fig.40 C, D). T cell activation (CD69 expression) and degranulation (CD107a surface expression) were significantly higher when cultured with cells expressing the WT gene, consistent with recognition of the variant lacking epitope editing by CAR-T ( Fig.40 C, D). In addition, surviving K562 reporter cells still expressed the targeted receptor at levels comparable to untreated controls ( Fig.39 C, D, and E, right). Untransduced T cells showed no target killing or CD69 upregulation when cultured under all conditions tested ( Fig.40D). To further confirm the strict epitope-specific killing of CAR-T cells, we co-cultured mixed populations of unmodified or base-edited dual-target cells (K562 cells expressing FLT3 and CD123) and observed that the epitope-edited populations exhibited selective resistance when plated with the corresponding CAR-T cells ( Fig.40 E).

[0580] Together, these data provide rigorous validation that cells overexpressing epitope-engineered FLT3, KIT, and CD123 variants are resistant to CAR-T cell recognition and killing.

[0581] Example 18: Effective epitope editing of human HSPCs

[0582] To efficiently introduce our nucleotide variants into endogenous genes in primary human HSPCs, we optimized the base editing protocol in mobilized peripheral blood (mPB)-derived CD34+ cells based on co-electroporation of chemically modified sgRNA and in vitro transcribed (IVT) SpRY-ABE8emRNA ( Fig.41 A and Fig.42 AC). After optimizing the mRNA in vitro transcription, culture and electroporation conditions as well as the editing time point after HSPC stimulation ( Fig.42 D, E, F), we achieved target A>G conversion rates of up to 86.6%, 78.6%, and 67.9% for FLT3, KIT, and CD123, respectively. We were able to efficiently edit the target adenine within the FLT3-18, KIT-Y, and CD123-R sgRNA windows ( Fig.41 B). Analysis of treated cells showed that in the presence of stem cell retaining compounds (StemRegenin, SR-1, and UM171; Fig.41 D and Fig.42 E) In the case of phenotypically identified progenitor cells (LMPP, CD90-45RA+; MPP, CD90-45RA-; HSC, CD90+45RA-) during in vitro culture, there was no deviation in the composition of phenotypically identified progenitor cells (LMPP, CD90-45RA+; MPP, CD90-45RA-; HSC, CD90+45RA-). 54 In contrast, expression of HSPCs in somatic cells, committed progenitor cells (CD90-), and more primitive HSPC subsets (CD90+45RA-; Fig.41 C), the base editing efficiencies are equivalent.

[0583] To confirm that FLT3 N399 and CD123 S59To investigate the resistance of epitope-engineered HSPCs to immunotherapy, we performed killing assays by plating HSPCs edited with 4G8 and CSL362 CAR-T cells at different E:T ratios 3-5 days after electroporation. Specific killing by FLT3- and CD123 CAR-Ts was most evident in the CD45RA+ and CD90+ subsets, respectively, which were therefore used to assess the results of these experiments by absolute counts. While cells edited at the control locus (AAVS1 safe genomic harbor) were eliminated by CAR-T cell co-culture, epitope-edited cells showed higher viability and absolute counts, similar to what we observed in K562 co-cultures ( Fig.41 E, F) Since KIT has known extrahematopoietic expression in humans 55 , we focused on the use of mAbs rather than CAR-T cells, which may result in less severe on-target toxicity and may be used for in vivo selection of cells for non-genotoxic opsonization or epitope engineering. By plating HSPCs edited with increasing concentrations of the dimerization-blocking Fab-79D mAb, we observed KIT H378 Edited HSPCs retain expansion kinetics in response to SCF, whereas AAVS1 BE The cells were inhibited in a dose-dependent manner ( Fig.41 G).

[0584] To confirm the retention of functionality of receptor-engineered CD34+ HSPCs, treated cells were cultured for an additional 4 days with increasing concentrations of their respective ligands without the addition of other cytokines. At the end of the culture, we observed dose-dependent HSPC proliferative expansion for all 3 targets, except for CD123 at 1-10 ng / mL IL-3. S59 Outside of BE, there were no differences between receptor-edited and AAVS1-edited controls ( Fig.42 H). Nevertheless, we did not observe counter-selection of BE HSPCs, confirming that CD34+ cells expanded uniformly regardless of CD123 epitope editing ( Fig.42 I). To further confirm the minimal effect on proliferation and evaluate the differentiation capacity of receptor-edited HSPCs, we performed cell culture and colony-forming unit (CFU) assays on HSPCs with base editing for FLT3, CD123, KIT, or AAVS1 genes, and observed absolute cell counts after in vitro expansion and the number of myeloid and erythroid colonies comparable to untreated controls ( Fig.41 H) Xenotransplantation of treated HSPCs into female NBSGW immunodeficient mice revealed expression of FLT3 N399 HSPCs retain the ability to engraft, re-engraft, and differentiate into multiple lineages ( Fig.41I, J), which was comparable to the AAVS1-edited control. The percentage of FLT3 editing was comparable to that measured in the input cells (BE efficiency approximately 35%) and remained stable up to 13 weeks after transplantation ( Fig.41 K), thus confirming the successful editing of the most primitive HSPC subset and the absence of FLT3 N399 Transplantation of bone marrow (BM) cells into secondary recipients resulted in high hematopoietic engraftment and no differences in lineage distribution up to 17 weeks after secondary transplantation ( Fig.43 A, B), and FLT3 editing levels remained comparable to those measured in the initial receptor ( Fig.41 K). Since mouse Flt31 has cross-reactivity with human FLT3, these results further confirm that epitope-engineered FLT3 N399 The function of the variant. Similarly, KIT H378 In vivo reconstitution capacity and multi-lineage differentiation of edited HSPCs with matched AAVS1 BE Comparatively ( Fig.43 CE), without lineage differentiation bias and counter-selection of edited cells, further confirming that the base editing procedure does not affect the fitness and function of the treated cells.

[0585] Together, these data demonstrate that epitope engineering of HSPCs can be effectively achieved by adenine base editors without compromising stem cell function and differentiation capacity.

[0586] Example 19: FLT3 BE HSPCs are resistant to 4G8CAR-T treatment in vivo

[0587] To evaluate whether FLT3 CAR-T cells can be effectively used to treat AML while preserving FLT3 N399 Hematopoiesis, we used CD34+HSPC (FLT3 BE or AAVS1 BE ) and human patient-derived AML xenografts (PDX-1) were implanted into NBSGW mice characterized by MLL-AF9 and FLT3-ITD mutations and previously transduced with a reporter gene - mNeonGreen - to facilitate its detection in mixed hematopoiesis ( Fig.43 F, G). 10 days after PDX challenge, mice were treated with 4G8 CAR-T cells, and their hematopoietic composition was monitored by cytofluorimetric analysis of serial blood samples, and at the end of the experiment, hematopoietic organs (BM, spleen, SP; Fig.44 As observed in previous experiments, transplanted mice showed similar peripheral blood components in both edited groups before AML PDX or CAR-T cell administration ( Fig.45A), and editing levels were comparable to input cells (~85%), with no differences in myeloid and lymphoid lineages (FACS-sorted CD33+ and CD19+ cells, respectively; Fig.44 B). Mice treated with 4G8 CAR-T showed CAR-T cell engraftment and complete AML eradication in BM and SP ( Fig.44 CF), and FLT3 in BM N399 Small but significant increases in cell fractions (88% vs. 90% in myeloid cells and 89% vs. 94% in lymphocytes; Fig.44 B) Multiparameter flow cytometric analysis of BM revealed that only AAVS1 BE CD19+B cells (pre-B cells and pro-B cells) were relatively depleted in the group, while FLT3 N399 HPSC-implanted mice were protected ( Fig.44 GI). In differentiated myeloid cells (CD33 / 66b+, excluding AML cells), FLT3 N399 Compared with mice, AAVS1 BE Immature granulocytes (CD14-10-11c-SSC high ) 56 The proportion of Fig.44 J) FLT3 N399 BE lineage-negative progenitor cells (lin-CD34+, Fig.45 BD) confers selective resistance, especially to granulocytic and monocytic progenitor cells (GMP, lin-CD34+38+45RA+FLT3+, Fig.44 K, L) and lymphoid primed multipotent progenitor cells (LMPP, lin-CD34+38-45RA+90-10-, Fig.44 N, O), and these resistances are in AAVS1 BE The expression of LMPP in AAVS1 BE and FLT3 N399 was almost completely eliminated (1.4% and 26.6% GMP w / in lin-CD34+38+ and 4.8% and 43.3% LMPP w / in lin-CD34+38+, respectively). - CD34+38-). To more precisely identify the hematopoietic subsets that were depleted by the 4G8 CAR and selectively protected by epitope engineering, we compared the FLT3 N399 With AAVS1 BE Absolute counts of different lineages between groups. BE Under these conditions, common myeloid progenitor cells (CMP, lin-CD34+38+CD45RA-FLT3+), dendritic cells (CD33+14-11c+FLT3+SSC low) and GMP absolute counts decreased (AAVS1 BE FLT3 N399 In the experiment, CMP decreased by 0.48 times, GMP decreased by 0.01 times, and cDC decreased by 0.41 times. Fig.44 M). In the lymphoid lineage and progenitor LMPP, pre-B / NK (lin-CD34+38+10+) and downstream subsets (B prolymphocytes, pro-B and pre-B) are expressed in FLT3 N399 With AAVS1 BE Protected in group (AAVS1 BE FLT3 N399 The changes in LMPP were 0.02 times, pre-B / NK 0.19 times, pro-B 0.2 times, and pre-B 0.18 times. Fig.44 P). The increase in mature B cells (FLT3-) under CAR treatment conditions may reflect the expansion in response to CAR-mediated crosstalk. In addition, AAVS1 exposed to 4G8 CAR BE The pre-B / NK, B prolymphocytes, pro-B and pre-B cells, monocytes and myeloid blasts (CD33 / 66b+14-11c-34-SSC low ) had a lower median fluorescence intensity (MFI) of FLT3 than that of FLT3 N399 Edit the group measured in the same group ( Fig.45 E), thus providing additional evidence that FLT3 N399 Cells can retain FLT3 expression while avoiding CAR-mediated killing. Interestingly, although the CAR-T cells detected at the end of the experiment showed similar phenotypes in all groups (mainly effector memory and central memory) ( Fig.45 F), but with AAVS1 BE Compared with controls, exposure to FLT3 N399 Hematopoietic CAR-T cells showed lower proliferation and significantly reduced PD-1 expression ( Fig.45 G), suggesting that exposure of CAR-T to a lower antigen load leads to an overall reduction in activation and / or exhaustion due to the lack of recognition of the epitope engineered by the hematopoietic stem cell. Importantly, FLT3 N399 Epitope editing was able to provide the same protection against 4G8 CAR killing, highlighting the possibility of selectively eliminating AML cells while preserving hematopoietic reconstitution.

[0588] In summary, these data confirm that in the NBSGW model, FLT3 CAR-T cell immunotherapy preferentially depletes B cells and progenitor cell subsets (GMP, LMPP), while FLT3 N399Epitope editing confers protection to these subpopulations.

[0589] Example 20: CD123 BE HSPCs are resistant to CSL362 CAR-T therapy in vivo

[0590] As with FLT3 epitope editing, we inserted CD123 S59 HSPC xenografts into NBSGW mice confirmed the expression of AAVS1 BE HSPC-like engraftment and multi-lineage reconstitution capabilities ( Fig.46 A and Fig.45 H), and the fraction of edited cells was high and stable ( Fig.46 B). The transplanted mice were then injected with PDX-1 ( Fig.43 G) and treated with CSL362 CAR-T cells 10 days later. Similar to 4G8 CAR-T therapy, CSL362 CAR-T cells almost completely eradicated AML cells ( Fig.46 C, D), and CD123 S59 In comparison, using AAVS1 BE HSPC-implanted mice showed higher expansion ( Fig.46 E) Flow cytometric analysis of BM at endpoint highlighting expression of AAVS1 BE Human hematopoietic cells (CD45+, after exclusion of AML and CAR T cells; Fig.46 F) The absolute counts of myeloid cells (CD33 / 66b+) were significantly reduced, including mature and immature granulocytes, while CD123 S59 HSPC progeny are protected ( Fig.46 HK). Different from the killing pattern observed with 4G8 CAR, in the lymphoid lineage, only AAVS1 was expressed in CSL362 CAR-T cells. BE The percentage of pro-B cells in mice showed a decreasing trend ( Fig.46 G). Dendritic cells (DC), including CD123 high Plasmacytoid DCs were depleted by CSL362 CAR-T therapy, whereas those in CD123 S59 They were retained in the BE group ( Fig.46 LN). Similar to FLT3 epitope editing, lin-CD34+ progenitor cells are S59 Relative retention in the group Fig.46 O and Fig.45 F, G). AAVS1 BEThe absolute counts of myeloid populations, including CMPs, GMPs, myeloid blasts, granulocytes, and DC subsets, were significantly decreased and were affected by CD123 S59 Protection from epitope editing. In lymphocytes, when AAVS1 BE With CD123 S59 When compared, we observed partial depletion of B prolymphocytes into mature B cells ( Fig.46 P, Q). As observed for FLT3, in CD123 S59 The median fluorescence intensity (MFI) of CD123 in GMPs, myeloid blasts, monocytes, cDCs, and pDCs that persisted during editing was higher than that in AAVS1 treated with CSL362 CAR. BE conditions were higher, and we did not observe relevant differences in lymphoid subpopulations ( Fig.47 A).

[0591] In conclusion, these data show that CD123 CAR-T cells can be used to treat CD123 S59 Epitope-edited hematopoiesis-induced on-target toxicity was reduced, which would otherwise result in depletion of myeloid lineages, DCs, and an overall decrease in absolute hematopoietic cell counts.

[0592] Example 21: Multiple editing makes AML therapy more effective

[0593] We reasoned that editing of two or more epitopes would make immunotherapy more effective by attacking multiple AML targets simultaneously without increasing hematopoietic toxicity. To evaluate the feasibility of multiple epitope editing on primary HSPCs, we co-electroporated SpRY-ABE8e mRNA with two gRNAs on CD34+ cells and observed editing efficiencies comparable to those measured on the same targets after a single BE, without a significant increase in cytotoxicity ( Fig.48 A and Fig.42 D, F). To obtain proof-of-concept of protective effects against multiple CAR-T therapies, we performed dual editing of FLT3 and CD123 on the dual-reporter K562 cell line (achieving >55% dual-edited cells, Fig.48 B), and the sorted single-edited and double-edited cells were treated with bispecific CAR-T cells obtained by co-transduction with 4G8 and CSL362 CAR. After 2 days of co-culture, only the dual-epitope edited cells did not induce T cell activation (CD69), degranulation (CD107a) or proliferation (CellTrace dilution) and showed complete protection from killing, while retaining the expression of FLT3 and CD123 ( Fig.48 B, C).

[0594] To mimic the increased efficacy conferred by dual-targeted immunotherapy, we identified an AML PDX that was treated with 4G8 CAR-T cells when xenografted alone or in combination with hematopoietic cells edited for the human FLT3 N399 epitope (PDX-2 characterized by MLL-AF10 and mutated TP53, Fig.43 F, G) cannot be effectively eradicated ( Fig.47 B, C) When FLT3 N399 When administered to mice transplanted with PDX-2, 4G8 CAR showed a trend toward higher anti-leukemic efficacy ( Fig.47 C), thus indicating that extratumoral CAR activation has a detrimental effect on therapeutic success. Next, we tested any CAR targeting the two antigens we selected. - We investigated whether T cell combinations could more effectively eliminate PDX-2 AML cells, and found that the combination of 4G8 CAR-T with Fab79-D and CSL362 CAR-T was the most effective ( Fig.47 D), which is consistent with the enhanced killing when targeting two essential AML antigens simultaneously. To obtain formal evidence that dual-edited HSPCs are resistant to combined CAR-T cell therapy, we combined dual FLT3 N399 / CD123 S59 Epitope editing of HSPC or AAVS1 BE Control xenografts were implanted into NBSGW mice. Multilineage engraftment was confirmed ( Fig.47 E) and after injection of PDX-2 AML cells, we co-infused 4G8 and CSL362 CAR-T cells (1:1 ratio, Fig.48 D) treated mice. As demonstrated by our CAR combination experiments, dual CAR-T therapy was able to completely eradicate AML cells from both BM and SP ( Fig.48 E, F). Both FLT3- and CD123-edited cells persisted until the endpoint and were detected in both lymphocytes and myeloid cells ( Fig.48 G) By analyzing non-malignant hematopoiesis, we observed that AAVS1 treated with dual CAR-T cells BE Mice showed widespread depletion of myeloid and lymphopoietic lineages, with the strongest depletion of GMPs, granulocytes, cDCs, LMPPs, pre-B / NK, pro-B cells, and pre-B cells, and less prominent but significant depletion in nearly all other subsets, suggesting a mixed depletion pattern between what we observed with 4G8 alone and with the CSL362 CAR ( Fig.48 H).

[0595] Together, these data provide proof-of-concept that multiple epitope engineering can be efficiently achieved in HSPCs and enable effective multitargeted immunotherapy with minimal overlapping on-target off-tumor hematopoietic toxicity.

[0596] References for Examples 15-21:

[0597] 1. Brentjens, RJ et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acutelymphoblasticleukemia. Sci Transl Med 5, 177ra38 (2013).

[0598] 2. Turtle, CJet al. Durable molecular remissions in chronic lymphocyticleukemia treated with CD19-specific chimeric antigenreceptor-modified T cells after failure of ibrutinib. J. Clin. Oncol. 35, 3010-3020 (2017).

[0599] 3. Fry, TJ et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat. Med. 24, 20 (2018).

[0600] 4. Brentjens, RJ et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed orchemotherapy refractory B-cell leukemias. Blood 118, 4817 (2011).

[0601] 5.Spiegel,J.Y.et al.CAR T cells with dual targeting of CD19 and CD22in adult patients with recurrent or refractory B cellmalignancies:a phase 1trial.Nat Med 27,1419(2021).

[0602] 6.Kantarjian,H.et al.Acute myeloid leukemia:current progress andfuture directions.Blood Cancer J 11,41(2021).

[0603] 7.Longo,D.L., H.,Weisdorf,D.J.&Bloomfield,C.D.Acute MyeloidLeukemia.n engl j med 12,1136-52(2015).

[0604] 8. H.et al.Diagnosis and management of AML in ad ults:2017 ELNrecommendations from an international expert panel.Blood vol.129 424-447Preprint at https: / / doi.org / 10.1182 / blood-2016-08-733196(2017).

[0605] 9.Isidori,A.et al.Immunotherapy in Acute Myeloid Leukemia:Where WeStand.Article 11,1(2021).

[0606] 10.Pollyea,D.A.&Jordan,C.T.Therapeutic targeting of acute myeloidleukemia stem cells.Blood vol.129 1627-1635Preprint at https: / / doi.org / 10.1182 / blood-2016-10-696039(2017).

[0607] 11.Hofmann,S.et al.Chimeric Antigen Receptor(CAR)T Cell Therapy inAcute Myeloid Leukemia(AML).J Clin Med 8,200(2019).

[0608] 12.Haubner,S.et al.Coexpression profile of leukemic stem cell markersfor combinatorial targeted therapy in AML.Leukemia 2018 33:133,64-74(2018).

[0609] 13.Kügler,M.et al.A recombinant trispecific single-chain Fvderivativedirected against CD123 and CD33 mediates effective elimination of acutemyeloid leukaemia cells by dual targeting.Br J Haematol 150,574-86(2010).

[0610] 14.Lambert,J.et al.Gemtuzumab ozogamicin for de novo acute myeloidleukemia:final efficacy and safety updates from the open-label,phase IIIALFA-0701 trial.Haematologica 104,113-119(2019).

[0611] 15.Chen,L.et al.Targeting FLT3 by chimeric antigen receptor T cellsfor the treatment of acute myeloid leukemia.Leukemia vol.31 1830-1834Preprint at https: / / doi.org / 10.1038 / leu.2017.147(2017).

[0612] 16.el Khawanky,N.et al.Demethylating therapy increases anti-CD123 CART cell cytotoxicity against acute myeloid leukemia.Nature Communications 202112:112,1-20(2021).

[0613] 17.Zhang,H.et al.Successful Anti-CLL1 CAR T-Cell Therapy in SecondaryAcute Myeloid Leukemia.Front Oncol 10,685(2020).

[0614] 18.Kenderian,S.S.et al.CD33-specific chimeric antigen receptor Tcells exhibit potent preclinical activity against human acute myeloidleukemia.Leukemia 29,1637-47(2015).

[0615] 19.Wang,J.et al.CAR-T cells targeting CLL-1 as an approach to treatacute myeloid leukemia.doi:10.1186 / s13045-017-0553-5.

[0616] 20.Casucci,M.et al.CD44v6-targeted T cells mediate potent antitumoreffects against acute myeloid leukemia and multiple myeloma.(2013)doi:10.1182 / blood-2013-04.

[0617] 21.Myburgh,R.et al.Anti-human CD117 CAR T-cells efficiently eliminatehealthy and malignant CD117-expressing hematopoietic cells.Leukemia 34,2688-2703(2020).

[0618] 22.Jetani,H.et al.CAR T-cells targeting FLT3have potent activityagainst FLT3-ITD+AML and act synergistically with the FLT3-inhibitorcrenolanib.Leukemia 32,1168-1179(2018).

[0619] 23.F,B.et al.Gene-edited stem cells enable CD33-directed immunetherapy for myeloid malignancies.Proc Natl Acad Sci U S A 116,11978-87

[0620] 24.Kim,M.Y.et al.Genetic Inactivation of CD33 in Hematopoietic StemCells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia.Cell 173,1439-1453.e19(2018).

[0621] 25.Ulyanova,T.,Blasioli,J.,Woodford-Thomas,T.A.&Thomas,M.L.Thesialoadhesin CD33 is a myeloid-specific inhibitoryreceptor.Eur.J.Immunol.29,3440-3449(1999).

[0622] 26.Paul,S.P.,Taylor,L.S.,Stansbury,E.K.&McVicar,D.W.Myeloid specifichuman CD33is an inhibitory receptor with differential ITIM function inrecruiting the phosphatases SHP-1and SHP-2.Blood 96,483-490(2000).

[0623] 27.Ishida,A.et al.Negative regulation of Toll-like receptor-4signaling through the binding of glycosylphosphatidylinositol-anchoredglycoprotein,CD14,with the sialic acid-binding lectin,CD33.J.Biol.Chem.289,25341-25350(2014).

[0624] 28.Jacoby,E.et al.CD19 CAR immune pressure induces B-precursor acutelymphoblastic leukaemia lineage switch exposing inherent leukaemicplasticity.Nat Commun 7,(2016).

[0625] 29.Ruella,M.&Maus,M.v.Catch me if you can:Leukemia Escape after CD19-Directed T Cell Immunotherapies.Comput Struct Biotechnol J 14,357-362(2016).

[0626] 30.Sotillo,E.et al.Convergence of Acquired Mutations and AlternativeSplicing of CD19 Enables Resistance to CART-19 Immunotherapy.Cancer Discov 5,1282-1295(2015).

[0627] 31.Vago,L.et al.Loss of mismatched HLA in leukemia after stem-celltransplantation.N Engl J Med 361,478-488(2009).

[0628] 32.Grafone,T.,Palmisano,M.,Nicci,C.&Storti,S.An overview on the roleof FLT3-tyrosine kinase receptor in acute myeloid leukemia:Biology andtreatment.Oncology Reviews vol.6 64-74 Preprint at https: / / doi.org / 10.4081 / oncol.2012.e8(2012).

[0629] 33.Mekawy,M.A.,Eissa,D.S.,Hamza,M.T.,Hamed,G.M.&Youssef,M.K.FLT3receptor / CD135 expression by flow cytometry in acute myeloid leukemia:Relation to FLT3 gene mutations and mRNA transcripts.EgyPtian Journal ofMedical Human Genetics 19,345-351(2018).

[0630] 34.F Kuchenbauer,W.K.C.S.A.K.W.H.T.H.Detailed analysis of FLT3expression levels in acute myeloid leukemia.Haematologica 90,1617-25(2005).

[0631] 35.Valverde,L.R.et al.C-kit receptor(CD117)expression in acuteleukemia.Ann Hematol 72,11-15(1996).

[0632] 36.Gao,X.et al.High Expression of c-kit mRNA Predicts UnfavorableOutcome in Adult Patients with t(8;21)Acute Myeloid Leukemia.PLoS One 10,e0124241(2015).

[0633] 37.Schwartz,S.et al.Expression of the c-kit receptor(CD117)is afeature of almost all subtypes of de novo acute myeloblastic leukemia(AML),including cytogenetically good-risk AML,and lacks prognosticsignificance.Leuk Lymphoma 34,85-94(1999).

[0634] 38.Bras,A.E.et al.CD123 expression levels in 846acute leukemiapatients based on standardized immunophenotyping.Cytometry B Clin Cytom 96,134(2019).

[0635] 39.Ehninger,A.et al.Distribution and levels of cell surfaceexpression of CD33 and CD123 in acute myeloid leukemia.Blood Cancer J 4,(2014).

[0636] 40.Haubner,S.et al.Coexpression profile of leukemic stem cell markersfor combinatorialtargeted therapy in AML.Leukemia 2018 33:133,64-74(2018).

[0637] 41.Perriello,V.M.et al.CD123 Is Consistently Expressed on NPM1-Mutated AML Cells.Cancers(Basel)13,496(2021).

[0638] 42.Kandeel,E.Z.,Madney,Y.,Eldin,D.N.&Shafik,N.F.Overexpression ofCD200 and CD123 is a major influential factor in the cl inical course ofpediatric acute myeloid leukemia.Exp Mol Pathol 118,(2021).

[0639] 43.Cheng,J.,Qu,L,Wang,J.,Cheng,L&Wang,Y.High expression of FLT3 is arisk factor in leukemia.Mol Med Rep 17,2885(2018).

[0640] 44.Hofmann,M.et al.Generation,selection and preclinicalcharacterization of an Fc-optimized FLT3 antibody for the treatment ofmyeloid leukemia.(2012)doi:10.1038 / leu.2011.372.

[0641] 45.Reshetnyak,A.V et al.Structural basis for KIT receptor tyrosinekinase inhibition by antibodies targeting the D4 membrane-proximalregion.doi:10.1073 / pnas.1317118110.

[0642] 46.Herzog,E.et al.Pharmacodynamic Activity and Preclinical Safety ofCSL362,a Novel Humanised,Affinity Matured Monoclonal Antibody Against HumanInterleukin 3Receptor.Blood 120,1524-1524(2012).

[0643] 47.Xie,L.H.et al.CD123 target validation and preclinical evaluationof ADCC activity of anti-CD123 antibody CSL362 in combination with NKs fromAML patients in remission.Blood Cancer J 7,(2017).

[0644] 48.Broughton,S.E.et al.Dual Mechanism of Interleukin-3 ReceptorBlockade by an Anti-Cancer Antibody.CellReports 8,410-419(2014).

[0645] 49.Li,Y.et al.A novel Flt3-deficient HIS mouse model with selectiveenhancement of human DC development.Eur J Immunol 46,1291-1299(2016).

[0646] 50.Warmuth,M.,Kim,S.,Gu,X.J.,Xia,G.&Adrián,F.Ba / F3 cells and theiruse in kinase drug discovery.Curr Opin Oncol 19,55-60(2007).

[0647] 51.el Khawanky,N.et al.Demethylating therapy increases anti-CD123 CART cell cytotoxicity against acute myeloid leukemia.Nat Commun 12,(2021).

[0648] 52.Vavassori,V.et al.Modeling,optimization,and comparable efficacy ofT cell and hematopoietic stem cell gene editing for treating hyper-IgMsyndrome.EMBO Mol Med 13,(2021).

[0649] 53.Cieri,N.et al.IL-7 and IL-15 instruct the generation of humanmemory stem T cells from naive precursors.Blood 121,573-584(2013).

[0650] 54.Genovese,P.et al.Targeted genome editing in human repopulatinghaematopoietic stem cells.Nature 510,235-240(2014).

[0651] 55.Lennartsson,J.& LStem cellfactor receptor / c-Kit:Frombasic Science to clinicalimplications.Physiol Rev 92,1619-1649(2012).

[0652] 56.Basso-Ricci,L.et al.Multiparametric Whole Blood Dissection:A one-shot comprehensive picture of the human hematopoietic system.Cytometry 91,952(2017).

[0653] 57.Dolgin,E.First CD123-targeted drug approved after wowing in rarecancer.Nat Biotechnol 37,202-203(2019).

[0654] 58.Biasco,L.et al.In Vivo Tracking of Human Hematopoiesis RevealsPatterns of Clonal Dynamics during Early and Steady-State ReconstitutionPhases.Cell Stem Cell 19,107-119(2016).

[0655] 59.Leibowitz,M.L.et al.Chromothripsis as an on-targetconsequence ofCRISPR-Cas9 genome editing.Nat Genet 53,895-905(2021).

[0656] 60.Schiroli,G.et al.Precise Gene Editing Preserves Hematopoietic StemCell Function following Transient p53-Mediated DNA Damage Response.Cell StemCell 24,551-565.e8(2019).

[0657] 61.Ferrari,S.et al.Efficient gene editing of human long-termhematopoietic stem cells validated by clonal tracking.Nat Biotechnol 38,1298(2020).

[0658] 62. Gill, S. et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood 123, 2343-2354 (2014).

[0659] 63. Russkamp, ​​NF, Myburgh, R., Kiefer, JD, Neri, D. & Manz, MGAnti-CD117immunotherapy to eliminate hematopoietic and leukemia stem cells. ExpHematol 95, 31-45 (2021).

[0660] 64. Hand, T et al. Catalytically Enhanced Cas9 through DirectedProtein Evolution. CRISPR Journal 4, 223-232 (2021).

[0661] Other Implementations

[0662] It should be understood that although the invention has been described in conjunction with its specific embodiments, the foregoing description is intended to illustrate rather than limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages and modifications are within the scope of the following claims.

Claims

1. A genetically engineered hematopoietic stem cell (HSPC) comprising a genetically engineered FLT3 gene, wherein the genetically engineered FLT3 gene is engineered so that the encoded protein has reduced binding to a therapeutic anti-FLT3 antibody.

2. The genetically engineered HSPC of claim 1, wherein the genetically engineered FLT3 gene comprises at least one mutation in exon 9 of the FLT3 gene.

3. The genetically engineered HSPC of claim 2, wherein at least one mutation in exon 9 of the genetically engineered FLT3 gene results in a polypeptide with a mutation at position N399.

4. The genetically engineered HSPC of claim 3, wherein the mutation at position N399 is N399D or N399G.

5. The genetically engineered HSPC of claim 1, wherein the therapeutic anti-FLT3 antibody is anti-FLT3 clone 4G8 antibody.

6. The genetically engineered HSPC of claim 1, wherein the therapeutic anti-FLT3 antibody is an antibody having the same six CDRs as the 4G8 antibody or competing with the 4G8 antibody.

7. The genetically engineered HSPC of claim 1, wherein the genetically engineered HSPC is genetically engineered using a CRISPR system comprising a guide nucleic acid and a nuclease.

8. The genetically engineered HSPC of claim 7, wherein the nuclease is Streptococcus pyogenes Cas9 (SpCas9), Staphylococcus aureus (SaCas9), Lachnospiraceae Cas12a (LbCas12a), or Acidaminococcus sp. BV3L6 (AsCas12a).

9. The genetically engineered HSPC of claim 8, wherein the CRISPR system comprises SpCas9.

10. The genetically engineered HSPC of claim 8 or claim 9, wherein the guide nucleic acid is selected from the group consisting of SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO:

16.

11. The genetically engineered HSPC of claim 10, wherein the CRISPR system further comprises a template DNA.

12. The genetically engineered HSPC of claim 11, wherein the template DNA is selected from the group consisting of SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42 and SEQ ID NO:

43.

13. The genetically engineered HSPC of claim 7, wherein the nuclease is a catalytically impaired SpCas9 linked to a base editor enzyme.

14. The genetically engineered HSPC of claim 13, wherein the base editor enzyme is a nucleotide deaminase.

15. The genetically engineered HSPC of claim 14, wherein the nucleotide deaminase is cytosine deaminase or adenosine deaminase.

16. The genetically engineered HSPC of claim 13, wherein the catalytically impaired SpCas9 is NG-SpCas9 or SpRY-SpCas9.

17. The genetically engineered HSPC of any one of claims 13-16, wherein the catalytically impaired SpCas9 comprises a mutation at position D10A.

18. The genetically engineered HSPC of claim 17, wherein the catalytically impaired SpCas9 further comprises a mutation at position K918N.

19. The genetically engineered HSPC of any one of claims 13-18, wherein the guide RNA is selected from the group consisting of SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, and SEQ ID NO:

23.

20. The genetically engineered HSPC of claim 1, wherein the genetically engineered FLT3 gene encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 51 or SEQ ID NO:

52.

21. A genetically engineered hematopoietic stem cell (HSPC) population comprising the genetically engineered HSPCs of any one of claims 1-20.

22. A method of treating a hematopoietic malignancy, the method comprising administering to a human subject: (a) the genetically engineered hematopoietic stem cell population of claim 21, and (b) a therapeutically effective amount of at least one agent comprising an anti-FLT3 antibody binding domain or an antibody or antibody fragment comprising the anti-FLT3 binding domain.

23. The method of claim 22, wherein the at least one agent comprises a chimeric antigen receptor-T (CAR-T) cell comprising the anti-FLT3 antibody binding domain.

24. The method of claim 22, wherein the hematopoietic malignancy is B lymphoblastic leukemia (BLL), acute myeloid leukemia (AML), or T-cell acute lymphoblastic leukemia (T-ALL).

25. The method of claim 22, further comprising obtaining HSPCs from a biological sample from the human subject, and genetically engineering the HSPCs in the biological sample from the human subject, thereby forming the genetically engineered HSPC population.

26. The method of claim 25, wherein the biological sample is bone marrow cells, blood, umbilical cord blood cells, or mobilized peripheral blood-derived CD34+ hematopoietic stem and progenitor cells.

27. A genetically engineered hematopoietic stem cell (HSPC) comprising a genetically engineered CD123 gene, wherein the genetically engineered CD123 gene is engineered such that the binding of its encoded protein to a therapeutic anti-CD123 antibody is reduced.

28. The genetically engineered HSPC of claim 27, wherein the therapeutic anti-CD123 antibody is clone 7G3 antibody or its humanized counterpart CSL362.

29. The genetically engineered HSPC of claim 28, wherein the genetically engineered CD123 gene comprises at least one mutation in exon 2 of the CD123 gene.

30. The genetically engineered HSPC of claim 29, wherein at least one mutation in exon 2 of the genetically engineered CD123 gene results in a polypeptide with a mutation at position S59.

31. The genetically engineered HSPC of claim 30, wherein the mutation at S59 is S59P or S59F.

32. The genetically engineered HSPC of claim 27, wherein the therapeutic anti-CD123 antibody is an anti-CD123 clone 6H6 antibody or an anti-CD123 clone S18016F antibody.

33. genetically engineered HSPC as described in claim 32, wherein the genetically engineered CD123 gene comprises at least one mutation in exon 3 of the CD123 gene.

34. genetically engineered HSPC as described in claim 32, at least one mutation in exon 3 of the CD123 gene of wherein said genetically engineered method results in a polypeptide with a mutation at position P88.

35. The genetically engineered HSPC of claim 34, wherein the mutation at P88 is P88L or P88S.

36. The genetically engineered HSPC of claim 31, wherein the genetically engineered HSPC is genetically engineered using a CRISPR system comprising a guide nucleic acid and a nuclease.

37. The genetically engineered HSPC of claim 36, wherein the guide nucleic acid is selected from the group consisting of SEQ ID NO: 24, SEQ ID NO: 27, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 33, and SEQ ID NO:

34.

38. The genetically engineered HSPC of claim 35, wherein the nuclease is a catalytically impaired SpCas9 linked to a base editor enzyme.

39. The genetically engineered HSPC of claim 38, wherein the base editor enzyme is a nucleotide deaminase.

40. The genetically engineered HSPC of claim 38, wherein the base editor enzyme is cytosine deaminase or adenosine deaminase.

41. The genetically engineered HSPC of claim 38, wherein the catalytically impaired SpCas9 is NG-SpCas9 or SpRY-SpCas9.

42. The genetically engineered HSPC of any one of claims 37-41, wherein the catalytically impaired SpCas9 comprises a mutation at position D10A.

43. The genetically engineered HSPC of claim 42, wherein the catalytically impaired SpCas9 further comprises a mutation at position K918N.

44. The genetically engineered HSPC of claim 27, wherein the genetically engineered CD123 gene encodes a polypeptide comprising the amino acid sequence SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, or SEQ ID NO:

58.

45. A genetically engineered hematopoietic stem cell (HSPC) population comprising the genetically engineered HSPCs of any one of claims 27-44.

46. ​​A method of treating a hematopoietic malignancy, the method comprising administering to a human subject: (a) the genetically engineered hematopoietic stem cell population of claim 45, and (b) a therapeutically effective amount of at least one agent comprising an anti-CD123 antibody binding domain or an antibody or antibody fragment comprising the anti-CD123 binding domain.

47. The method of claim 46, wherein the at least one agent comprises a chimeric antigen receptor-T (CAR-T) cell comprising the anti-CD123 antibody binding domain.

48. The method of claim 46, wherein the hematopoietic malignancy is B lymphoblastic leukemia (BLL), acute myeloid leukemia (AML), T-cell acute lymphoblastic leukemia (T-ALL), or blastic plasmacytoid dendritic cell leukemia (BPCDN).

49. The method of claim 46, further comprising obtaining HSPCs from a biological sample from the human subject, and genetically engineering the HSPCs in the biological sample from the human subject, thereby forming the genetically engineered HSPC population.

50. The method of claim 49, wherein the biological sample is bone marrow cells, blood, umbilical cord blood cells, or mobilized peripheral blood-derived CD34+ hematopoietic stem and progenitor cells.

51. A genetically engineered hematopoietic stem cell (HSPC) population comprising: (i) a genetically engineered FLT3 gene, wherein the genetically engineered FLT3 gene encodes a protein that has reduced binding to a therapeutic anti-FLT3 antibody, and (ii) a genetically engineered CD123 gene, wherein the genetically engineered CD123 gene encodes a protein that has reduced binding to therapeutic anti-CD123 antibodies.

52. The HSPC population of claim 51, wherein the genetically engineered FLT3 gene comprises at least one mutation in exon 9 of the FLT3 gene.

53. The HSPC population of claim 52, wherein at least one mutation in exon 9 of the genetically engineered FLT3 gene results in a polypeptide with a mutation at position N399.

54. HSPC colonies as described in claim 51, wherein the CD123 gene of the genetic engineering approach comprises at least one mutation in exon 2 of the CD123 gene.

55. HSPC groups as described in claim 54, at least one mutation in exon 2 of the CD123 gene of wherein said genetically engineered approach results in a polypeptide with a mutation at position S59.

56. The HSPC population of claim 51, wherein the therapeutic anti-FLT3 antibody is an anti-FLT3 clone 4G8 antibody.

57. HSPC populations as described in claim 51, wherein the therapeutic anti-CD123 antibody is an anti-CD123 clone 7G3 antibody or a CSL362 antibody.

58. The HSPC population of claim 51, wherein the HSPC population is genetically engineered using a CRISPR system comprising at least two guide nucleic acids and a nuclease.

59. The HSPC population of claim 58, wherein the at least two guide nucleic acids are 1) SEQ ID NO: 18 or SEQ ID NO: 20 and 2) SEQ ID NO: 24 or SEQ ID NO:

27.

60. The HSPC population of claim 59, wherein the at least two guide nucleic acids are SEQ ID NO: 20 and SEQ ID NO:

27.

61. The HSPC population of claim 58, wherein the nuclease is a catalytically impaired SpCas9 linked to a base editor enzyme.

62. The HSPC population of claim 61, wherein the base editor enzyme is a nucleotide deaminase.

63. The HSPC population of claim 61, wherein the base editor enzyme is cytosine deaminase or adenosine deaminase.

64. The HSPC population of claim 61, wherein the catalytically impaired SpCas9 is NG-SpCas9 or SpRY-SpCas9.

65. The HSPC population of any one of claims 61 to 64, wherein the catalytically impaired SpCas9 comprises a mutation at position D10A.

66. The HSPC population of claim 65, wherein the SpCas9 further comprises a mutation at position K918N.

67. A method of treating a hematopoietic malignancy, the method comprising administering to a human subject: (a) a HSPC population according to any one of claims 51 to 66, and (b) a therapeutically effective amount of at least one agent, wherein the at least one agent comprises one or both of the following: (1) an anti-FLT3 antibody binding domain, or an antibody or antibody fragment comprising the anti-FLT3 binding domain, and / or (2) an anti-CD123 antibody binding domain, or an antibody or antibody fragment comprising the anti-CD123 binding domain.

68. The method of claim 67, wherein the at least one agent comprises a chimeric antigen receptor-T (CAR-T) cell comprising the anti-FLT3 antibody binding domain and / or the anti-CD123 antibody binding domain.

69. The method of claim 67, wherein the hematopoietic malignancy is B lymphoblastic leukemia (BLL), acute myeloid leukemia (AML), T-cell acute lymphoblastic leukemia (T-ALL), or blastic plasmacytoid dendritic cell leukemia (BPCDN).

70. The method of claim 67, further comprising obtaining HSPCs from a biological sample from the human subject, and genetically engineering the HSPCs in the biological sample from the human subject, thereby forming the genetically engineered HSPC population.

71. The method of claim 70, wherein the biological sample is bone marrow cells, blood, umbilical cord blood cells, or mobilized peripheral blood-derived CD34+ hematopoietic stem and progenitor cells.

72. A genetically engineered hematopoietic stem cell (HSPC) comprising a genetically engineered KIT gene, wherein the genetically engineered KIT gene is engineered such that the encoded protein has reduced binding to a therapeutic anti-KIT antibody.

73. The genetically engineered HSPC of claim 72, wherein the genetically engineered KIT gene comprises at least one mutation in exon 7 of the KIT gene.

74. The genetically engineered HSPC of claim 73, wherein at least one mutation in exon 7 of the genetically engineered KIT gene results in a polypeptide with a mutation at position H378.

75. The genetically engineered HSPC of claim 74, wherein the mutation at position H378 is H378R.

76. The genetically engineered HSPC of claim 72, wherein the therapeutic anti-KIT antibody is an anti-KIT clone Fab79D antibody.

77. The genetically engineered HSPC of claim 72, wherein the genetically engineered HSPC is genetically engineered using a CRISPR system comprising a guide nucleic acid and a nuclease.

78. The genetically engineered HSPC of claim 72, wherein the guide nucleic acid is selected from the group consisting of SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, and SEQ ID NO:

39.

79. The genetically engineered HSPC of claim 77, wherein the nuclease is a catalytically impaired SpCas9 linked to a base editor enzyme.

80. The genetically engineered HSPC of claim 79, wherein the base editor enzyme is a nucleotide deaminase.

81. The genetically engineered HSPC of claim 79, wherein the base editor enzyme is cytosine deaminase or adenosine deaminase.

82. The genetically engineered HSPC of claim 79, wherein the catalytically impaired SpCas9 is NG-SpCas9 or SpRY-SpCas9.

83. The genetically engineered HSPC of any one of claims 79-82, wherein the catalytically impaired SpCas9 comprises a mutation at position D10A.

84. The genetically engineered HSPC of claim 83, wherein the SpCas9 further comprises a mutation at position K918N.

85. A genetically engineered hematopoietic stem cell (HSPC) population comprising the genetically engineered HSPCs of any one of claims 72-84.

86. A method of treating a hematopoietic malignancy, the method comprising administering to a human subject: (a) the genetically engineered hematopoietic stem cell population of claim 85, and (b) a therapeutically effective amount of at least one agent comprising the anti-KIT antibody binding domain or an antibody or antibody fragment comprising the anti-KIT binding domain.

87. The method of claim 86, wherein the at least one agent comprises a chimeric antigen receptor-T (CAR-T) cell comprising the anti-KIT antibody binding domain.

88. The method of claim 86, wherein the hematopoietic malignancy is B lymphoblastic leukemia (BLL), acute myeloid leukemia (AML), or T acute lymphoblastic leukemia (T-ALL).

89. The method of claim 86, further comprising obtaining HSPCs from a biological sample from the human subject, and genetically engineering the HSPCs in the biological sample from the human subject, thereby forming the genetically engineered HSPC population.

90. The method of claim 89, wherein the biological sample is bone marrow cells, blood, umbilical cord blood cells, or mobilized peripheral blood-derived CD34+ hematopoietic stem and progenitor cells.

91. A genetically engineered hematopoietic stem cell (HSPC) population comprising: (i) a genetically engineered KIT gene, wherein the genetically engineered KIT gene encodes a protein that has reduced binding to a therapeutic anti-KIT antibody, and (ii) a genetically engineered CD123 gene, wherein the genetically engineered CD123 gene encodes a protein that has reduced binding to therapeutic anti-CD123 antibodies.

92. The HSPC population of claim 91, wherein the genetically engineered KIT gene comprises at least one mutation in exon 7 of the KIT gene.

93. The HSPC population of claim 92, wherein at least one mutation in exon 7 of the genetically engineered KIT gene results in a polypeptide with a mutation at position H378.

94. HSPC colonies as described in claim 91, wherein the genetically engineered CD123 gene comprises at least one mutation in exon 2 of the CD123 gene.

95. HSPC colonies as described in claim 94, at least one mutation in exon 2 of the CD123 gene of wherein said genetically engineered approach results in a polypeptide with a mutation at position S59.

96. The HSPC population of claim 91, wherein the therapeutic anti-KIT antibody is an anti-KIT clone Fab79D antibody.

97. HSPC populations as described in claim 91, wherein the therapeutic anti-CD123 antibody is an anti-CD123 clone 7G3 antibody or a CSL362 antibody.

98. The HSPC population of claim 91, wherein the HSPC population is genetically engineered using a CRISPR system comprising at least two guide nucleic acids and a nuclease.

99. The HSPC population of claim 98, wherein the at least two guide nucleic acids are 1) SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38 or SEQ ID NO:39 and 2) SEQ ID NO:24 or SEQ ID NO:

27.

100. The HSPC population of claim 99, wherein the at least two guide nucleic acids are SEQ ID NO: 37 and SEQ ID NO:

27.

101. The HSPC population of claim 98, wherein the nuclease is a catalytically impaired SpCas9 linked to a base editor enzyme.

102. The HSPC population of claim 101, wherein the base editor enzyme is a nucleotide deaminase.

103. The HSPC population of claim 101, wherein the base editor enzyme is cytosine deaminase or adenosine deaminase.

104. The HSPC population of claim 101, wherein the catalytically impaired SpCas9 is NG-SpCas9 or SpRY-SpCas9.

105. The HSPC population of any one of claims 101 to 104, wherein the catalytically impaired SpCas9 comprises a mutation at position D10A.

106. The HSPC population of claim 105, wherein the SpCas9 further comprises a mutation at position K918N.

107. A method of treating a hematopoietic malignancy, the method comprising administering to a human subject: (a) a HSPC population as described in any one of claims 91-106, and (b) a therapeutically effective amount of at least one agent comprising one or both of: (1) an anti-KIT antibody binding domain, or an antibody or antibody fragment comprising the anti-KIT binding domain, and / or (2) an anti-CD123 antibody binding domain, or an antibody or antibody fragment comprising the anti-CD123 binding domain.

108. The method of claim 107, wherein the at least one agent comprises a chimeric antigen receptor-T (CAR-T) cell comprising the anti-KIT antibody binding domain and / or the anti-CD123 antibody binding domain.

109. The method of claim 107, wherein the hematopoietic malignancy is B lymphoblastic leukemia (BLL), acute myeloid leukemia (AML), T-cell acute lymphoblastic leukemia (T-ALL), or blastic plasmacytoid dendritic cell leukemia (BPCDN).

110. The method of claim 107, further comprising obtaining HSPCs from a biological sample from the human subject, and genetically engineering the HSPCs in the biological sample from the human subject, thereby forming the genetically engineered HSPC population.

111. The method of claim 110, wherein the biological sample is bone marrow cells, blood, umbilical cord blood cells, or mobilized peripheral blood-derived CD34+ hematopoietic stem and progenitor cells.

112. A genetically engineered hematopoietic stem cell (HSPC) population comprising: (i) a genetically engineered FLT3 gene, wherein the genetically engineered FLT3 gene encodes a protein that has reduced binding to a therapeutic anti-FLT3 antibody, and (ii) a genetically engineered KIT gene, wherein the genetically engineered KIT gene encodes a protein that has reduced binding to a therapeutic anti-KIT antibody.

113. The HSPC population of claim 112, wherein the genetically engineered FLT3 gene comprises at least one mutation in exon 9 of the FLT3 gene.

114. The HSPC population of claim 113, wherein at least one mutation in exon 9 of the genetically engineered FLT3 gene results in a polypeptide with a mutation at position N399.

115. The HSPC population of claim 112, wherein the genetically engineered KIT gene comprises at least one mutation in exon 7 of the KIT gene.

116. The HSPC population of claim 115, wherein at least one mutation in exon 7 of the genetically engineered KIT gene results in a polypeptide with a mutation at position H378.

117. The HSPC population of claim 112, wherein the therapeutic anti-FLT3 antibody is anti-FLT3 clone 4G8 antibody.

118. The HSPC population of claim 112, wherein the therapeutic anti-KIT antibody is an anti-KIT clone Fab79D antibody.

119. The HSPC population of claim 112, wherein the HSPC population is genetically engineered using a CRISPR system comprising at least two guide nucleic acids and a nuclease.

120. The HSPC population of claim 119, wherein the at least two guide nucleic acids are 1) SEQ ID NO: 18 or SEQ ID NO: 20 and 2) SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38 or SEQ ID NO:

39.

121. The HSPC population of claim 120, wherein the at least two guide nucleic acids are SEQ ID NO: 20 and SEQ ID NO:

37.

122. The HSPC population of claim 119, wherein the nuclease is a catalytically impaired SpCas9 linked to a base editor enzyme.

123. The HSPC population of claim 122, wherein the base editor enzyme is a nucleotide deaminase.

124. The HSPC population of claim 122, wherein the base editor enzyme is cytosine deaminase or adenosine deaminase.

125. The HSPC population of claim 122, wherein the catalytically impaired SpCas9 is NG-SpCas9 or SpRY-SpCas9.

126. The HSPC population of any one of claims 122 to 125, wherein the catalytically impaired SpCas9 comprises a mutation at position D10A.

127. The HSPC population of claim 126, wherein the SpCas9 further comprises a mutation at position K918N.

128. A method of treating a hematopoietic malignancy, the method comprising administering to a human subject: (a) a HSPC population according to any one of claims 112 to 127, and (b) a therapeutically effective amount of at least one agent comprising one or both of: (1) an anti-FLT3 antibody binding domain, or an antibody or antibody fragment comprising the anti-FLT3 binding domain, and / or (2) an anti-KIT antibody binding domain, or an antibody or antibody fragment comprising the anti-KIT binding domain.

129. The method of claim 128, wherein the at least one agent comprises a chimeric antigen receptor-T (CAR-T) cell comprising the anti-FLT3 antibody binding domain and / or the anti-KIT antibody binding domain.

130. The method of claim 128, wherein the hematopoietic malignancy is B lymphoblastic leukemia (BLL), acute myeloid leukemia (AML), T-cell acute lymphoblastic leukemia (T-ALL), or blastic plasmacytoid dendritic cell leukemia (BPCDN).

131. The method of claim 128, further comprising obtaining HSPCs from a biological sample from the human subject, and genetically engineering the HSPCs in the biological sample from the human subject, thereby forming the genetically engineered HSPC population.

132. The method of claim 131, wherein the biological sample is bone marrow cells, blood, umbilical cord blood cells, or mobilized peripheral blood-derived CD34+ hematopoietic stem and progenitor cells.

133. A chimeric antigen receptor (CAR) comprising a polypeptide comprising: (a) one or more epitope-binding fragments that bind to an epitope of one or more cell surface lineage-specific proteins, (b) Hinge domain, (c) transmembrane domain, (d) a co-stimulatory domain, and (e) a cytoplasmic signaling domain, Wherein the one or more cell surface lineage-specific proteins are selected from FLT3, CD123 and / or KIT.

134. The CAR of claim 133, wherein the cell surface lineage-specific protein is FLT3 and the CAR comprises the amino acid sequence of SEQ ID NO:

73.

135. The CAR of claim 133, wherein the cell surface lineage-specific protein is FLT3 and the one or more epitope binding fragments comprise one or more epitope binding fragments from SEQ ID NO:

73.

136. A CAR as described in claim 133, wherein the cell surface lineage-specific protein is FLT3 and the one or more epitope binding fragments comprise the following CDR sequences: GYTFTSYWMH (SEQ ID NO: 96), EIDPSDSYKDYNQKFK (SEQ ID NO: 97), RAITTTPFDF (SEQ ID NO: 98), RASQSISNNLH (SEQ ID NO: 99), YASQSIS (SEQID NO: 100) and QQSNTWPYT (SEQ ID NO: 101).

137. The CAR of claim 133, wherein the cell surface lineage-specific protein is CD123 and the CAR comprises the amino acid sequence of SEQ ID NO: 75, SEQ ID NO: 86 or SEQ ID NO:

87.

138. The CAR of claim 133, wherein the cell surface lineage-specific protein is CD123 and the one or more epitope binding fragments include one or more epitope binding fragments from SEQ ID NO: 75, SEQ ID NO: 86, or SEQ ID NO:

87.

139. The CAR of claim 133, wherein the cell surface lineage-specific protein is CD123 and the one or more epitope binding fragments comprise the following CDR sequences: GYSFTDYYMK (SEQ ID NO: 104), DIIPSNGATFYNQKFKG (SEQ ID NO: 105), ARSHLLRASWFAY (SEQ ID NO: 106), SQSLLNSGNQKNYLT (SEQ ID NO: 107), WASTRES (SEQ ID NO: 108) and QNDYSYPYT (SEQ ID NO: 109).

140. The CAR of claim 133, wherein the cell surface lineage-specific protein is CD123 and the one or more epitope binding fragments comprise the following CDR sequences: DIIPSNGATFYNQKFKG (SEQ ID NO: 105), SQSLLNSGNQKNYLT (SEQ ID NO: 107), WASTRES (SEQ ID NO: 108) and QNDYSYPYT (SEQ ID NO: 109).

141. The CAR of claim 133, wherein the cell surface lineage-specific protein is KIT and the CAR comprises the amino acid sequence of SEQ ID NO: 69 or SEQ ID NO:

71.

142. The CAR of claim 133, wherein the cell surface lineage-specific protein is KIT and the one or more epitope binding fragments comprise one or more epitope binding fragments from SEQ ID NO: 69 or SEQ ID NO:

71.

143. The CAR of claim 133, wherein the cell surface lineage-specific protein is KIT and the one or more epitope binding fragments comprise the following CDR sequences: GFNISVYMMH (SEQ ID NO: 88), SIYPYSGYTYYADSVKG (SEQ ID NO: 89), ARYVYHALDY (SEQ ID NO: 90), RASQRGLRNVAVA (SEQ ID NO: 91), SASSLYS (SEQ ID NO: 92) and QQWAVHSLIT (SEQ ID NO: 93).

144. The CAR of claim 133, wherein the one or more cell surface lineage-specific proteins are FLT3 and CD123 and the CAR comprises the amino acid sequence SEQ ID NO: 77 or SEQ ID NO:

79.

145. The CAR of claim 133, wherein the one or more cell surface lineage-specific proteins are FLT3 and CD123 and the one or more epitope binding fragments comprise one or more epitope binding fragments from SEQ ID NO: 77 or SEQ ID NO:

79.

146. The CAR of claim 133, wherein the one or more cell surface lineage-specific proteins are FLT3 and CD123 and the one or more epitope binding fragments comprise the following CDR sequences: GYTFTSYWMH (SEQ ID NO: 96), EIDPSDSYKDYNQKFK (SEQ ID NO: 97), RAITTTPFDF (SEQ ID NO: 98), RASQSISNNLH (SEQ ID NO: 99), YASQSIS (SEQ ID NO: 100), QQSNTWPYT (SEQ ID NO: 101), GYSFTDYYMK (SEQ ID NO: 104), DIIPSNGATFYNQKFKG (SEQ ID NO: 105), ARSHLLRASWFAY (SEQ ID NO: 106), SQSLLNSGNQKNYLT (SEQ ID NO: 107), WASTRES (SEQ ID NO: 108), and QNDYSYPYT (SEQ ID NO: 109).

147. A CAR as described in any one of claims 133 to 146, wherein the hinge domain is a CD28 hinge, an IgG4 hinge, or a CD8α hinge.

148. The CAR of any one of claims 133 to 147, wherein the transmembrane domain is CD28 TM, CD8α TM or 4-1BB TM.

149. A CAR as described in any one of claims 133 to 148, wherein the co-stimulatory domain is CD28z, 4-1BB, ICOS or OX40.

150. The CAR of any one of claims 133 to 149, wherein the cytoplasmic signaling domain is CD3z.

151. A cell expressing the CAR described in any of claims 133-150.

152. The cell of claim 151, wherein the cell is an immune cell.

153. The cell of claim 152, wherein the immune cell is a T cell.

154. A method of treating a hematopoietic malignancy, the method comprising administering to a human subject: (a) a population of genetically engineered hematopoietic stem cells, and (b) The cell of any one of claims 151-153.

155. A polypeptide sequence comprising a polypeptide sequence that is at least 80% identical to the sequence shown in SEQ ID NO: 51, wherein the polypeptide sequence comprises a mutation at N399D, and wherein the polypeptide sequence has reduced binding to a therapeutic anti-FLT3 antibody.

156. A polypeptide sequence comprising a polypeptide sequence that is at least 80% identical to the sequence shown in SEQ ID NO: 52, wherein the polypeptide sequence comprises a mutation at N399G, and wherein the polypeptide sequence has reduced binding to a therapeutic anti-FLT3 antibody.

157. A polypeptide sequence comprising a polypeptide sequence that is at least 80% identical to the sequence shown in SEQ ID NO: 54, wherein the polypeptide sequence comprises a mutation at S59P, and wherein the binding of the polypeptide sequence to a therapeutic anti-CD123 antibody is reduced.

158. A polypeptide sequence comprising a polypeptide sequence that is at least 80% identical to the sequence shown in SEQ ID NO: 55, wherein the polypeptide sequence comprises mutations at Y58H and S59P, and wherein the binding of the polypeptide sequence to a therapeutic anti-CD123 antibody is reduced.

159. A polypeptide sequence comprising a polypeptide sequence that is at least 80% identical to the sequence shown in SEQ ID NO: 56, wherein the polypeptide sequence comprises a mutation at S59F, and wherein the binding of the polypeptide sequence to a therapeutic anti-CD123 antibody is reduced.

160. A polypeptide sequence comprising a polypeptide sequence that is at least 80% identical to the sequence shown in SEQ ID NO: 57, wherein the polypeptide sequence comprises a mutation at P88S, and wherein the binding of the polypeptide sequence to a therapeutic anti-CD123 antibody is reduced.

161. A polypeptide sequence comprising a polypeptide sequence that is at least 80% identical to the sequence shown in SEQ ID NO: 58, wherein the polypeptide sequence comprises a mutation at P88L, and wherein the binding of the polypeptide sequence to a therapeutic anti-CD123 antibody is reduced.

162. A polypeptide sequence comprising a polypeptide sequence that is at least 80% identical to the sequence shown in SEQ ID NO:67, wherein the polypeptide sequence comprises mutations at F316S, M318V, I319K, V323I, I334V, E360K, P363V, E366D, E376Q and H378R, and wherein the polypeptide sequence has reduced binding to a therapeutic anti-KIT antibody.

163. A polypeptide sequence comprising a polypeptide sequence that is at least 80% identical to the sequence shown in SEQ ID NO: 68, wherein the polypeptide sequence comprises a mutation at H378R, and wherein the polypeptide sequence has reduced binding to a therapeutic anti-KIT antibody.

164. A nucleic acid encoding the polypeptide of any one of claims 155-163.

Citation Information

Patent Citations

  • Unconstrained Genome Targeting with near-PAMless Engineered CRISPR-Cas9 Variants

    US20210284978A1

  • Engineered crispr-cas9 nucleases with altered PAM specificity

    WO2016141224A1

  • Engineered crispr-cas9 nucleases

    WO2017040348A1